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ABSTRACT
IL-6 is an inflammatory cytokine that contributes to the pathogenesis of many
immunological diseases including rheumatoid arthritis, multiple sclerosis, systemic
lupus erythematosus, allergic asthma, as well as the protection against infections caused
by various pathogens. These are linked to its role in regulating CD4 T cell
differentiation and effector function.
Most of these functions are dependent on the IL-6-mediated signaling through
the transcription factor Stat3. In this thesis, we identify a novel molecular mechanism
by which IL-6 regulates CD4 T cell effector function. We show that IL-6-dependent
signal raises the levels of mitochondrial Ca2+ late during activation of CD4 T cells. This
is further used to prolong the expression of effector cytokines IL-4 and IL-21. The
modulation of mitochondrial Ca2+ is mediated by the regulation of mitochondrial Stat3
and the formation of respiratory supercomplexes. Thus, in addition to the canonical
signaling of IL-6 through Stat3 as a transcription factor, IL-6 also modulates
mitochondrial Stat3 to regulate mitochondrial function in CD4 T cells. This could be an
alternative pathway by which IL-6 regulates effector function of CD4 T cells and it
could contribute to the pathogenesis of inflammatory disease.
Little is known about the effects of IL-6 on CD8 T cells. In this thesis, we reveal
a paradigm-shifting mechanism by which IL-6 regulates antibody production by
converting CD8 T cells into B cell helpers through IL-21. Briefly, IL-6 promotes the
differentiation of a subset of naïve CD8 T cells into a unique population of effector
CD8 T cells characterized by the production of high levels of IL-21. IL-21-producing
CD8 T cells provide help to B cells to induce isotype switching and protective antibody
production during infection.
In summary, this thesis provides new insights into both mechanistic and
functional aspects of IL-6 in regulating T cell function. These findings may shed light
on the development of new therapeutic approaches in treating autoimmune disorders
and preventing infectious diseases.
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CHAPTER 1: Comprehensive Literature Review

1. The Immune System

1.1 Innate Immunity
The human body is constantly engaged in an internal war against a vast array of
pathogens. Pathogens like bacteria, parasites, fungi or viruses always seek to break
through our bodies’ defense for their fitness, causing infectious diseases. To fight off
pathogens, our body is equipped with cells and molecules responsible for the immune
response, the collective and coordinated reaction of the immune system to pathogens.
Moreover, non-infectious foreign substances and even self-tissues in some pathological
conditions can lead to immune response. This mechanism that in normal conditions
protects individuals from infection can also cause tissue damage and pathological
diseases in certain situations, known as autoimmune diseases. The immune system’s
overzealous response to non-pathogenic environmental stimuli can also lead to the
pathogenesis of allergy and atopy. Thus, the immune system is a double-edged sword
that protects us from infectious microbes in physiological context but causes
autoimmune diseases, allergy and atopy when the system is not well balanced. The
studies of immunology aim at treating and preventing infectious, autoimmune and
allergic diseases by understanding the underlying cellular and molecular mechanisms of
1

the immune reaction.
Defense against microbes is mediated by the early reaction of innate immunity
and later responses of adaptive immunity. The innate immune response and the
adaptive immune response make up the two arms of the immune system. Innate
immunity consists of cellular and biochemical components that are already in place
even before infection, and responds rapidly to infections. Epithelial cells comprise the
first line of host innate immunity (Fig. 1). Firstly, epithelial cells provide a physical
barrier to numerous microorganisms. Patients with burn wounds or damaged epithelial
integrity are prone to severe infection (Church et al., 2006; Man et al., 2000). Besides
this, epithelial cells secrete antimicrobial peptides (AMPs) (Fig. 1), such as highly
cationic defensins and cathelicidins, which directly permeabilize bacterial membranes
to form transmembrane pores that kill the bacteria (Brogden, 2005; Jenssen et al.,
2006). In addition, epithelial cells also produce inflammatory cytokines and
chemokines after sensing the presence of invading microorganisms (Fig. 1) (Gandhi
and Vliagoftis, 2015). This leads to the activation of immune cells and the recruitment
of inflammatory leukocytes to the site of infection (Borish and Steinke, 2003).
Upon breach of the epithelial barrier, monocytes in blood are recruited to the
site of infection by chemokines, such as CCL2 and CCL7, induced by microbial
components (Shi and Pamer, 2011). Once recruited, monocytes differentiate into
macrophages. Together with tissue resident macrophages, they comprise another
2

important line of the innate immune response (Fig. 1). Macrophages recognize
microbes using different receptors and clear them using receptor mediated phagocytosis
(Aderem and Underhill, 1999). Similar to epithelial cells, upon recognizing different
microbes through an array of receptors that respond to certain patterns of pathogens,
macrophages release cytokines and chemokines that are critical to initiating,
perpetuating, and even resolving the inflammatory response (Fig. 1). Several pyogenic
cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1) act at the central
nervous system (CNS), mediating the coordinated responses resulting in fever, a
systemic response to infection (Netea et al., 2000). Interleukin-6 (IL-6), another
cytokine released by macrophages and epithelial cells, triggers an acute phase response
in which the liver synthesizes acute phase proteins, especially C-reactive protein (CRP)
and serum amyloid A (SAA) (Heinrich et al., 1990). CRP binds to microbial capsular
ligands, and aggregates to trigger complement system, a network of plasma proteins
that can be activated directly by pathogens, leading to a cascade of reactions that
eventually kill microbes (Pepys and Hirschfield, 2003; Zipfel and Skerka, 2009). SAA
amplifies inflammatory reaction by inducing the synthesis of several cytokines (Eklund
et al., 2012). Chemokines released by macrophages and epithelial cells attract
monocytes/macrophages and adaptive immune cells such as T cells and B cells to the
site of infection (Fig. 1). All these immune cells orchestrate both the rapid and longterm immunity against pathogens. Importantly, in addition to phagocytosis and the
3

release of cytokines and chemokines, macrophages also function as a major bridge
between the innate and adaptive immune system by presenting small peptides from
phagocytosed microbes to T cells by major histocompatibility complex (MHC), a
process known as antigen presentation (Unanue, 1984).

Figure 1. Immune cellular and molecular components at the site of infections.
Another innate immune cell type that is recruited to the site of infection
immediately after infection is the neutrophil. Chemokines, primarily interleukin-8 (IL8), CXCL2 and CXCL1, and bacterial proteins containing N-formylmethionine recruit
them to the site of infections (Chin and Parkos, 2007). Similar to macrophages,
neutrophils destroy pathogens through phagocytosis and fusion with lysosomes.
Furthermore, neutrophils release and extrude a meshwork of fibers that consist of their
chromatin and DNA (known as neutrophil extracellular traps, NET) to kill pathogens.
Additionally, microbial components stimulate neutrophils to make reactive oxygen
4

species (ROS), nitric oxide (NO) and hypochlorous acid (HOCl) by NADPH oxidase,
inducible nitric oxide synthetase (iNOS) and myeloperoxidase (MPO), respectively.
These highly oxidizing products result in microbial cell death during many infections.
Resting dendritic cells (DC) reside in both peripheral tissues and lymphoid
tissues under normal conditions. When DC recognize invading microbes, they uptake the
microbes through specific receptors and non-specific macropinocytosis (Sallusto et al.,
1995). After uptake, DC process and load peptides derived from microbes onto their
surface MHC complexes. They present pathogen-derived antigens to T cells, which leads
to the activation and differentiation of T cells (Guermonprez et al., 2002). DC
constitutively expresses MHC class II molecules that enable it to present antigens derived
from pathogens to naïve CD4 T cells to stimulate them. In addition to DC, B cells and
macrophages also share the same mechanism. Therefore, they are known as antigen
presenting cells (APC). Through antigen presentation, APC bridges the gap between
innate and adaptive immune responses.
Natural Killer cells (NK cells) are another important type of innate immune cell.
NK cells are lymphocytes of the innate immune system that control several types of
tumors and microbial infections by limiting their spread and subsequent tissue damage
(Vivier et al., 2008). During infection, activating NK cell receptors, such as the stressinduced self ligands recognized by NKG2D, detect the presence of ligands on the stressed
cells (Vivier et al., 2008). NK cells also recognize viral products such as CMV-m157
5

through their receptor Ly49H (Vivier et al., 2008). In addition, NK cells express the lowaffinity Fc receptor CD16, enabling them to detect antibody-coated target cells and to kill
them through antibody-dependent cell cytotoxicity (ADCC) (Vivier et al., 2008). NK
cells induce target cell death by the formation of a lytic immunological synapse between
the NK cell and its target. The polarized exocytosis of secretory lysosomal enzymes,
including granzymes and perforin, eventually execute the killing (Topham and Hewitt,
2009).
Eosinophils and mast cells are also part of the innate immune system. They both
develop from precursors in the bone marrow. Eosinophils expanded from progenitors in
the bone marrow in response interleukin-5 (IL-5), and are recruited into tissues in
response to eotaxin chemokines (Rosenberg et al., 2013). Mast cells reside in peripheral
tissues that are close to host-environment interfaces, especially skin and mucosal tissues
(Marshall, 2004; Wernersson and Pejler, 2014). In response to stimuli, eosinophils and
mast cells rapidly undergo degranulation. Eosinophils release leukotrines, prostaglandins
and cationic granule proteins to mediate local inflammation. This contributes to the
airways dysfunction and tissue remodeling in allergic asthma (Jacobsen et al., 2007).
Mast cells release histamine, serotonin, dopamine, lysozymes, and cytokines such as IL-5
and IL-4 through which mast cells contribute to the pathogenesis of anaphylaxis, allergic
asthma, skin hypersensitivity and protection against parasitic infections (Marshall, 2004;
Wernersson and Pejler, 2014). Basophils are a distinct lineage of circulating innate
6

immune cell with functional similarity to those of mast cells.
Cells from the innate immune system recognize pathogens (e.g. bacteria, fungi,
viruses) through pattern recognition receptors (PRRs). They detect conserved structures
shared by many pathogens, termed pathogen-associated molecular patterns (PAMPs)
(Janeway et al., 1996; Janeway and Medzhitov, 2002; Medzhitov and Janeway, 2000;
Medzhitov et al., 1997; Poltorak et al., 1998). Most PRRs can be classified into one of
five families based on protein domain homology, including Toll-like receptors (TLRs),
C-type lectin receptors (CLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs)
and the AIM2-like receptors (ALRs) (Brubaker et al., 2015).
Among the PRRs, TLRs are the most extensively studied (Mogensen, 2009).
The discovery of the TLR, began with the identification of Toll, a receptor that is
essential for dorsoventral embryogenesis and immune response against fungal infection
in insects (Hashimoto et al., 1988; Lemaitre et al., 1996). To date, 10 and 12 members of
the TLR family have been identified in human and mice (Pandey et al., 2015). TLRs are
widely expressed in almost all mammalian cells. The wide expression of TLRs correlates
with the nature of innate immunity that all host cells have an intrinsic capability to fight
off pathogens. TLR1 is ubiquitously expressed and TLR2, TLR3, TLR4 and TLR5 are
more restricted to myeloid cells, especially neutrophils, monocytes, macrophages and
DCs (Muzio et al., 2000). While most of these TLRs are expressed on the cell surface,
some TLRs including TLR3, TLR7, TLR8 and TLR9 are mostly present in endosomes
7

(Fig. 2) (Kawai and Akira, 2010; Liu et al., 2007). These receptors recognize a variety of
different microbial ligands that are shared by groups of pathogens (Fig. 2). TLR1 forms
heterodimers with TLR2 (TLR1/2) and recognizes triacyl lipopeptides (Takeuchi et al.,
2002) (Fig. 2). In addition to TLR1, TLR2 also forms hetrodimers with TLR6 to
recognize diacyl lipopeptides (Takeuchi et al., 2001) (Fig. 2). Both diacyl and tricyl
lipopeptides are commonly found in bacteria. TLR4 recognizes lipopolysaccharides
(LPS), which are found in the outer membrane of almost all Gram-negative bacteria
(Medzhitov et al., 1997; Poltorak et al., 1998) (Fig. 2). TLR5 recognizes bacterial
flagellin (Hayashi et al., 2001) (Fig. 2). In contrast to TLR1, TLR2, TLR4, TLR5 and
TLR6 that reside on the outer membrane, TLR3, TLR7, TLR8 and TLR9 locate at the
endosomal membrane, which determines their ability to respond to completely different
sets of ligands (Fig. 2). TLR3 recognizes double-stranded RNA (dsRNA), which is found
in a diverse group of RNA viruses (Alexopoulou et al., 2001) (Fig. 2). TLR7 and TLR8
are responsive to single-stranded RNA (ssRNA) found during viral replication (Heil et
al., 2004) (Fig. 2). TLR9 recognizes unmethylated deoxycytidyl-phosphatedeoxyguanosine (CpG) motifs commonly present in bacterial and viral genomes (Hemmi
et al., 2000) (Fig. 2). Compared with TLR1-9, the role of TLR10, TLR11 and TLR12 is
less understood. While the ligand for TLR10 is still unknown, TLR11 and TLR12 have
been shown to directly recognize profilin in Toxoplasma gondii (Koblansky et al., 2013;
Yarovinsky et al., 2005).
8

Figure 2. Human TLR signaling pathway. (adapted from Liu et al., 2007)
Although these TLRs recognize different microbial components, they lead to
similar signaling pathway since they share the similar cytoplasmic Toll interleukin-1
receptor (TIR) domains that interact with downstream adaptor proteins required for
signaling (Fig. 2) (Kawai and Akira, 2010; Pandey et al., 2015). TLRs signal through
MyD88 (myeloid differentiation primary-response protein 88) and/or TRIF (TIR-domailcontaining adaptor protein inducing IFN-β) adaptor proteins, and subsequently activate
NF-κB, IFN-regulatory factor 3 (IRF3) and mitogen-activated protein kinase (MAPK)
pathways (Pandey et al., 2015). Adaptor proteins MyD88 and TRIF are essential for the
signaling transduction of TLRs. Notably, MyD88 is shared by the signaling transduction
9

by all TLRs except for TLR3. MyD88 deficiency in mice leads to susceptibility to a
broad range of pathogens in experimental models of infection (Adachi et al., 1998; Hoebe
et al., 2003; Kawai et al., 1999). Children with autosomal recessive MyD88 deficiency
suffer from life-threatening and recurrent pyogenic bacterial infections, including
invasive pneumococcal disease (Picard et al., 2011; von Bernuth et al., 2008). These are
due to the defects in transducing signals from TLRs to downstream NF-κB and MAPK
activation. The other adaptor protein, TRIF, however is, used by TLR4 and TLR3 to
transduce signaling to the transcription factor IRF3 (Kawai and Akira, 2010). In TRIF
deficient mice, TLR3 and TLR4 ligands elicit impaired activation of IRF3 and decreased
expression of IFN-inducible genes (Yamamoto et al., 2003). Autosomal recessive and
dominant TRIF deficiency leads to susceptibility to Herpes simplex encephalitis in
children due to defects in TLR3 signaling (Sancho-Shimizu et al., 2011). Activation of
these signaling pathways leads to several end products. Activation of the NF-κB and
MAPK pathways upregulates macrophage colony-stimulating factor (M-CSF) and
granulocyte/macrophage colony-stimulating factor (GM-CSF), and elevated M-CSF and
GM-CSF promote the differentiation and mobilization of bone-marrow precursor cells
into mature myeloid cells such as macrophages (Hamilton, 2008). In addition, activation
of NF-κB and MAPK pathways leads to the expression and production of a core panel of
cytokines and chemokines such as TNF, IL-8 and IL-6 (Libermann and Baltimore, 1990;
Pandey et al., 2015). Through the activation of NF-κB and MAPK pathways, TLR
10

stimulation mediates the activation and maturation of APCs, which further initiate
adaptive immunity (Barr et al., 2007). Activation of the IRF3 pathway results in the
production of anti-viral type I interferons such as interferon α (IFNα) and interferon β
(IFNβ) (Hiramatsu et al., 2010).
In contrast to TLRs, the RLR family does not have as many members. Only
three RLRs have been discovered so far, including retinoic acid-inducible gene-I (RIG-I),
melanoma differentiation gene 5 (MDA5), and laboratory of genetics and physiology 2
(LGP2) (Brubaker et al., 2015). RLRs are cytosolic proteins that detect the presence of
foreign RNA within the cytosol, which is common to genomes and replication
intermediates of viruses (Hornung et al., 2006; Kato et al., 2008; Pichlmair et al., 2006;
Pichlmair et al., 2009). RIG-I and MDA5 activate the adaptor MAVS through their
CARD domains (Seth et al., 2005). This subsequently stimulates the downstream NF-κB,
IRF7 and IRF3 pathways, culminating in the expression of type 1 IFN, pro-inflammatory
cytokines and IFN-stimulated genes (ISGs).
Another very important group of PRRs is the NLR family. A significant subset
of NLRs in vitro can activate the inflammasome, a multi-protein complex that elicits
immunological function by activating caspase activities for cytokine processing or
programmed cell death. NLRP1, 2, 3, 6, 12, NLRC4 and NOD2 when ectopically
expressed with caspase-1 and apoptosis-associated speck-like protein containing a
caspase recruitment domain (ASC), can facilitate the activation of caspase-1 and
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subsequently IL-1β and IL-18 processing (Agostini et al., 2004; Davis et al., 2011;
Grenier et al., 2002; Martinon et al., 2002; Poyet et al., 2001; Wang et al., 2002). NLRP1,
NLRP3 and NLRC4 are better characterized for their ability to activate the
inflammasome in vivo (Davis et al., 2011). NLRP3 is activated by diverse endogenous
agonists, including extracellular ATP, uric acid, amyloid β aggregates, cholesterol
crystals, and exogenous agonists, including ultraviolent radiation, hemolysins from S.
aureus and listeriolysin O from L. monocytogenes (Davis et al., 2011). NLRC4 is
activated by intracellular flagellin (Franchi et al., 2006; Miao et al., 2006). In response to
stimuli, NLRP3 undergoes deubiquitination while ASC adaptor is ubiquininated and
phosphorylated for inflammasome assembly to occur. NLRP3 nucleates ASC large
cytosolic aggregates through PYD-PYD interactions (Cai et al., 2014; Lu et al., 2014).
This serves as a scaffold to recruit the inactive pro-caspase-1. Oligomerization of procaspase-1 leads to the autoproteolytic cleavage into active caspase-1 (Yang et al., 1998b),
which subsequently cleaves pro-IL-1β and pro-IL-18 into biologically active IL-1β and
IL-18. Thus, through PRRs, innate immune cells compose the first line of defense against
pathogens.

1.2 Adaptive Immunity
While the innate immune system responds to a wide range of microbes by
recognizing patterns, there are only less than 100 PRRs characterized in mammals.
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Therefore, our immune system needs more receptors that elicit higher and wider
specificity to microbial products. This is where adaptive immunity comes in place. The
adaptive immune system is comprised of T and B lymphocytes. In contrast to the innate
immune system that only has a limited number of PRRs, T and B cells contain up to 1015
unique antigen receptors. In addition, in contrast to innate immunity that primarily
mounts immune response against patterns of danger signals (Janeway et al., 1996;
Matzinger, 1994, 1998), adaptive immunity develops immune response through antigen
receptors against distinct molecules of microbes with exquisite specificity.
T cells and B cells express antigen receptors, known as T cell receptor (TCR)
and B cell receptor (BCR), respectively. TCR and BCR determine the antigen specificity
during adaptive immune responses. The majority of T cells express a TCR that is
comprised of α and β polypeptide chains (TCRαβ). TCRαβ recognizes antigen loaded
MHC molecules. T lymphocytes comprise CD4 and CD8 T cells. While CD8 T cells
preferentially recognize antigens presented by MHC class I (York and Rock, 1996), CD4
T cells recognize the antigens presented by MHC class II (Guermonprez et al., 2002).
MHC class I molecules are constitutively expressed on virtually all nucleated cells,
whereas MHC class II molecules are expressed only on APCs and a few other cell types
(Abbas et al., 2010). MHC class I consist of two noncovalently linked polypeptide
chains, an MHC-encoded α chain and a non-MHC subunit – β2-microglobulin. In
contrast, MHC class II molecules are composed of two noncovalently associated
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polypeptide chains α and β, both of which are encoded by the MHC gene locus (Abbas et
al., 2010). Each MHC class I or class II molecule has a single peptide-binding cleft that
binds one peptide at a time.
MHC class I presents peptides produced by proteolytic degradation of cytosolic
proteins. Peptides derived from degradation are transported to endoplasmic reticulum
(ER) where the assembly occurs. Thus, the sources of MHC class I peptides are mostly
cytosolic proteins or products of viruses or other intracellular microbes that are
synthesized in infected cells. In contrast, MHC class II presents peptides derived from
endocytosed antigens in endocytic vesicles. These peptides then bind to MHC class II
molecules in these vesicles for assembly. Therefore, most MHC class I peptides are from
the extracellular environment, such as self extracellular proteins or extracellular microbes
that are engulfed by APCs. During infection, MHC class I molecules on infected cells
present peptides derived from intracellular pathogens to CD8 T cells, whereas MHC class
II molecules on APCs present peptides from extracellular microbes to CD4 T cells. CD4
T and CD8 T cells with specific TCRs that are able to recognize MHC-peptide complexes
are activated to initiate the adaptive immune response.
In addition to T cells, B cells are another important component of adaptive
immunity. B cells are unique because they express clonally diverse cell surface
immunoglobulin (Ig) receptors that recognize specific epitopes but that do not require
presentation by MHC molecules (LeBien and Tedder, 2008). During infection, B cells
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undergo a series of differentiation steps and function by providing protective antibodies
that neutralize microbes. Similar to TCRs, BCRs represent a substantial repertoire that is
generated through a process known as V(D)J recombination. This secures that our
immune system can generate adequately diverse antibodies to fight off infections.

Figure 3. The Adaptive Immunity: antibody-mediated immunity and T cellmediated immunity.
Adaptive immune responses consist of antibody-mediated immunity and T cellmediated immunity (Fig. 3). Antibody production is one of the major mechanisms against
extracellular microbes and their toxins due to accessibility. Antibodies are produced by B
cells when they are stimulated (Fig. 3). During infection, some CD4 T cells are also
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differentiated into specific effector CD4 T helper cells to provide help to B cell antibody
production (Allen and Sutherland, 2014; Crotty, 2011). Antibodies precisely recognize
microbial antigens, neutralize microbes, and clear microbes through various mechanisms.
Antibodies neutralize microbes directly. They also promote the ingestion of microbes by
host phagocytes by binding to microbes, known as opsonization. In addition, some
antibodies bind to microbes and subsequently guide cytotoxic cells such as NK cells to
clear the pathogens, known as ADCC. In addition, some antibodies opsonize microbes
for complement-mediated killing of microbes (Parren and Burton, 2001). In contrast, T
cell-mediated immunity primarily targets intracellular microbes such as viruses and some
bacteria. Since intracellular microbes that survive and proliferate inside host cells are
usually inaccessible to circulating antibodies, this mechanism becomes the major means
to destroy intracellular pathogens (Fig. 3). During intracellular infection, phagocytes such
as macrophages sense danger signals and phagocytose the infected cells. Some CD4 T
cells are activated and differentiated into specific effector CD4 T cells to promote
phagocytosis of infected cells and killing of phagocytosed microbes by phagocytes (Fig.
3) (Constant and Bottomly, 1997). CD8 T cells are also activated and differentiated into
cytotoxic T lymphocytes (CTL). CTLs clear intracellular pathogens using their lytic
machinery (Fig. 3). In particular, CTLs induce the death of infected cells by granule- and
FAS- mediated pathways (Barry and Bleackley, 2002). CTLs release granules containing
lytic enzymes, especially granzyme B, perforin and granulysin to kill the infected cells.
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CTLs also express high levels of Fas ligand (FasL) on surface that bind to FAS of target
cells, which initiates a cell death cascade in cells infected with intracellular microbes.
Both antibody-mediated immunity and CTL-mediated immunity are indispensible for
adaptive immunity (Fig. 3).
The innate immune system and the adaptive immune system work in a highly
coordinated manner to fight off pathogens. The innate immune system controls the early
phase of infection while the adaptive immune system takes over prolonged infection,
chronic infection and long-term memory. Cellular and molecular components of the
innate immune system initiate and guide the activation of adaptive immunity. In turn, the
adaptive immune system, typically from the cytokines produced by CD4 T helper cells,
affect and “tune” the effector functions of the leukocytes and non-hematopoietic cells that
contribute to the innate immune system.

1.3 T and B Cell Development

Figure 4. T and B cell development (Adapted from Abbas et al., 2010)
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Lymphocytes, especially T cells and B cells, predominate adaptive immunity.
Lymphocytes arise from bone marrow where common lymphoid precursors differentiate
into B lymphocyte progenitors and T lymphocyte progenitors (Fig. 4) (Abbas et al.,
2010).

Figure 5. Thymocyte development (adaptive from Germain, 2002)
T lymphocyte progenitor cells migrate to the thymus where T cell development
takes place (Fig. 4 and 5) (Abbas et al., 2010; Germain, 2002; Zuniga-Pflucker, 2004).
Developing T cells in the thymus are called thymocytes. The early stage of thymocyte
development occurs in the thymic cortex. The most immature cortical thymocytes do not
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express CD4 or CD8, and are defined as double-negative (DN) cells (Fig. 5). DN1
(CD44+CD25-) thymocytes are at the most immature stage, and differentiate into and
DN2 (CD44+CD25+). When DN2 cells transition to DN3 (CD44-CD25+), rearrangement
of TCR β begins. This is mediated by a molecular process known as V(D)J
recombination.
The genetic locus that encodes TCR β chain includes N-terminal variable (V)
gene segments, diversity (D) segments and joint (J) segments (Fig. 6). Constant (C)
region genes are located just 3’ of the J segments in TCR β (Fig. 6). Two recombinases,
recombination-activating gene 1 (Rag 1) and recombination-activating gene 2 (Rag 2)
play essential roles in controlling the recombination. Specifically, Rag 1 and Rag 2
cleave the DNA sequence at the junction within the V segments, D segments and J
segments (Fig. 6) (Bassing et al., 2002; Fugmann et al., 2000; Gellert, 2002). These
broken ends are then further modified by the addition or removal of several bases. As a
result, greater levels of TCR junctional diversity are generated. The DNA doublestranded breaks (DSB) are subsequently brought together and ligated by a DNA repair
mechanism known as nonhomologous end joining (NHEJ) following a D-to-J
recombination followed by V-DJ joining (Fig. 6) (Bassing et al., 2002; Fugmann et al.,
2000; Gellert, 2002). Thus, one V segment, one J segment and one D segment in each T
cell rearrange and form a single VDJ gene that will code for the variable region of TCR
β chain (Fig. 6) (Abbas et al., 2010; Turner et al., 2006).
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Following the completion of TCR β chain rearrangement, TCR β chain pairs
with the surrogate α chain, pTα, to form pre-TCR. The signaling from functional preTCR prevents further TCRβ rearrangement on the opposite allele (allelic exclusion) and
promotes DN-to-DP transition (Borgulya et al., 1992; Fehling et al., 1995; von Boehmer
et al., 1998). In contrast, cells that fail to produce a functional pre-TCR are eliminated by
apoptosis. This process is referred to as β−selection (Dudley et al., 1994), which
functions as a quality check step that eliminates thymocytes that have made nonfunctional TCRs.
During β−selection, thymocytes progress to DN4 stage (CD44-CD25-) and
subsequently proliferate and differentiate into double-positive (DP) cells expressing both
CD4 and CD8 (CD4+CD8+) (Fig. 5). During DN4 to DP transitioning, thymocytes
rearrange their TCR α chain (Abbas et al., 2010). Rearrangement of TCR α chain is also
mediated by V(D)J recombination. However, in contrast to TCR β chain, only one V
segment and one J segment, but not D segment, rearrange and form a VJ gene for the
TCR α chain. Completion of TCR rearrangement at the DP stage results in the expression
of complete TCR α and β chains (Germain, 2002; Zuniga-Pflucker, 2004). Thus, each
individual T cell has a unique TCR containing a TCRα that is formed by randomly
recombined V and J segments and a TCRβ that consists of randomly recombined V, D
and J segments (Fig. 6). TCRβ locus contains 50 unique V segments, 12 J segments and
2 D segments that can be read in all 3 reading frames. In addition, TCRα locus also
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contains 45 unique V segments and 55 unique J segments. Through random
recombination of both α and β chains, as well as additional junctional diversity, T cells
develop as many as 1015-16 diverse TCRs in their antigen receptor repertoire (Abbas et al.,
2010; Bassing et al., 2002; Fugmann et al., 2000; Turner et al., 2006).
Following the completion of TCR formation, DP thymocytes go through
additional steps for their eventual maturation. DP thymocytes that are capable of
recognizing MHC class I or class II molecules survive and differentiate into single
positive (SP) CD8 or CD4 cells, respectively (Germain, 2002; Zuniga-Pflucker, 2004).
This is known as positive selection. In addition, cells also go through negative selection
step in which autoreactive T cells are eliminated by apoptosis (Germain, 2002; ZunigaPflucker, 2004). Therefore, single-positive (SP) CD4 or CD8 cells that do not respond to
self-antigens are capable of emigrating to peripheral lymphoid tissues for to participate in
adaptive immune responses through their activation through their highly-specific TCRs.
B lymphocyte progenitors go through several differentiation steps to generate
immature B cells in the bone marrow (Fig. 4), and go through additional maturation steps
in peripheral lymphoid organs such as lymph nodes and spleens to become mature naïve
B cells. During B cell development, BCR rearrangement is critical. The BCR is a
membrane-bound immunoglobulin M (IgM) protein. Each BCR consists of two Ig heavy
chains and two Ig light chains, coded by three separate loci, the IgM heavy chain locus,
the Ig κ light chain and the Ig λ light chain. Similar to TCRα and β chains, each Ig locus
21

also contains V segments, J segments and C region. Ig κ and λ loci do not have D
segments but Ig heavy chain has functional D segments (Bassing et al., 2002; Fugmann et
al., 2000). In the bone marrow, developing B cells utilize the same V(D)J recombination
mechanism used by T cells to generate antigen receptor diversity (Fugmann et al., 2000;
Schatz and Ji, 2011; Schatz et al., 1989; Schatz and Swanson, 2011). Ig rearrangement by
V(D)J recombination typically generates up to 1011 diverse BCRs in their antigen
receptor repertoire (Abbas et al., 2010). Therefore, after development and maturation, T
cells and B cells are patrolling and are ready to fight incoming infections.

Figure 6. TCR rearrangement (Adapted from Turner et al. 2006)

1.4 T Cell Activation
Although the adaptive immune system has a large antigen receptor repertoire,
the frequency of predetermined T cells that are specific to a given antigen is very low due
to the nature of T cell development. The primary goal of T cell activation is to generate a
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large number of functional antigen specific effector T cells from a small pool of naïve T
cells (Abbas et al., 2010; Cantrell, 1996; Smith-Garvin et al., 2009).
The activation of T cells requires antigen recognition (Abbas et al., 2010;
Cantrell, 1996; Smith-Garvin et al., 2009). CD4 T cells TCRs recognize the pathogenderived peptides presented by MHC class II molecules on APCs. However, CD8 T cells
TCRs recognize the peptides derived from cytoplasmic foreign proteins presented by
MHC class I molecules on APCs (Fig. 7) (Abbas et al., 2010). Antigen recognition by
TCR leads to a cascade of downstream phosphorylation events (Abbas et al., 2010;
Cantrell, 1996; Smith-Garvin et al., 2009). The downstream effects of T cell activation
are controlled by complex signaling cascades following TCR ligation (Fig. 8). Since TCR
has no intrinsic enzymatic activity, transduction of its signals instead depends on the
kinase activity of the Src family kinases (SFKs), particularly SFK member lymphocytespecific protein tyrosine kinase (Lck). Following TCR triggering, Lck phposphorylates
TCR-associated CD3 immunoreceptor tyrosine-based activation motifis (ITAMs) as well
as SYK family kinase ZAP70 (Artyomov et al., 2010; Brownlie and Zamoyska, 2013;
Veillette et al., 1988) (Fig. 8). Phosphorylated ZAP70 undergoes conformational change
that subsequently phosphorylates the key adaptor protein – linker for activation of T cells
(LAT) (Deindl et al., 2007) (Fig. 8). Phosphorylated ZAP70 then recruit multiple
signaling molecules that constitute a complex named the signalosome (Brownlie and
Zamoyska, 2013) (Fig. 8). LAT signalosome branches signaling into three major
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pathways, the Ca2+ signaling, the MAPK pathway and the NF-κB signaling, leading to
gene expression essential for the growth and survival of T cells during activation
(Brownlie and Zamoyska, 2013) (Fig. 8).
However, TCR signal itself is not sufficient to induce T cell activation. Instead,
T cells remain in a non-responsive state and fail to respond to restimulation when only
TCR signal is provided, known as anergy (Schwartz, 2003). A signal from costimulation
provides another critical signal to T cell activation for anergy avoidance and productive T
cell activation (Abbas et al., 2010; Cantrell, 1996; Smith-Garvin et al., 2009). A
costimulatory signal is provided by the stimulation of T cell surface CD28 molecule by
directly binding to B7 molecules, mostly B7-1 (CD80) and B7-2 (CD86), on APCs
(Acuto and Michel, 2003; Alegre et al., 2001). Costimulation promotes T cell
proliferation, cytokine production, cell survival and supportive cellular metabolism, all of
which are required for the full activation of T cells (Fig. 7) (Acuto and Michel, 2003).

Figure 7. T cell activation (Adapted from Alegre et al., 2001)
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In addition, CD4 and CD8 T cells produce growth factors especially interleukin2, to maintain the strength of T cell activation. A signal from IL-2 promotes the
expansion of antigen-specific T cells that share the same TCR specificity to antigens. IL2 also enhances the survival of T cells undergoing activation (Bachmann and Oxenius,
2007; Blattman et al., 2003; Boyman and Sprent, 2012; Feau et al., 2011). When these
activation signals are in place, naïve T cells acquire powerful functional switches,
including clonal expansion and differentiation into effector T cells (Abbas et al., 2010;
Cantrell, 1996; Smith-Garvin et al., 2009). During effector T cell differentiation, CD4 T
cells differentiate into effector helper cells and CD8 T cells differentiate into CTLs.

Figure 8. T cell activation signaling transduction (Adapted from Brownlie et
al.)

1.5 Effector CD4 T Cells
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Effector CD4 T cells are characterized by their ability to express and to produce
cytokines that help other immune cells such as B cells and macrophages (Abbas et al.,
2010; Zhou et al., 2009). Th1, Th2, Th17, induced regulatory T cells (iTreg) and Tfh
cells constitute the majority of effector CD4 T cell subsets (Magombedze et al., 2013;
Nurieva and Chung, 2010; Zhou et al., 2009). These different effector CD4 T helper cells
(Th) have different transcriptional and epigenetic signatures. They produce different
cytokines to determine their various effector functions in an immune response. The
diverse biologic activities of effector CD4 T cells determine the versatility of their
biological functions.
The fate of differentiation is predominantly governed by the priming cytokines
in the environment where CD4 T cells are activated, and to a minor extent, by the
strength of the interaction of TCR with APCs (Boyton and Altmann, 2002; O'Shea and
Paul, 2010; Zhou et al., 2009). A lot of work has been done to uncover the mechanism
that guides CD4 T cell differentiation and the functional outcomes of different T helper
subsets.
1.5.1 Th1 cells. Th1 differentiation is driven mainly by interleukin-12 (IL-12)
and IFNγ produced by APCs and innate cells during T cell activation (Szabo et al., 2003).
IL-12 signals through primarily the transcription factor Stat4 and subsequently upregulates IFNγ expression (Gately et al., 1998) (Fig. 9). In contrast, IFNγ signals through
Stat1 and induces the expression of transcription factor T-bet, the master regulator of Th1
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differentiation (Lighvani et al., 2001; Szabo et al., 2000; Zhang and Yang, 2000). T-bet
together with Stat4 modify epigenetic chromatin changes and program the activated CD4
T cells into fully determined Th1 subset (Fig. 9) (Lazarevic et al., 2013; Miller and
Weinmann, 2010; Szabo et al., 2000). Th1 cells secrete IFNγ, which promotes more Th1
differentiation and thus amplifies the reaction (Fig. 9). Th1 cells elicit their biological
function through IFNγ (Fig. 9). As an effector cytokine, IFNγ promotes phagocytosis and
degradation of intracellular pathogens. On phagocytes, IFNγ up-regulates the expression
of FcγRI receptors, which are used to uptake opsonized microbes. Also, IFNγ upregulates the expression of MHC molecules on macrophages, which in turn promotes
antigen presentation by APCs (Steimle et al., 1994). It also promotes the production of
reactive oxygen species for the oxidative burst-mediated killing. In addition, together
with several other cytokines, IFNγ induces the expression of several adhesion molecules
on endothelial cell surface to attract monocytes and effector T cells to the site of infection
(Schroder et al., 2004). Defects in several essential proteins in Th1 differentiation,
including IL12B, IL12RB1, STAT1, IFNGR1 and IFNGR2, result in susceptibility to
several life-threatening infections by intracellular pathogens, such as weakly virulent
mycobacteria such as BCG vaccines and environmental mycobacteria (Casanova, 2015;
de Beaucoudrey et al., 2010; Lammas et al., 2000).
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Figure 9. Effector CD4 T cell differentiation (Adapted from O’Shea and Paul, 2010)
1.5.2 Th2 cells. In contrast to Th1 cells, Th2 differentiation is promoted
predominantly by IL-4. Th2 differentiation occurs in response to allergens and parasitic
worms (Abbas et al., 2010; Ansel et al., 2006; Constant and Bottomly, 1997). They
largely dertermine the pathogenesis of allergic asthma and hypersensitivity disorders
(Barnes, 2001) (Kidd, 2003). IL-4 signals through the transcription factor Stat6, which,
together with nuclear factor of activated T cells (NFAT) and AP-1 activate the
transcription of the Il4 locus and the Th2 master regulator GATA3 (Ansel et al., 2006;
Zheng and Flavell, 1997) (Fig. 9). In addition, transcription factor c-maf also promotes
Th2 differentiation, including Th2-specific expression of the IL-4 gene in vivo (Ho et al.,
1998). Another source of IL-4 for initial priming comes from recently defined group 2
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innate lymphoid cell (ILC2) (Mirchandani et al., 2014). The differentiation of Th2 cells
results in autocrine feedback loop of IL-4 production, which further acts positively to
amplify Th2 differentiation (Ansel et al., 2006). IL-6 has also been shown to contribute to
Th2 polarization by up-regulating transcription factors NFAT and c-maf (Diehl et al.,
2002; Yang et al., 2005). During Th2 differentiation, the Il4 locus, which consists of Il4,
Il5 and Il13 genes, is epigenetically potentiated for strong transcriptional activities during
restimulation (Ansel et al., 2006; Zheng and Flavell, 1997) (Fig. 9). Th2 cells stimulate
high titers of IgE production through IL-4 (Kuhn et al., 1991; Snapper et al., 1991). IL-5
produced by Th2 cells stimulates hematopoietic production of eosinophils as well as the
activation of eosinophils (Allen and Sutherland, 2014; Constant and Bottomly, 1997;
Satoh et al., 1994). IL-13 is another effector cytokine produced by Th2 cells. Similar to
IL-4, IL-13 also promotes IgE production by B cells (Wynn, 2003). IL-13 is a central
mediator of Th2-mediated allergic asthma where it promotes mucus production in
pulmonary tracts and regulates eosinophilic inflammation (Wynn, 2003). IL-13 is also
important for worm expulsion and IgE-mediated elimination. Through these effector
cytokines, Th2 cells contribute to the development and progression of allergic asthma.
1.5.3 Th17 cells. Th17 cells are characterized as preferential producers of
interleukin-17A (IL-17A), interleukin-17F (IL-17F) and interleukin-22 (IL-22) (Bettelli
et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006). Th17 differentiation is primarily
triggered by the combination of TGF-β and IL-6 (Bettelli et al., 2006; Korn et al., 2009;
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Mangan et al., 2006; Veldhoen et al., 2006). However, the mechanistic interaction
between TGF-β and IL-6 in inducing Th17 is still not fully understood. TGF-β is
required for the full induction of the master transcriptional regulator of Th17 – the steroid
receptor-type nuclear receptor RORγt, a splicing variant of RORγ in T cells (Ivanov et al.,
2006; Manel et al., 2008). However, its expression and function is suppressed by excess
TGF-β. Only when IL-6 is present is RORγt relived from inhibition (Ivanov et al., 2006;
Manel et al., 2008). IL-6 signals through transcription factor Stat3, which contributes to
the expression of RORγt and another retinoid nuclear receptor family, RORα (Yang et al.,
2007). Both Stat3 and RORγt bind to Il17 promoters to up-regulate interleukin-17 (IL-17)
expression (Chen et al., 2006; Korn et al., 2009). RORγt also initiates the expression of
IL-23R during T cell activation, which confers interleukin-23 (IL-23) responsiveness. IL23 further matures Th17 cells and fulfills the terminal commitment of Th17 cells (Korn et
al., 2009). Th17 differentiation is inhibited by IL-4 and IFNγ (Korn et al., 2009). Th17
cells exert their biological functions through the production of IL-17A, IL-17F and IL-22.
IL-17A and IL-17F can exist as IL-17A homodimers, IL-17F homodimers and IL-17AIL-17F heterodimers (Liang et al., 2007; Ouyang et al., 2008). Both IL-17A and IL-17F
induce proinflammatory cytokines IL-6, granulopoietic factor G-CSF, chemokines
including IL8, MCP1, CXCL1, CXCL2 and CXCL5 in humans and mice (Fossiez et al.,
1996; Kawaguchi et al., 2001; Laan et al., 1999; Ouyang et al., 2008). Through the
induction of IL-8, IL-17 promotes the recruitment of neutrophils, especially in airways
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(Hoshino et al., 1999; Laan et al., 1999). In addition, IL-17 can also stimulate neutrophil
activity in the airway through inducing the release of IL-6 and IL-8 from bronchial
epithlium and fibroblasts (Fossiez et al., 1996). Similar to IL-17, IL-22 induces
proinflammatory cytokines primarily in epithelial cells. IL-22 drives the production of
many AMPs at mucosal surfaces or epidermal tissues (Ouyang et al., 2008; Wolk et al.,
2004). IL-17 signaling protects hosts from fungal infection. Human subjects who have
defects in Th17 pathway are more susceptible to mucocutaneous candidiasis (CMC) – a
recurrent infection with Candida albicans (Casanova, 2015; de Beaucoudrey et al., 2008;
Holland et al., 2007; Ling et al., 2015; Ma et al., 2008; Milner et al., 2008; Okada et al.,
2015; Puel et al., 2012; Renner et al., 2008). Through IL-17 and IL-22 production, Th17
cells play an important role in the pathogenesis of autoimmune diseases such as colitis,
multiple sclerosis, psoriasis and inflammatory bowel disease (Ouyang et al., 2008).
Consequently, a humanized anti-IL-17A antibody (secukinumab) has already been
approved in treating patients with psoriasis. Therefore, Th17 plays important role in host
defense and autoimmune diseases.
1.5.4 Tfh cells. Tfh – follicular helper CD4 T cells, are the specialized effector
CD4 T cells that provide help to B cell antibody production (Crotty, 2011). Interleukin21 (IL-21) is the major effector cytokine produced by Tfh cells (Crotty, 2011) and IL-6 is
the major factor that promotes IL-21 production in vitro (Dienz et al., 2009; Nurieva et al.,
2008; Suto et al., 2008). In vivo, both IL-6 and IL-21 seem to contribute to the generation
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of Tfh cells through the transcription factor Stat3 (Fig. 9) (Bryant et al., 2007; Crotty,
2011; Ettinger et al., 2005; Good et al., 2006; Kuchen et al., 2007; Ozaki et al., 2004;
Ozaki et al., 2002). IL-21 is the most potent cytokine in driving plasma cell
differentiation (Bryant et al., 2007; Crotty, 2011; Ettinger et al., 2005; Good et al., 2006;
Kuchen et al., 2007; Ozaki et al., 2004; Ozaki et al., 2002) (Fig. 10). IL-21 stimulates
Bcl6 expression in vivo in B cells (Ozaki et al., 2004). Germinal center formation is
impaired in mice deficient for IL-21 signaling (Ozaki et al., 2002). The B cells that are
activated in the abscense of IL-21 signaling are short-lived and have reduced somatic
mutations in their V regions accompanied by a reduced expression of activation-induced
cytidine deaminase (AID), suggesting that IL-21 is required for somatic affinity
maturation – a process that further increases antibody affinity to antigens (Ettinger et al.,
2005; Linterman et al., 2010; Yu et al., 2009; Zotos et al., 2010). Besides Bcl6, IL-21
induces Blimp-1 – another transcription factor important for the differentiation of plasma
cells (Johnston et al., 2009; Ozaki et al., 2004). In addition to naïve B cell differentiation,
IL-21 also differentiates memory B cells into antibody-producing plasma cells (Ettinger
et al., 2005). Thus, IL-21 guides the B cell antibody response in both primary and
secondary immune reactions.
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Figure 10. Tfh function (adapted from Ma et al., 2012)
As a signature of Tfh cells, they express high levels of the chemokine receptor –
CXCR5 (Breitfeld et al., 2000; Kim et al., 2001; Schaerli et al., 2000). CXCR5 on Tfh
receives CXCL13, a chemokine that recruits B cells to B cell zone of lymph nodes and
spleens, which guides Tfh cells to where B cells reside (Johnston et al., 2009; Kim et al.,
2001; Schaerli et al., 2000). The close proximity between B cells and Tfh cells brought
by CXCR5 signaling facilitates the B cell helper function of Tfh cells. In addition, Tfh
express ICOS on their surface that receives a signal from ICOS ligand (ICOSL)
expressed on the B cell surface. This interaction feeds back to Tfh cells to reinforce Tfh
differentiation and commitment (Nurieva et al., 2008). CD40L is also highly expressed
by Tfh cells and gives cognate interaction with corresponding B cells to promote B cell
activation, proliferation and survival (Crotty, 2011; Takahashi et al., 1998). In conclusion,
Tfh provides B cell help for protective antibody production through the expression of IL21 and unique surface molecules.
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1.5.5 Th9 and Th22 cells. In addition to Th1, Th2, Th17 and Tfh, several other
T helper subsets have been reported, such as Th9 and Th22. Th9 cells are characterized
as an IL-9-producing T cell subset. They are believed to be generated by a combination
of TGF-β and IL-4 during antigen stimulation (Kaplan, 2013; Schmitt et al., 2014). Th9
cells contribute to the immunopathology in allergy and several autoimmune diseases
through the production of IL-9, which increases mast cell numbers (Kaplan, 2013;
Schmitt et al., 2014). Th22 cells are characterized by IL-22 production, and were first
described in patients with epidermal hyperplasia (Akdis et al., 2012; Eyerich et al., 2009).
Since IL-22 induces keratinocyte proliferation and epidermal hyperplasia (Fujita, 2013),
targeting IL-22 and Th22 using blocking anti-IL-22 antibody has been an emerging
approach in treating patients with skin disorders such as atopic dermatitis (Nograles et al.,
2009). Interestingly, Th22 cells have been demonstrated to contribute to host protection
against enteropathogenic bacteria (Basu et al., 2012). Conclusively, defining whether Th9
and Th22 are committed to play more specific roles in host immune response and
autoimmune disease requires further investigations.
1.5.6 Treg cells. In contrast to most effector CD4 T cells that promote
inflammatory responses, a specific subset of cells called regulatory T cells (Treg)
suppress the magnitude of effector T cell responses and play a key role in the
establishment of immunological tolerance (Bilate and Lafaille, 2012). Natural Treg cells
(nTreg) are developed from the thymus during T cell selection, however, induced Treg
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cells (iTreg) come from mature T cells during T cell activation. The differentiation of
peripheral iTreg cells likely occurs in reponse to allergens, food, and the commensal
microbiota (Apostolou et al., 2002; Hsieh et al., 2006; Josefowicz et al., 2012;
Kretschmer et al., 2005). Strong TCR signals and suboptimal costimulatory signals
together with TGF-β induce the differentiation of iTreg (Josefowicz et al., 2012). IL-2 is
also required for the expansion of Treg cells (Davidson et al., 2007; Horwitz et al., 2008).
The coordinated contributions of the aforementioned signals lead to the expression of the
master regulator of iTreg – Forkhead box P3 (Foxp3) (Fig. 9). Mutations in human Foxp3
causing iTreg deficiency result in IPEX (immune dysregulation, polyendocrinophathy,
enteropathy, X-linked) syndrome (Bennett et al., 2001; Brunkow et al., 2001; Chatila et
al., 2000; Wildin et al., 2001).
The iTreg-induced immunologic suppression is primarily mediated by several
mechanisms. iTreg cells express CTLA-4 on their surface. CTLA-4 directly interacts
with costimulatory molecules CD80 and CD86 on APCs, leading to the transendocytosis-mediated down-regulation of CD80/CD86 on APCs (Qureshi et al., 2011).
APCs with less costimulatory ligands have less potency in activating T cells. iTreg cells
can also provide negative signals to responder effector Th cells via the up-regulation of
cyclic AMP (cAMP), which leads to the inhibition of T cell proliferation (Bopp et al.,
2007). In addition, some studies have proposed that since iTreg express high levels of IL2 Receptor α (CD25) on their surface, they may deprive T cells of IL-2 – a cytokine
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important for the survival and expansion of other effector T cells (Josefowicz et al., 2012;
Pandiyan et al., 2007). Importantly, novel therapeutic approaches in treating autoimmune
diseases have been developed or are under development by manipulating Treg functions
(Riley et al., 2009).

1.6 Effector CD8 T Cells
Effector CD8 T cells (CTLs) combat infection through two major mechanisms –
the cytolysis of infected cells and the release of effector cytokines (Harty et al., 2000).
CTLs produce the pore forming protein perforin and serine protease granzymes. Perforin
and granzymes largly determine the cytolytic activities of CTLs. Perforin initially binds
to and oligomerizes on the membrane to form a pre-pore structure of many monomers.
Following pre-pore formation, monomers undergo conformational changes that lead to
unwinding and insertion into the membrane to assemble a pore (Voskoboinik et al., 2010).
The formation of pores enables serine proteases, especially granzymes, to diffuse into the
cytosol of infected target cells (Voskoboinik et al., 2010; Voskoboinik et al., 2015).
Granzyme B induces apoptosis following a caspase cascade in target cells by cleaving
target cell proteins at aspartate residues (Heibein et al., 2000; Voskoboinik et al., 2010;
Voskoboinik et al., 2015). Granzyme A cleaves proteins at sites after basic amino acids,
and inducing a slower form of cell death (Voskoboinik et al., 2015). In addition to
granzymes, CTLs also express another effector protein in their granules, known as
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granulysin. Granulysin is a small antibacterial toxin that is expressed by CD8 T cells in
human but not rodents (Pena et al., 1997). Similar to granzymes, the functions of
granulysin are also dependent on the presence of pores mediated by perforin
(Voskoboinik et al., 2010; Voskoboinik et al., 2015). However, unlike granzymes,
granulysin kills intracellular bacteria directly by disrupting their membrane lipid layers
(Voskoboinik et al., 2015).
In addition, Fas and Fas ligand (FasL) make up another important pathway in
CTL-mediated cytolysis. FasL or CD95L is a transmembrane protein that belongs to the
TNF family. Its binding with its receptor, Fas, induces apoptosis (Nagata, 1999). CTLs
express high levels of FasL on their cell surface. When CTLs recognize infected target
cells, FasL on the CTL surface binds to the Fas on target cells, leading to the activation of
caspases and subsequently apoptosis of target cells (Nagata, 1999). In perforin-deficient
mice, the Fas/FasL pathway is sufficient to clear influenza virus infection in lung
epithelia, suggesting that Fas/FasL provides a nonredundant mechanism for CTLmediated cytolysis (Topham et al., 1997). Thus, CTL-mediated cytolysis through
perforin/granzymes, Fas or granulysins are the predominant mechanisms in controlling
intracellular infection.
In addition to cytolysis of target cells, effector CD8 T cells also elicit their
function through the production of cytokines. After antigen recognition or restimulation,
the major cytokines that effector CD8 T cells produce are IFNγ and TNF (Harty et al.,
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2000). As discussed above, IFNγ promotes phagocytosis, degradation of intracellular
pathogens and enhances antigen presentation in macrophages. IFNγ contributes to
resistance to several viral infections. In IFNγ Receptor (IFNγR) deficient mice, LCMVspecific CD8 T cells have a delayed in cellular response, leading to delayed virus
clearance (Harty et al., 2000; Lohman and Welsh, 1998). Several severe viral infections,
including herpes virus infection, pareinfluenza virus infection and respiratory syncytial
virus infection, were found in children with IFNγR deficiency (Dorman et al., 1999).
CD8 T cell derived IFNγ is also critical in immunity to intracellular bacteria such as
Chlamydia infection (Lampe et al., 1998). TNF derived from CD8 T cells contributes to
CTL-mediated immunity by promoting the maximal activation of antibacterial activities
in macrophages against listeria (Portnoy et al., 1989).
Although IFNγ and TNF are the major cytokines produced by effector CD8 T
cells, other cytokines including IL-4, IL-5 and IL-17 are produced by effector CD8 T
cells, but only when cells encounter the appropriate environment. Together with other
cytokines and blocking antibodies, the presence of IL-4 during effector CD8 T cell
generation promotes the differentiation of CD8 T cells into Tc2 cells that make IL-4 and
IL-5 (Croft et al., 1994; Seder et al., 1992). Compared with regular CTLs, Tc2 cells are
less capable of target cell killing (Cerwenka et al., 1998; Cerwenka et al., 1999;
Dobrzanski et al., 1999, 2001). IL-4 and IL-5 derived from Tc2 cells could lead to a local
elevation in lung-derived chemoattractants and subsequently the accumulation of
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lymphocytes. This results in efficient lung tumor rejection (Dobrzanski et al., 2001). An
effector CD8 T cell subset analogous to Th17 has also been identified when IL-2, IL-1β,
IL-6, TGF-β, IL-21, IL-23 and blocking anti-IL-4 and anti-IFNγ antibodies are added to
naïve CD8 T cells during activation (Hamada et al., 2009). Tc17 cells are present during
primary immune responses to influenza A virues. However, in contrast to CTLs and Tc2,
Tc17 cells are less efficient in cytolytic activities due to their low expression of granzyme
B and perforin (Hamada et al., 2009). IL-17 derived from Tc17 cells promotes local
inflammation, accompanied by an increased neutrophil infiltration (Hamada et al., 2009).
Tc17 cells also play important roles in the pathogenesis of autoimmune diseases,
especially psoriatic skin disease (Cheuk et al., 2014; Liang et al., 2015; Res et al., 2010).
However, CD8 effector T cells that are analogous to other effector CD4 T cells, such as
Tfh, are still not known. In this thesis, we show for the first time that a subset of CD8 T
cells also differentiate into effector cells that produce IL-21 when IL-6 is present. These
IL-21-producing CD8 T cells contribute to B helper cell function by promoting protective
antibody production in vitro and in vivo.

1.7 T Cell Memory Response
Adaptive immunity has an ability to “remember” and respond more vigorously
to the same pathogens to which they are repeatedly exposed. During clonal expansion, T
cell activation generates long-lived memory cells, which mount more vigorous immune
39

responses than naïve T cells. These long-lived memory cells are suggested to provide
life-long protection against pathogens (Farber et al., 2014; Mueller et al., 2013). Memory
T cells confer immediate protection in peripheral tissues during recall responses to the
antigen that the immune system experienced previously (Sallusto et al., 2004). Memory T
cells consist of effector memory T cells (TEM) and central memory T cells (TCM) (Sallusto
et al., 2004). TCM cells are believed to be long-lived memory cells, whereas TEM cells are
short-lived but respond rapidly to re-infecting pathogens (Sallusto et al., 2004). While
TEM mediates protective memory by displaying immediate effector function in inflamed
peripheral tissues, TCM that home to spleens or lymph nodes confer reactive memory by
proliferating and differentiating into effector cells in response to antigenic stimulation
(Farber et al., 2014; Mueller et al., 2013; Sallusto et al., 2004). TCM are memory cells that
have constitutive CCR7 and CD62L expression. The expression of chemokine receptor
CCR7 guides TCM migration to T cell areas of secondary lymphoid organs (Campbell et
al., 1998; Forster et al., 1999).
In contrast to naïve T cells, TCM activation is less dependent on the
costimulatory signal. Immediately following TCR triggering, TCM expand clonally and
differentiate into a highly heterogeneous population of effector cells. Some TCM cells can
be induced to differentiate into Th1 or Th2 cells upon restimulation in the presence of
different priming cytokines, while some cells remain in a noneffector stage under neutral
conditions (Sallusto et al., 2004). Thus, upon restimulation, TCM cells produce a mix of
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heterogeneous cytokines including IL-2, IL-4, IFNγ and others. Instead, TEM cells retain
their pre-determined effector cell phenotype upon re-challenge. Compared with TCM, TEM
are characterized by rapid effector function without further differentiation steps. For
example, TEM CD8 T cells already carry large amounts of perforin, which make them
ready for immediate effector function. The relative proportions of TCM and TEM vary in
CD4 and CD8 T cells. TCM is predominant in CD4 T cells but TEM predominates CD8 T
cells (Sallusto et al., 2004). Memory T cells persist in the immune system. Their
prolonged survival is dependent on the increased expression of antiapoptotic proteins and
their ability to self-renew, both of which are mediated by cytokines. Memory T cells
express high levels of interleukin-7 receptor (IL-7R or CD127), which constantly receive
the signal from IL-7 for the maintenance of memory T cells. IL-15 is another cytokine
that is critical for memory T cells persistence (Schluns and Lefrancois, 2003). All these
mechanisms secure that memory cells can provide optimal defense against pathogens that
are repeatedly encountered (Abbas et al., 2010; Farber et al., 2014; Mueller et al., 2013;
Sallusto et al., 2004).

1.8 B Cell Activation and Function
The B cell is the dominant player in antibody response – an immune process
that generates five different immunoglobulin (Ig) isotypes, including IgM, IgD, IgG, IgE
and IgA, to fight off pathogens. IgM plays important role in protecting against bacteria
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with polysaccharide-rich capsules. IgM binds to the bacterial surface and subsequently
activates the complement system to induce phagocytosis and lysis of bacteria. IgG blocks
the entry of many viruses and bacteria and also promotes phagocytosis by macrophages.
IgG is also the major protective antibody following vaccination. In addition, as one of the
most abundant proteins in human serum, IgG can be further divided into 4 subclasses in
humans (IgG1, IgG2, IgG3 and IgG4) and 3 subclasses in mice (IgG1, IgG2 and IgG3)
(Schur, 1988; Vidarsson et al., 2014). However, the functional difference among the 4
IgG subclasses is still not clear (Schur, 1988; Vidarsson et al., 2014). IgE participates in
eosinophil-mediated immunity against helminths. IgA is produced by some B cells in
mucosal tissues. It is the antibody class that is most efficiently transported by the
polymeric immunoglobulin receptor through epithelial cells into the mucosal lumen,
where IgA directly prevents mucosa from infections (Schroeder and Cavacini, 2010).
Prior to any stimulation, naïve B cells express BCR (also known as IgM and
IgD) on their cell surface (Abbas et al., 2010). During antigen encounter or B cell
activation, naïve B cells begin to proliferate clonally and produce IgG, IgE and IgA rather
than IgM and IgD. Especially, a large portion of B cells differentiate into plasma cells
that specialize in producing large amounts of high affinity IgG antibodies for long
periods of time.
B cell activation is controlled by signals from BCR, CD40, TLRs, and cytokine
receptors in a highly coordinated manner (Pone et al., 2010; Xu et al., 2012). These B cell
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activation signals are separated into T cell dependent and T cell independent stimuli (Fig.
11) (Pone et al., 2010; Xu et al., 2012). BCR crosslinking – a T cell independent stimulus
provides an important type of B cell activation signal. When several BCRs on the same
cell recognize a microbial product, Igα, Igβ, CD19, CD21, CD81 and adaptor proteins
are brought together to form the BCR complex that initiates downstream signaling (Fig.
11) (Abbas et al., 2010; Pone et al., 2010; Xu et al., 2012). This leads to the activation of
PI3K and PLCγ2 pathways. NF-κB is also activated to induce expression of important
maturation and differentiation proteins.
However, BCR signal per se is not sufficient to induce full activation of B cells.
Instead, it synergizes with signals from other stimuli including CD40, TLRs and cytokine
stimulation to induce final B cell activation and differentiation (Abbas et al., 2010; Pone
et al., 2010; Xu et al., 2012). The engagement of CD40 on B cells by CD40L expressed
by Tfh cells provides another important stimulus in a T cell-dependent mechanism
(Abbas et al., 2010; Grivennikov et al., 2006; Pone et al., 2010; Xu et al., 2012). In B
cells, CD40 signal is required for a variety of T-dependent B cell activation, germinal
center reaction, antibody production, plasma and memory B cell differentiation (Fig. 11)
(Abbas et al., 2010; Cerutti et al., 1998; Elgueta et al., 2009; Kawabe et al., 1994; Klaus
et al., 1997; Pone et al., 2010; Xu et al., 2012). Another TNFR superfamily member –
transmembrane activator and CAML interactor (TACI), transduces T cell independent
signals (Fig. 11). TACI binds both BAFF and APRIL (Abbas et al., 2010; Pone et al.,
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2010; Xu et al., 2012), which are both TNF trimers produced by innate immune cells and
epithelial cells (Abbas et al., 2010; Pone et al., 2010; Xu et al., 2012) that enhance B cell
differentiation and activation (Castigli et al., 2005; He et al., 2006; He et al., 2003;
Sakurai et al., 2007). Additionally, TLR signaling, another important type of T cell
independent stimuli, is essential in B cell activation (Fig. 11). Most TLRs are highly
expressed in B cells. These TLRs respond to the stimulation from TLR ligands expressed
by pathogens, damaged tissues or other PAMPs or DAMPs. TLR engagement by PAMPs
such as LPS or CpG DNA induces B cell proliferation and differentiation through TLR4
and TLR9, respectively (He et al., 2004; Krieg, 2006; Pasare and Medzhitov, 2005). TLR
stimulation of B cells in combination with cytokines drives the production of antibodies
with specific isotypes (Fig. 11) (Abbas et al., 2010; Pone et al., 2010; Xu et al., 2012).

Figure 11. B cell activation signals (Adapted from Xu et al., 2012)
Cytokines direct B cell antibody isotype specificity in combination with primary
B cell activation stimuli such as TLRs signals. During B cell primary activation provided
by stimuli such as CD40 or LPS engagement, IL-4 induces the activation of transcription
factor Stat6 that binds to Iγ1 and Iε promoters to induce the production of IgG1 and IgE
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(Abbas et al., 2010; Pone et al., 2010; Xu et al., 2012). TGFβ induces the switch to IgG2b
and IgA by stimulating Smud and Runx, which bind to Iγ2b and Iα promoters,
respectively (Stavnezer et al., 2008). Intriguingly, IL-21 seems a master regulator of the
production of all IgG isotypes (Ozaki et al., 2002). Mice deficient in IL-21 signaling
have impaired antibody production in all IgG isotypes (Ozaki et al., 2002). In summary,
B cell stimuli work in a synergistic way to modulate B cell activation.

1.9 B Cell Class Switch Recombination and Somatic Hypermutation
During B cell activation, antibody production switches from IgM and IgD in
naïve cells to IgG, IgA and IgE in activated B cells. This switch is mediated by a
molecular process known as class switching recombination (CSR) (Abbas et al., 2010;
Kinoshita and Honjo, 2001). Specifically, during CSR, VDJ exons that encode an Ig
heavy chain V domain recombines with a specific downstream C region gene and the
intervening DNA is deleted (Fig. 12). This is mediated by the activation-induced
deaminase (AID) (Di Noia and Neuberger, 2007). The CSR occurs at specific nucleotide
sequence located in the introns between J and each C segment (Cµ, Cγ, Cε, Cα segments
– encoding for constant region for IgM, IgG, IgE and IgA, respectively) (Abbas et al.,
2010; Kinoshita and Honjo, 2001). Briefly, at both switch regions for Cµ region and
particular heavy chain locus (one of the Cµ, Cγ, Cε, Cα segments) determined by B cell
activation and cytokine environment, double-stranded breaks (DSBs) are generated by
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AID-mediated deamination followed by a DNA-repair mechanism (Abbas et al., 2010;
Kinoshita and Honjo, 2001). Subsequently, the DSBs at the Cµ region and downstream
particular switch region are joined together by NHEJ repair (Fig. 12). For instance, in IL4 stimulated activating B cells, in addition to the DSB at the Cµ region, IL-4 guides the
AID to generate the other DSB at the Cε switch region, and eventually, a Ig locus specific
for IgE transcription but containing the same V region as that of the original IgM is
recombined and generated by NHEJ repair (Fig. 12) (Abbas et al., 2010; Kinoshita and
Honjo, 2001).

Figure 12. Class switch recombination. (Adapted from Kinoshita and Honjo, 2001)
Following B cell activation and CSR, as the antibody response develops,
activated B cells that produce antibodies in the dark zone of germinal centers undergo a
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cellular process that increases the affinity of antibodies to antigens by mutating Ig heavy
chain variable region at very high rates, known as somatic hypermutation (SHM). The
key enzyme required for SHM is also AID (Di Noia and Neuberger, 2007). SHM is
induced by CD40 signal provided by helper CD4 T cells (Di Noia and Neuberger, 2007).
AID converts C residues of the V region to U residues for mutation. This process induces
high frequency and random mutations at the V region (Di Noia and Neuberger, 2007).
Activated germinal center B cells with a mutated V region express a large pool of
different surface Abs in germinal centers where antigens are displayed to these B cells. B
cells with high affinity survive but cells with insufficient affinity are selected out (Di
Noia and Neuberger, 2007). Thus, through SHM, B cells not only further broaden their
antibody diversity but also largely increase the antibody affinity to specific antigens
(Abbas et al., 2010; Di Noia and Neuberger, 2007). In summary, activated B cells
undergo a series of steps, including CSR and SHM, to eventually develop into producers
of highly diverse antibodies with strong affinity to antigens.
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2. Interleukin-6

2.1 Interleukin-6 and Its Expression
Interleukin-6 (IL-6) was originally identified in 1988 as a B cell growth factor
due to its positive effects on promoting plasma cell growth, and was initially named
stimulator factor 2, hybridoma/plasmacytoma growth factor, IFN-β2 and hepatocytestimulating factor (Hirano et al., 1986; Kishimoto, 2005, 2010; Tanaka and Kishimoto,
2012). IL-6 is produced in response to a wide variety of stimuli by a broad spectrum of
cells, including leukocytes, such as macrophages, neutrophils, dendritic cells, mast cells
and B cells (Hirano, 1998), and also non-leukocytes such as epithelial cells, astrocytes,
epithelial cells, fibroblasts and cancer cells (Hirano, 1998; Kishimoto, 2005). The
transcriptional regulation of the IL-6 gene is complex and involves several different
transcription factors. The expression of IL-6 is triggered by a variety of stimuli including
UV, irradiation, ROS, microbial products, viruses or pro-inflammatory cytokines
(Rincon, 2012).
The promoter region of the IL-6 gene contains multiple response elements,
including a cyclic AMP (cAMP) response element site (CRE), NF-κB binding sequence,
CCAAT enhancer/binding protein (C/EBP) element, and an activator protein-1 (AP-1)
site (Fig. 13) (Cahill and Rogers, 2008; Hershko et al., 2002; Matsusaka et al., 1993;
Xiao et al., 2004). NF-κB is a potent transcription factor in inducing IL-6 expression in
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response to a variety of stimuli that activate TLR signaling such as LPS and doublestranded RNA poly I:C, as well as TNFα and PMA (Libermann and Baltimore, 1990;
Zhang et al., 1990). NF-κB binds to the -73 to -64 position in the promoter region of the
IL-6 gene (Libermann and Baltimore, 1990). A number of studies using genetic
approaches to activate or inhibit NF-κB signaling demonstrated that NF-κB is a key
transcription factor for the induction of IL-6 gene expression (Filipe-Santos et al., 2006;
Ngo et al., 2011; Picard et al., 2011; Strober et al., 2006; Ting et al., 2006). In humans,
loss-of-function mutations in genes that act as negative regulators of NF-κB signaling
leads to autoinflammatory diseases accompanied by increased IL-6 production (Strober et
al., 2006; Ting et al., 2006). In contrast, loss-of-function mutations of NEMO, an IKK
complex subunit, impairs IL-6 production (Filipe-Santos et al., 2006).

Figure 13. IL-6 promoter (Adapted from Juretic et al., 2006)
C/EBP protein is another important transcription factor in regulating IL-6
expression. In the 1980s, molecular biologists found that transcription factor C/EBPβ or
NF-IL-6 binds to the IL-6 promoter region and strongly induces IL-6 expression in
response to IL-1 stimulation. Recombinant C/EBPβ binds to a C/EBP element in the IL-6
promoter to induce IL-6 expression in vitro (Fig. 13) (Akira et al., 1990; Akira and
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Kishimoto, 1992). C/EBPβ is not normally expressed in cells. However, stimuli such as
LPS, TNF and IL-1 can stimulate the expression of C/EBPβ in vitro (Akira et al., 1990;
Akira and Kishimoto, 1992). In addition to its role in IL-6 induction, C/EBPβ also drives
expression of downstream genes regulated by IL-6 (Akira and Kishimoto, 1992). For
example, C/EBPβ is important for the expression of acute phase genes in response to IL6 (Akira and Kishimoto, 1992). C/EBPβ also directly associates with p65 of NF-κB,
leading to the synergistic activation of both C/EBP element and NF-κB binding element
in the IL-6 promoter region (Matsusaka et al., 1993). Although the molecular
mechanisms by which C/EBPβ induces IL-6 expression have been desmonstrated, the
role of C/EBPβ in IL-6 induction in vivo was questioned by the finding that C/EBPβ
deficient mice have higher circulating IL-6 (Screpanti et al., 1995).
In addition to NF-κB and C/EBPβ, other mechanisms have also been proposed
to induce IL-6 expression. A cyclic AMP response element (CRE) site has been identified
in the IL-6 promoter region (Fig. 13). Vasoactive intestinal peptide induces IL-6
expression in cortical astrocytes through cAMP and protein kinase A (PKA) activation
(Schettini et al., 1994). The cAMP response element binding protein (CREB) is
subsequently phosphorylated by activated protein kinase A (PKA) and this canonical
pathway leads the binding of CREB to the CRE site in the IL-6 promoter and IL-6
expression (Fig. 13). An AP-1 binding site is also present in IL-6 promoter, suggesting
that AP-1 also contributes to IL-6 induction (Fig. 13) (Grassl et al., 1999).
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IL-6 expression is also negatively regulated by several pathways, among which
steroid hormone receptors (e.g. estrogen and glucocorticoids receptors) are the most well
understood. Estrogen receptors, upon stimulation, prevent the binding of the transcription
factors c-rel and RelA (subunits of NF-κB) to the IL-6 promoter and thus, suppress IL-6
expression (Galien and Garcia, 1997; Liu et al., 2005; Ray et al., 1990).
In addition to transcriptional regulation of IL-6 gene expression, IL-6
production is also regulated through post-transcriptional mechanisms. IL-6 mRNA
stability has an important role in the levels of IL-6 production. The AU-rich elements
(AREs) in the 3’-untranslated region (UTR) of IL-6 mRNA largely determine the
stability of IL-6 mRNA. p38 MAPK interacts with and phosphorylates ARE binding
proteins, especially ARE1, ARE2 and ARE5, that subsequently interact with and stabilize
IL-6 mRNA (Winzen et al., 1999; Zhao et al., 2008). IL-6 mRNA stabilization can also
be mediated by the phosphorylation of MAPK–activated protein kinase 2 (MK2). p38
MAPK is required for the activation of MK2 (Neininger et al., 2002). IL-6 protein levels
are also regulated at the translational level. In human keratinocytes, p38 MAPK activates
MAPK integrating kinase-1 (MNK1) in response to IL-1β stimulation. Activated MNK1
phosphorylates the eukaryotic initiation factor 4E (eIF4E), which subsequently binds to
the 5’ capping region of IL-6 transcript to initiate translation (Kjellerup et al., 2008;
Rowlett et al., 2008). This mechanism was also found to be critical in fungal extractmediated IL-6 translation in lung epithelial cells (Neveu et al., 2011). Thus, multiple
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mechanisms involving both transcriptional and post-transcriptional regulation determine
the production of IL-6.

2.2 Interleukin-6 Signaling Pathway
The IL-6 Receptor (IL-6R) was cloned soon after the discovery of IL-6
(Kishimoto, 2005; Yamasaki et al., 1988), and is an 80 kDa protein that binds IL-6
directly. IL-6R expression is restricted to leukocytes and hepatocytes (Rincon, 2012). The
presence of only a very short cytoplasmic domain within IL-6R led to the hypothesis that
there could be another partner that serves as signal transducer (Kishimoto, 2005). A
surface glycoprotein of 130 kDa was precipitated with IL-6R in response to IL-6
stimulation. This protein was identified as the signal transducer associated with IL-6R,
known as gp130 (Hibi et al., 1990). Although IL-6R expression is restricted, gp130 has a
ubiquitous pattern of expression (Hibi et al., 1990). gp130 is not a specific partner of IL6R. It also associates with other cytokine receptors to mediate signals triggered by
cytokines including interleukin-11 (IL-11), leukaemia inhibitory factor (LIF), oncostatin
M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CTF1) and
cardiotrophin-like cytokine (CLC) (Heinrich et al., 2003).
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Figure 14. Crystal structure of IL-6-IL-6Rα-gp130 complex (adapted from
Boulanger et al., 2003)

The crystal structure of the extracellular IL-6 signaling complex reveals a
hexameric, interlocking assembly of IL-6, IL-6Rα and gp130 (Fig. 14) (Boulanger et al.,
2003). IL-6 is first engaged by IL-6Rα, and then presented to gp130 to facilitate the
formation of a high-affinity hexamer that comprises two IL-6, two IL-6Rα and two
gp130 molecules (Fig. 14) (Boulanger et al., 2003). The formation of the hexameric IL-6
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signaling complex triggers the activation of Janus kinase (JAK) family proteins,
especially JAK1, JAK2 and Tyk2 (Heinrich et al., 2003; Lutticken et al., 1994; Stahl et
al., 1994). Among these three JAK kinases, JAK1 is the predominant kinase, because in
cells lacking JAK1, IL-6 signal transduction is almost completely abolished (Guschin et
al., 1995; Rodig et al., 1998). Tyk2 does not seem to be involved in IL-6 signaling
(Kreins et al., 2015).
Activated JAKs lead to the phosphorylation and activation of the major
transcription factor regulated by IL-6, Stat3 (Akira et al., 1994). Stat3 is phosphorylated
at two well-studied phosphorylation sites, Tyr705 and Ser727. The inactive form of Stat3
mostly remains in the cytoplasm, but after Tyr705 phosphorylation by JAKs, Stat3 forms
homodimers that are actively transported to the nucleus to induce downstream gene
transcription (Fig. 15) (Zhong et al., 1994b). Stat1 has also been suggested to be involved
in IL-6 signaling, although to a lesser extent (Gerhartz et al., 1996; Zhong et al., 1994a).
Stat3 forms heterodimers with Stat1 in response to IL-6. However, the physiology of
Stat1:Stat3 heterodimers is less known (Zhong et al., 1994a). The phosphorylation of
Ser727 is also induced by IL-6 stimulation. Regulation of Ser727 phosphorylation is more
complex as different activation signals lead to serine phosphorylation by different
kinases, including ERK1, ERK2, p38, JNK and MAP kinases (Decker and Kovarik,
2000). Ser727 phosphorylation at the trans-activating domain is considered a secondary
event after phosphorylation of Tyr705 and is required for the maximal transcriptional
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activity of Stat3 (Wen et al., 1995). Surprisingly, Stat3 (mitoStat3) was also found
localized in mitochondria, where it functions as a positive regulator of the mitochondrial
electron transport chain (ETC) (Gough et al., 2009; Wegrzyn et al., 2009). Although not
clearly established, IL-6 signaling contributes to mitoStat3 regulation in pancreatic cells
(Kang et al., 2012a; Kang and Tang, 2012; Kang et al., 2012b). In this thesis, we
demonstrate for the first time that IL-6 contributes to ETC activity and mitochondrial
functions in T cells through the regulation of mitoStat3 and provide a new mechanism
through which IL-6 contributes to T cell effector function.

Figure 15. IL-6 signaling pathway (Adapted from Dienz and Rincon, 2009)
In addition to STAT family members, IL-6 stimulation also activates transcription
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factors C/EBPβ and C/EBPδ (Poli, 1998; Ramji et al., 1993). Signaling through IL-6R
complex activates the Ras/Erk MAPK cascade through the protein Src homology protein2 tyrosine phosphatase-2 (SHP-2) (Fig. 15) (Dienz and Rincon, 2009), phosphorylateing
C/EBPβ to stimulate the expression of genes, including C/EBPδ (Dienz and Rincon, 2009;
Ramji et al., 1993). C/EBP transcription factors activated by IL-6 signaling also bind to
the C/EBP binding element in the NFATc2 promoter region to up-regulate NFATc2
expression in hepatocytes (Fig. 15) (Yang et al., 2006). Additionally, the IL-6R complex
also triggers the activation of phosphatidylinositol 3-kinase (PI3K) that subsequently
phosphorylates protein kinase B (also known as Akt) to promote cell proliferation and
survival (Chen et al., 1999; Wegiel et al., 2008).
In addition to classical IL-6 signaling through the membrane IL-6R complex,
IL-6 trans-signaling is another mechanism by which cells transduce IL-6 signaling (RoseJohn, 2012). Although IL-6Rα expression is restricted to hepatocytes and leukocytes,
cells that do not have IL-6Rα also respond to IL-6 in vivo, contributing to the pleiotropy
of this cytokine. This is mediated by a soluble form of IL-6Rα (sIL-6R) (Novick et al.,
1989; Rose-John, 2012). In humans, the sIL-6R can be generated by proteolysis of the
membrane bound receptor by the matalloproteases ADAM10 and ADAM17, a process
known as shedding, and by translation of a differentially spliced mRNA (Lust et al., 1992;
Mullberg et al., 1993). However, in mice, only shedding but not alternative splicing is
characterized (Rose-John, 2012).
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The sIL-6R binds IL-6 with comparable affinity as the membrane bound IL6Rα. IL-6-sIL-6R complexes engage gp130 on cell surface to transduce cellular signaling
(Rose-John, 2012). Targeting IL-6-trans-signaling using a soluble gp130 fusion protein
gp130Fc has shown some benefits in treating some autoimmune diseases. gp130Fc is
now in clinical trials treating patients with Crohn’s disease (Jones et al., 2011). In
addition, tocilizumab (commercially known as Actemra), a humanized monoclonal
antibody targeting IL-6R, has been widely used in treating patients with rheumatoid
arthritis, Castleman’s disease and Systemic Juvenile Idiopathic Arthritis (Tanaka and
Kishimoto, 2012). Tocilizumab is highly efficient in blocking not only membrane IL-6
signaling but also the trans-signaling by sIL-6R (Tanaka and Kishimoto, 2012).

2.3 IL-6 Function in the Innate Immune Response
Elevated serum IL-6 levels are associated with several inflammatory diseases
and infections. Thus, many scientists and physicians believed for a long time that IL-6
was a byproduct of the inflammatory response and a marker of inflammation (Rincon,
2012). However, we now know that IL-6 is essential for a functional immune response
rather than just a byproduct. IL-6 is produced by a broad spectrum of cell types in
response to microbial products and tissue damage. Thus, IL-6 is produced at early phase
of an immune response. Importantly, IL-6 elicits some important functions in the innate
immune reaction. IL-6 is the major inducer of acute phase protein synthesis in liver
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(Heinrich et al., 2003; Heinrich et al., 1990; Schultz and Arnold, 1990). IL-6 also
promotes neutrophil recruitment and survival. IL-6-sIL-6R complex stimulates
endothelial cells to express chemokines for neutrophils such as IL-8 and also adhesion
molecules, indicating that IL-6 signaling contributes to neutrophil recruitment to the site
of infection (Romano et al., 1997). IL-6 is also essential for the resolution of influenza
infection by protecting neutrophils from virus-induced apoptosis (Dienz et al., 2012). In
addition, IL-6 prevents neutrophils from apoptosis in osteomyelitis (Asensi et al., 2004).
Thus, IL-6 contributes to some aspects of the innate immune response.

2.4 IL-6 Function in B cells
Early studies identified IL-6 as a B cell growth factor that induces the
maturation of B cells into antibody-secreting cells (Kishimoto, 2005, 2010; Tanaka and
Kishimoto, 2012). IL-6 was shown to enhance antibody production in a B cell line and
support the growth of B cell neoplasms (Hirano et al., 1986; Kallen et al., 1999;
Suematsu et al., 1989). Likewise, IL-6-deficient mice have an impaired IgG production
upon immunization (Kopf et al., 1994). IL-6 has also been linked to B cell biology in
clinical situations, among which Castleman’s disease is the most apparent (Yoshizaki et
al., 1989). Patients with this complex disease have B cell hyperplasia associated anemia,
an important pathology that results in clinical symptoms. This is accompanied by
extremely high level of serum IL-6 (Yoshizaki et al., 1989). The use of tocilizumab has
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been effective in alleviating the symptoms (Tanaka and Kishimoto, 2012). Although IL-6
has been linked to B cell biology by early studies, B cells were found to express only
very low levels of IL-6R compared other lymphocytes (Dienz et al., 2009). Indeed, many
effects of IL-6 on B cells are actually due to its indirect effects on effector T cells,
especially Tfh cells (Dienz et al., 2009).

2.5 IL-6 Function in CD4 T cells
IL-6 is critical in regulating CD4 T cell differentiation and effector cytokine
production (Fig. 16). IL-6 skews the Th1/Th2 balance towards Th2 differentiation by
promoting IL-4 production during T cell activation (Fig. 16) (Diehl et al., 2002; Rincon
et al., 1997). IL-4 serves as an autocrine positive feedback loop that further promotes IL4 expression and Th2 commitment (Diehl et al., 2002; Rincon et al., 1997). IL-6 also
increases the levels of GATA3, the master regulator of Th2 cells. However, this increase
in GATA3 expression was dependent on endogenous IL-4 induced by IL-6. Instead, the
IL-6-mediated IL-4 expression and Th2 differentiation is mediated by the up-regulation
of NFATc2 which is almost absent in naïve CD4 T cells (Diehl et al., 2002). The
molecular mechanism by which IL-6 upregulates NFATc2 in CD4 T cells is still not
clear. In this thesis, we uncover a novel mechanism by which IL-6 regulates NFATc2
nuclear translocation through the regulation of mitochondrial Ca2+. This leads to the
induction of IL-4 in CD4 T cells by IL-6. In addition, IL-6 also upregulates the
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transcription factor c-maf, which promotes IL-4 expression and Th2 differentiation (Kim
et al., 1999). Both NFATc2 and c-maf promote IL-4 expression but not the production of
IL-5, another important effector cytokine produced by Th2 cells. Therefore, IL-6
promotes Th2 differentiation and effector function through the induction of IL-4.
In addition to Th2 skewing, IL-6 modulates Th1/Th2 balance by inhibiting Th1
differentiation (Fig. 16) in vitro and in vivo during Borrelia burgdoferi infection (Diehl et
al., 2000; Diehl and Rincon, 2002). The molecular mechanism of inhibition of Th1
differentiation results from a negative feedback pathway. IL-6 induces the expression of
Silencer of Cytokine Signaling (SOCS) 1, a negative feedback regulator expressed in
cells receiving too much Stat1 or Stat3 signaling (Diehl et al., 2000; Yoshimura et al.,
2007). The induction of SOCS1 inhibits IFNγ signaling. Thus, IL-6 suppresses the
positive feedback loop through endogenous IFNγ, resulting a reduced IFNγ production
and an impaired Th1 phenotype of CD4 T cells (Fig. 16) (Diehl et al., 2000).
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Figure 16. Effects of IL-6 on T helper cell differentiation and effector
cytokine production (Adapted from Dienz and Rincon, 2009)
Additionally, IL-6 is an essential differentiation factor for Th17 cells (Fig. 16)
(Korn et al., 2009). IL-6 together with TGFβ induces the differentiation of Th17 cells
(Bettelli et al., 2006; Korn et al., 2009; Mangan et al., 2006; Veldhoen et al., 2006).
Although TGFβ is required for the fate of Th17 differentiation, IL-6 sustains the maximal
expression of both RORγT and RORα through Stat3 (Durant et al., 2010). Briefly,
activated Stat3 modulates chromatin permissiveness by regulating H3K4me3 on Rorc and
Rora genes, which encode RORγT and RORα respectively (Durant et al., 2010).
Transcription factor Stat3 stimulated by IL-6, together with RORγT, directly binds to
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Il17a and Il17f promoters to induce their gene expression (Durant et al., 2010). IL-6 is
also essential for the induction of IL-22, another critical effector cytokine produced by
Th17 cells (Basu et al., 2012). Therefore, IL-6 is critical in Th17 differentiation and
effector function (Fig. 16).
In contrast to Th17 cells, iTreg differentiation is suppressed by the presence of
IL-6 (Fig. 16). IL-6 inhibits TGFβ-driven Foxp3 expression, which inhibits iTreg
differentiation (Fig. 16) (Bettelli et al., 2006). Mice deficient for gp130 transducer have
enhanced conversion of peripheral CD4 T cells into iTregs, suggesting that IL-6 is
essential in inhibiting iTreg induction (Korn et al., 2008). Patients with rheumatoid
arthritis (RA) who have received tocilizumab treatment have a sustained elevated
frequency of Tregs (Samson et al., 2012; Thiolat et al., 2014). However, the mechanisms
by which IL-6 skews CD4 T differentiation towards Th17 from Tregs are still not
completely understood.
Furthermore, IL-6 induces IL-21 production, an essential effector cytokine
produced by Tfh cells (Fig. 16) (Diehl et al., 2012; Dienz et al., 2009; Nurieva et al.,
2007; Suto et al., 2008). Upon IL-6 stimulation, Stat3 binds to the Il21 promoter to
stimulate gene expression (Durant et al., 2010). IL-6 enhances antibody production by
promoting IL-21 production by effector CD4 T cells (Dienz et al., 2009). In vitro, IL-6
stimulation has been shown to differentiate CD4 T cells into a Tfh phenotype, including
expression of Bcl6 and CXCR5, two important markers for Tfh (Nurieva et al., 2008). In
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in vivo immunization and viral infection models, the opitimal differentiation of Tfh
requires both IL-6 and IL-21 (Eto et al., 2011). Thus, IL-6 promotes IL-21 production to
help antibody responses through optimizing the function of Tfh cells. In this thesis, we
demonstrate a novel mechanism by which IL-6 promotes IL-4 and IL-21 production
through the regulation of mitochondrial Stat3 and mitochondrial function, instead of the
commonly accepted canonical Stat3 pathway.
In addition to regulating effector T cell differentiation, to a lesser extent, IL-6
enhances T cell survival, migration and proliferation of T cells (Dienz and Rincon, 2009).
IL-6 prolongs CD4 T cell survival by maintaining Bcl-2 expression in the isolated T cells
in vitro (Takeda et al., 1998; Teague et al., 1997). The survival effects elicited by IL-6
are primarily on the cells that had undergone five or more divisions (Rochman et al.,
2005) and has also been shown to promote the homeostatic proliferation of CD4 T cells
in some models (Sawa et al., 2006). IL-6 has also been linked to the migration of
activated T cells in vitro (Weissenbach et al., 2004). Therefore, by promoting these
general functions, IL-6 could contribute to the effector functions of some subsets of CD4
T cells.

2.6 IL-6 Function in CD8 T cells
In contrast to CD4 T cells, the role of IL-6 in regulating CD8 T cell effector
function is less studied (Cox et al., 2013). IL-6 can signal through gp130 and Stat3 in
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CD8 T cells as in CD4 T cells (Teague et al., 1997). IL-6 combined with other cytokines,
such as IL-15 and IL-7, synergistically promotes granzyme B expression by CD8 T cells
as well as CD8 T cell proliferation (Gagnon et al., 2008). In other studies, IL-6 in synergy
with IL-7 signaling sustains elevated memory cell generation after vaccination compared
with IL-7 alone (Castellino and Germain, 2007). Our studies in this thesis show for the
first time that IL-6 also induces IL-21 production in effector CD8 T cells. This leads to
the differentiation of CD8 T cells into a unique effector subset that is capable of helping
B cells with protective antibody response.

2.7 IL-6 in Infectious Diseases
As such a critical cytokine in modulating multiple aspects of immune reactions,
IL-6 plays an important role in controlling the progression of infectious diseases.
Although mice deficient in IL-6 develop normally, they have increased susceptibility to
several types of viral infections including vaccinia virus, vesicular stomatitis virus
(VSV), herpes simplex virus type 1 (HSV1) and H1N1 influenza A virus (IAV) (Dienz et
al., 2012; Kopf et al., 1994; LeBlanc et al., 1999). In addition to viral infection, IL-6 is
also crucial in controlling bacterial infections. IL-6 KO mice cannot control L.
monocytogenes or M. tuberculosis (Dalrymple et al., 1995; Ladel et al., 1997). IL-6deficient mice also develop more severe Lyme arthritis following B. burgdorferi infection
(Anguita et al., 1998). IL-6 is also critical in restraining fungal infection. IL-6-deficient
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mice are more susceptible to virulent C. albicans and some live vaccine strains of yeasts
(Romani et al., 1996). IL-6-deficient mice are also more susceptible to developing
invasive pulmonary aspergillosis (IPA) following intranasal infection with A. fumigatus
condidia (Cenci et al., 2001). Moreover, several parasitic infections are affected by the
presence of IL-6. Compared with wild-type mice, IL-6-deficient mice are highly
susceptible to Giardia lamblia and Trypanosoma cruzi infection (Bienz et al., 2003; Gao
and Pereira, 2002). Interestingly, a child with autoantibodies against IL-6 developed
recurrent episodes of staphylococcal cellulitis and absecesses that are not commonly seen
in genetically healthy children (Puel et al., 2008). Thus, IL-6 participates in controlling a
wide variety of infectious pathogens.

2.8 IL-6 in Rheumatoid Arthritis and Autoimmune Disorders
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease
characterized by debilitating articular manifetations including pain, tender, swollen joints
and morning stiffness, as well as systemic symptoms. Although the disease course varies
among patients, RA could develop progressively into joint destruction and loss of
function, leading eventually to physical disability. IL-6 signaling impacts several aspects
of RA manifestations. In murine collagen induced arthritis (CIA), a model analogous to
human RA, IL-6 is critical for disease progression through initiating the differentiation of
Th17 cells that further exacerbate the pathology by amplifying local inflammation
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(Alonzi et al., 1998; Fujimoto et al., 2008). In addition, IL-6 contributes to joint
destruction in RA by inducing endothelial cells to produce IL-8 and MCP-1, which
recruit leukocytes to involved joints (Suzuki et al., 2010). IL-6 in synovial fluid also
promotes synoviocyte proliferation and osteoclast differentiation through the induction of
receptor activator of NF-κB ligand (RANKL) expression (Kotake et al., 1996; Palmqvist
et al., 2002). These lead to synovial inflammation and bone destruction, two important
pathological features of RA. Lacking IL-6 in the CIA model suppresses clinical
symptoms of arthritis (Alonzi et al., 1998).
In patients with RA, IL-6 is elevated in both serum and synovial fluid (Hirano et
al., 1988). Importantly, these levels correlated with the severity of RA, while successful
treatment with disease modifying antirheumatic drugs (DMARDs), including
methotrexate or TNF inhibitors, has been shown to reduce serum IL-6 concentrations
(Madhok et al., 1993; Straub et al., 1997). Furthermore, reduction in IL-6 levels during
treatment is associated with better clinical outcomes (Straub et al., 1997). As discussed
above, tocilizumab has been approved worldwide for treating patients with moderate to
severe RA (Kishimoto, 2010). The mechanism underlying the outstanding efficacy of
tocilizumab is still not understood. However, a study has proposed that it could be due to
the selective role of anti-IL-6R blockade in reducing IL-21 production by CD4 T cells,
which could further lead to the reduction of autoantibody production in RA patients
(Carbone et al., 2013).
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IL-6 has also been linked to other autoimmune diseases, including inflammatory
bowel disease (IBD), multiple sclerosis and systemic lupus erythematosus (SLE). Serum
IL-6 levels are significantly higher in patients with Crohn’s disease (CD) than healthy
controls (Mahida et al., 1991). Importantly, serum IL-6 levels correlate with the CD
activity index in CD patients (Reinisch et al., 1999). Analysis of endoscopic biopsy
samples from CD patients demonstrated that the colonic mucosa from patients with active
disease contain very high levels of Il6 expression (Mitsuyama et al., 1991), suggesting
that colonic mucosa could be the major source of IL-6 in CD patients. Targeting IL-6
signaling as a therapeutic approach for CD has been tested in a pilot clinical trial.
Tocilizumab showed promising results with an 80% response rate (Ito et al., 2004).
Further development in using this drug to treat CD is anticipated. In addition, another
anti-IL-6 antibody is currently in a phase 2 study for treating CD. The pathogenesis of
experimental autoimmune encephalomyelitis (EAE), a model of human multiple sclerosis
(MS), is also tightly regulated by IL-6 (Samoilova et al., 1998). Mice deficient in IL-6 are
resistant to the induction of EAE (Samoilova et al., 1998). Moreover, mice deficient in
gp130 also develop less severe EAE pathology (Korn et al., 2008). This is likely due to
the effects of IL-6 on Th17 differentiation, the major driver of disease pathology
(Fletcher et al., 2010; Serada et al., 2008), suggesting that tocilizumab might be
promising in treating MS patients. Systemic lupus erythematosus (SLE), a systemic
autoimmune disease characterized by hypergammaglobulinemia, production of a variety
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of autoantibodies, and glomerulonephritis, is also linked to IL-6. SLE patients have
elevated serum IL-6 levels that correlate with disease activity or anti-DNA antibody
levels (a clinical diagnostic marker for SLE) (Grondal et al., 2000; Linker-Israeli et al.,
1991; Peterson et al., 1996). IL-6 is elevated in the cerebrospinal fluid of patients with
central nervous system (CNS) lupus (Hirohata and Miyamoto, 1990). Blocking IL-6
signaling in B cells from SLE patients significantly reduced spontaneous Ig production
(Linker-Israeli et al., 1991). Tocilizumab is currently in clinical trials to evaluate its
efficacy as a therapeutic approach to relieve SLE.

2.9 IL-6 in Asthma and Other Pulmonary Diseases
Allergic asthma is a chronic inflammatory disease of the airway characterized
by the narrowing of airway and mucus hypersecretion (Barnes, 2001). Some asthma
occurs in response to inhaled allergens. As noted above, Th2 cells drive the pathogenesis
of asthma. High levels of IL-6 in serum, induced sputum and brochoalveolar lavage fluid
(BALF) have been found in asthmatic patients (Neveu et al., 2010; Tillie-Leblond et al.,
1999; Yokoyama et al., 1995). In addition, lung epithelial cells in patients with asthma
express high levels of IL-6 (Marini et al., 1992; Stadnyk, 1994). The high levels of IL-6
could also be explained by the inflammation in asthma since IL-6 has long been
considered a general marker of inflammation together with TNFα and IL-1β. However,
only IL-6, but not TNFα and IL-1β, is elevated in induced sputum of mild asthmatic
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patients (Neveu et al., 2010), suggesting that IL-6 itself may contribute to allergic
asthma.
Although IL-6 is highly produced in asthma, the role of IL-6 in asthma has been
controversial. Using an ovalbumin sensitization model in mice, initial studies indicated
that the lack of IL-6 increased eosinophilia and Th2 cytokines as well as airway response
to methacholine (Wang et al., 2000). Another study also suggested that the lack of IL-6
enhanced airway inflammation and fibrosis in a chronic asthma model (Qiu et al., 2004).
In contrast, in another mouse model using extracts from A. fumigatus, a more relevant
and complex environmental allergen, lungs produced large amounts of IL-6 upon
challenge. IL-6 null mice in this model demonstrated that IL-6 contributes mucus
hypersecretion by airway epithelial cells (Neveu et al., 2009). IL-6 promotes IL-13
production in CD4 T cells. The impaired mucus production in IL-6 null mice correlates
with the profound reduction in IL-13 production, suggesting that IL-6 contributes to
asthma pathology by promoting mucus production through IL-13 (Neveu et al., 2009).
Several genetic studies further confirm the pathogenic role of IL-6 in allergic
asthma. The small nucleotide polymorphism (SNP), rs4129267, in the intron of the IL-6R
gene is assoticated with increased asthma risk. Intriguingly, the minor T allele in this
SNP is associated with increased levels of sIL-6R in serum (Rafiq et al., 2007; Reich et
al., 2007). The SNP, rs2228145, resulting in a single amino acid change from Asp358 to
Ala358, is associated with lung function in asthmatic subjects. This single amino acid
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substitution results in increased levels of sIL-6R (Hawkins et al., 2012), suggesting that
IL-6 signaling may be linked to asthma clinical symptoms. In addition, the presence of
IL-6 in the lung is associated with altered lung function in a prospective cross-sectional
study with asthmatic patients. The levels of IL-6 in sputum are inversely correlated with
FEV1 percent predicted (Dixon et al., 2008; Morjaria et al., 2011). IL-6 is now emerging
as a new target for the treatment of asthma. Several pharmaceutical companies have
announced clinical trials using anti-IL-6 or anti-IL-6R antibodies to target allergic
asthma.
Among many other lung diseases, chronic obstructive pulmonary disease
(COPD) is increasingly becoming one of the major causes of death in most countries.
Interestingly, IL-6 seems to also be involved in COPD pathogenesis (Rincon and Irvin,
2012). Similar to asthma, increased levels of IL-6 were found in induced sputum of
COPD patients. Furthermore, IL-6 levels are inversely correlated with lung function of
COPD patients (Donaldson et al., 2005; Eickmeier et al., 2010; Grubek-Jaworska et al.,
2012; Rincon and Irvin, 2012). Therefore, IL-6 is also likely a player in the pathogenesis
of COPD.
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3. Metabolism in T Cells

3.1 Mitochondria and Oxidative Phosphorylation
Similar to all other cell types in the body, to perform many tasks functionally, T
cells require energy. Mitochondrial metabolism and glycolytic metabolism comprise the
basics of cellular metabolism. Mitochondria are believed to have arisen from alphaproteobacteria engulfed by eukaryotic progenitors (Lane and Martin, 2010).
Mitochondria contain a circular genome encoding 13 genes essential for mitochondrial
function (Nunnari and Suomalainen, 2012; Sazanov, 2015). However, mitochondria also
contain more than 1,500 proteins that are expressed in tissue- and cell-dependent
manners, demonstrating that functional mitochondria are also dependent on the proteins
encoded by the nuclear genome (Nunnari and Suomalainen, 2012; Pagliarini et al., 2008;
Sazanov, 2015). Mitochondria function as the “power plants” of cells, because a majority
of cellular ATP is produced in mitochondrial matrix through a process known as
oxidative phosphorylation (OXPHOS) (Fig. 17) (Nunnari and Suomalainen, 2012;
Sazanov, 2015).
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Figure 17. The mitochondrial electron transport chain (Adapted from Sazanov, 2015)
The mitochondrial respiratory chain, also known as the electron transport chain
(ETC), is largely responsible for ATP production in mitochondria (Nunnari and
Suomalainen, 2012; Sazanov, 2015). The oxidation of nutrients generates metabolic
intermediates that carry large amounts of electrons, such as NADH and FADH2 (Nunnari
and Suomalainen, 2012; Sazanov, 2015). The mammalian mitochondrial ETC consists of
a series of protein complexes that transfer electrons from metabolic intermediates to
electron acceptors, including NADH-ubiquinone oxidoreductase (Complex I), succinate
dehydrogenase (Complex II), cytochrome bc1 complex (Complex III), cytochrome c
oxidase (Complex IV), ATP synthase (Complex V) and associated electron carriers (Fig.
17) (Nunnari and Suomalainen, 2012; Sazanov, 2015). Electrons from NADH enter the
ETC through Complex I (Fig. 17). Specifically, the electrons from NADH are transferred
to coenzyme Q (CoQ), a small lipid soluble molecule that carries electrons from Complex
I through the membrane, reducing ubiquinone to ubiquinol (Fig. 17). In contrast,
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Complex II, as part of the Tricarboxylic acid cycle (TCA cycle), receives electrons from
TCA cycle intermediate, succinate. These electrons are carried by FADH2. Similar to
NADH, electrons from FADH2 are transferred to CoQ through Complex II (Fig. 17).
Ubiquinol is subsequently used by Complex III to reduce cytochrome c in the
intermembrane space (IMS) of mitochondria (Fig. 17) (Nunnari and Suomalainen, 2012;
Sazanov, 2015). Complex IV uses reduced cytochrome c to reduce the final electron
acceptor, oxygen (O2), to generate water (Fig. 17) (Nunnari and Suomalainen, 2012;
Sazanov, 2015). Among these four complexes, the steps at Complexes I, III and IV (but
not Complex II) are accompanied by the release of free energy that is used to pump
protons across the inner mitochondrial membrane (IMM) into the IMS to establish a
proton gradient, also known as mitochondrial membrane potential (MMP) (Fig. 17)
(Mitchell, 1966; Nunnari and Suomalainen, 2012; Sazanov, 2015). Since protons within
IMS cannot move freely across the IMM, Complex V is the only channel that allows
proton moving through IMS into mitochondrial matrix (Fig. 17). The proton transfer
through Complex V is coupled to the synthesis of ATP from ADP, known as oxidative
phosphorylation (OXPHOS) (Fig. 17). The energy associated with the return of protons is
coupled to ATP synthesis by the F1 portion of the Complex V (Abrahams et al., 1994;
Mitchell, 1966; Nunnari and Suomalainen, 2012; Sazanov, 2015) (Fig. 17). Similar to
their role in all other mammalian cells, mitochondria are indispensible for efficient ATP
production in T cells. Deficiency in mitochondrial complexes leads to not only major
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organ failures but also severe T cell functional defects (Reichenbach et al., 2006).

3.2 Other Function elicited by ETC
In addition to their role in ATP production, mitochondria have other critical
functions in cellular homeostasis, among which reactive oxygen species (ROS)
generation is highly relevant (Murphy, 2009). Superoxide (O2•−) is the proximal ROS
generated within the mitochondrial matrix (Murphy, 2009). When a normal electrochemical coupling or NADH/NAD+ balance is impaired, Complex I and Complex III of
the ETC produce large amounts of O2•− (Murphy, 2009). Complex I is the predominant
site for ROS production. Inhibition of the respiratory chain by damage, mutation,
ischaemia, loss of cytochrome c or by the build up of NADH will increase the
NADH/NAD+ ratio and subsequently lead to excessive O2•− production (Boveris et al.,
1972; Hansford et al., 1997; Kudin et al., 2004; Kushnareva et al., 2002; Kussmaul and
Hirst, 2006; Murphy, 2009). Although Complex III has been shown to produce O2•− in
the presence of the inhibitor antimycin, it produces much less or almost negligible levels
of ROS under physiological conditions (Murphy, 2009). Mitochondrial ROS have been
long believed to damage mitochondria and cellular function in a range of pathologies
(Balaban et al., 2005; Murphy, 2009). However, emerging studies reveal that
mitochondrial ROS also contribute to redox signaling during physiological responses
(Droge, 2002; Murphy, 2009). During T cell activation, mitochondrial ROS contribute to
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T cell activation and IL-2 expression. Mitochondrial ROS, especially H2O2 derived from
O2•−, act as a redox signal that feeds back to T cell signal transduction that promotes the
nuclear localization of the transcription factor NFAT (Murphy and Siegel, 2013; Sena et
al., 2013). Thus, mitochondria are indispensable for a variety of physiological functions
by serving as the cellular engine and providing redox signaling.
Mitochondria also serve as major regulators of cellular Ca2+ homeostasis
through the ETC (Rizzuto et al., 2012). Mitochondria were among one of the first
intracellular organelles to be associated with Ca2+ storage (Deluca and Engstrom, 1961;
Vasington and Murphy, 1962). They play an active role in buffering intracellular Ca2+
levels (Rizzuto et al., 2012). While a major function of the mitochondrial membrane
potential is to drive the synthesis of ATP by OXPHOS, it is also used to regulate Ca2+
uptake into the mitochondria (Rizzuto et al., 2012). The uptake of Ca2+ into the
mitochondrial matrix through the ion impermeable inner mitochondrial membrane is
mediated by the recently identified mitochondrial calcium uniporter (MCU), using the
mitochondrial membrane potential gradient (Baughman et al., 2011; De Stefani et al.,
2011; Shanmughapriya et al., 2015). Mitochondrial Ca2+ is released into the cytosol by
the mitochondrial Na+/Ca+ exchanger (mNCX) and mitochondrial H+/Ca2+ exchanger
(mHCX) (Crompton et al., 1977; Palty et al., 2010; Rizzuto et al., 2012). Mitochondria
uptake the Ca2+ that is released through IP3 Receptor (IP3R) from the ER, the major
intracellular Ca2+ store, on the proximal ER membrane (Fig. 18) (Fracchia et al., 2013;
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Rizzuto et al., 2012). Mitochondria accomplish this by directly detecting changes in Ca2+
at ER microdomains (Rizzuto et al., 1993). It has been shown that mitochondria actively
buffer intracellular Ca2+ by uptaking between 25% to 50% of the Ca2+ released by ER,
depending on different cell types (Fig. 18) (Pacher et al., 2000).
Mitochondria also uptake Ca2+ from extracellular sources. Mitochondria
translocate to sites close to the cell surface in order to uptake extracellular Ca2+ imported
by Ca2+ release-activated Ca2+ (CRAC) channels (Fig. 18) (Fracchia et al., 2013; Rizzuto
et al., 2012). Mitochondrial Ca2+ has been shown to play a critical role in regulating T
cell functions. Upon antigen recognition, naïve T cells initiate an immediate burst of
cytosolic Ca2+ spike that is released primarily from the ER in response to IP3 binding to
IP3R on ER (Hogan et al., 2010). Increased cytosolic Ca2+ activates NFAT1 transcription
factor that further governs the expression of same early T cell activation genes (Macian,
2005). The effectiveness of long-lasting activation of Ca2+ signaling during T cell
activation requires Ca2+ influx from extracellular sources through CRAC channels
(Hogan et al., 2010). Importantly, upon T cell activation, CRAC channels accumulate at
the immune synapse and mitochondria also translocate to sites in proximity to immune
synapse (Barr et al., 2008). At the immune synapse, mitochondria uptake Ca2+ from
CRAC channels to prevent the Ca2+-dependent inactivation of the channels (Cogliati et
al., 2013; Quintana et al., 2007; Schwindling et al., 2010). This leads to long-lasting Ca2+
spikes for the optimal activation of T cells.
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Figure 18. Mitochondrial Ca2+ in T cells (Adapted from Fracchia et al., 2013)
Mitochondrial Ca2+ activates key mitochondrial enzymes involved in metabolic
pathways that may lead to more efficient T cell metabolism (Fig. 18) (Tarasov et al.,
2012). Specifically, several rate limiting enzymes involved in the TCA cycle, including
pyruvate dehydrogenase (PDH), isocitrate dehydrogenase (IDH) and α-ketoglutarate
dehydrogenase (α-KG), are activated by mitochondrial Ca2+ (Fig. 18) (Rizzuto et al.,
2012). When stimulated by mitochondrial Ca2+, these enzymes ramp up the TCA cycle
and subsequently generate increased NADH and FADH2 (key substrates for
mitochondrial OXPHOS). Although this mechanism has not been specifically tested in T
cells, it has been widely revealed in many tissues and cell types. Thus, it is likely to be a
common mechanism that is also shared by T cells. Therefore, mitochondrial Ca2+ is also
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essential in regulating T cell functions. In this thesis, we show for the first time that
mitochondrial Ca2+ modulation by IL-6 also contributes to the function of CD4 effector T
cells, particularly the production of the effector cytokines IL-4 and IL-21.

3.3 Glycolysis
Glycolysis is another important arm of T cell metabolism. Glucose is
transported into T cells via the high affinity Glucose transporter 1 (Glut1), which is the
major glucose transporter on T cells (Wieman et al., 2007; Wofford et al., 2008). Glucose
is metabolized by the rate limiting enzyme hexokinase and then enters glycolytic
metabolism. During this process, each glucose molecule is broken down into pyruvate
with a net production of two ATP molecules in contrast to 36 molecules of ATP per
glucose molecule generated by OXPHOS. Instead of entering the TCA cycle, pyruvate
can also be reductively metabolized to organic acids or alcohols such as lactate, acetate or
ethanol, a process known as fermentation (Lunt and Vander Heiden, 2011).
In rapidly dividing cells, most of the glucose is converted to lactate through
glycolytic pathway even when cells are in an oxygen rich environment. This is
characterized as aerobic glycolysis or the Warburg effect (Lunt and Vander Heiden,
2011; Vander Heiden et al., 2009; Warburg et al., 1958). Although less efficient in terms
of ATP production, aerobic glycolysis generates ATP at a faster rate (Pfeiffer et al.,
2001). This may be preferred to meet the high demands of dividing cells given an
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abundant supply of glucose. More importantly, aerobic glycolysis fits perfectly into rapid
dividing environment by providing macromolecular biosynthesis. Through aerobic
glycolysis, glucose supplies cells with large amounts of metabolic intermediates for the
synthesis of lipids, protein, carbohydrates, and nucleic acids (Lunt and Vander Heiden,
2011). In addition, aerobic glycolysis produces less ROS so that dividing cells are less
damaged by endogenous ROS production (Spitz et al., 2000; Wu and Zhao, 2013). The
balance between glycolysis and OXPHOS depends on the needs of cells, and contributes
to multiple aspects of T cell function (Pearce et al., 2013; Vander Heiden et al., 2009;
Warburg et al., 1958).

3.4 Metabolism in Different Phases of Mature T Cells
3.4.1 Naïve T cells. Naïve T cells have low requirements that serve to fuel only
the basal energy generation and replacement biosynthesis, known as metabolic
quiescence (MacIver et al., 2013). Naïve resting T cells continue to migrate through
lymphoid tissues on immune surveillance, which requires constant cytoskeletal
rearrangement. This process costs significant levels of ATP and requires only minimal
biosynthesis (MacIver et al., 2013). In addition, naïve resting T cells require efficient
ATP synthesis to fuel their long-term survival (van der Windt and Pearce, 2012). To
maintain these basic metabolic requirements, naïve resting T cells primarily utilize
OXPHOS to generate energy. Specifically, resting T cells predominantly rely on the high
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energy-yielding processes of fatty-acid β-oxidation and puryvate and glutamine oxidation
via the TCA cycle and OXPHOS (Fig. 19 and 20) (Buck et al., 2015; Fox et al., 2005;
MacIver et al., 2013; O'Sullivan and Pearce, 2015; Pearce et al., 2013; van der Windt and
Pearce, 2012; Yusuf and Fruman, 2003).

Figure 19. Metabolism in T cells (Adapted from Buck et al., 2015)
Although less known, extrinsic signals contribute to maintaining this basal
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energy-generating catabolic metabolism in naïve resting T cells. In addition to the wellknown function of IL-7 in promoting survival, IL-7 maintains the stability of naïve
resting T cells by metabolic modulation. Normally, in the absence of extrinsic signals,
even when the nutrient supply is abundant, lymphocytes are not able to maintain either
cell size or viability and undergo atrophy and apoptosis (Rathmell et al., 2000). Signaling
through IL-7R regulates glucose uptake through the activation of the PI3K/Akt/mTOR
pathway, which largely promotes the surface trafficking of Glut1 (Barata et al., 2004;
Rathmell et al., 2001; Wofford et al., 2008), thereby maintaining cellular metabolism and
cell size homeostasis. Conditional deletion of the IL-7R in mature T cells leads to cellular
atrophy and an inability to maintain glycolysis in vivo (Jacobs et al., 2010). Additionally,
IL-7 maintains the stability of CD8 T cells through upregulating amino acid transporters,
implying that IL-7 also contributes to naïve T cell homeostasis through maintaining
amino acid metabolism (Pearson et al., 2012).
3.4.2 T cells undergoing activation. In contrast to naïve T cells, upon TCR
antigen recognition and costimulation, T cells undergo drastic metabolic changes (van der
Windt and Pearce, 2012). To support rapid biomass synthesis, DNA replication, cellular
proliferation and protein synthesis during T cell activation, T cells adapt to an anabolic
metabolism for effective biosynthesis (Buck et al., 2015; O'Sullivan and Pearce, 2015;
Pearce et al., 2013; van der Windt and Pearce, 2012). T cells undergoing antigen
stimulation skew their metabolism towards aerobic glycolysis to supply cells with large
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amounts of metabolic intermediates for the synthesis of lipids, protein, carbohydrates,
and nucleic acids, which is a state also known as the Warburg effect (Fig. 19 and 20)
(Pearce et al., 2013; Vander Heiden et al., 2009; Warburg et al., 1958). Glucose-6phosphate (G6P) and 3-phosphoglycerate (3PG) are intermediates of aerobic glycolysis.
They are actively metabolized in the pentose phosphate pathway (PPP) and serine
biosynthesis pathways, respectively, to generate important precursors for nucleotide and
amino acid synthesis, which are required for cell proliferation (Buck et al., 2015; Pearce
et al., 2013). At the same time, metabolic reprogramming to aerobic glycolysis restrains
the generation of ROS from mitochondria, thus keeping the balance of cellular ROS
under control (Pearce et al., 2013; Vander Heiden et al., 2009; Warburg et al., 1958).

Figure 20. Metabolism in naïve, activated and memory T cells (Adapted
from MacIver et al., 2013)
Although much attention has been paid to the shift towards glycolysis during T
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cell activation, mitochondrial OXPHOS is also important during T cell antigen
recognition (Fig. 19 and 20) (Pearce et al., 2013). Oligomycin, a specific inhibitor of
mitochondrial ATP synthase (Complex V), inhibits normal T cell activation and the
subsequent T cell proliferation, suggesting that mitochondrial ATP synthesis is required
for an optimal T cell activation (Chang et al., 2013). Aerobic glycolysis needs ATP
derived from mitochondrial OXPHOS to fuel hexokinase, a rate-limiting enzyme
involved in aerobic glycolysis or Warburg effect. Thus, while excessive ROS damages T
cells, a balanced ROS production from mitochondria is still required for T cell activation.
Using mice deficient for a functional component of Complex III of the ECT, ROS were
demonstrated to act as a redox signal that feeds back to T cell signal transduction to
activate IL-2 expression and promote antigen-specific proliferation (Sena et al., 2013).
In addition, T cell exhaustion, the state of T cell nonresponsiveness as a result
of constant antigen exposure during diseases such as chronic viral infection and cancer, is
also affected by metabolic profiles (Shin and Wherry, 2007; Zajac et al., 1998). The
expression of glycolytic genes is reduced in exhausted CD8 T cells; however, the
expression of genes involved in oxidative metabolism is upregulated (Wherry et al.,
2007). This suggests that defects in glycolytic metabolism may lead to CD8 T cell
exhaustion. Likewise, ligation of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and
programmed death-1 (PD-1), two important effector receptors on exhausted T cells,
results in the inhibition of PI3K/Akt/mTOR pathway and subsequently the suppression of
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glycolytic metabolism (Francisco et al., 2009; Parry et al., 2005). Thus, suppression of
glycolysis may contribute to the generation of exhausted T cells.
3.4.3 Effector CD4 T cells. Following activation, CD4 T cells differentiate into
multiple helper subsets, as discussed above. Several signaling pathways govern the
switches between different metabolic stages of T cells during T cell activation and
differentiation. A key regulator of T cell metabolism is mTOR, which functions in two
distinct pathways, mTORC1 and mTORC2 (Chi, 2012). In particular, the scaffolding
proteins Raptor and Rictor define the downstream substrates for mTORC1 and mTORC2
activation, respectively (Pollizzi and Powell, 2015). TCR antigen recognition,
costimulatory signals and defined cytokine stimulation activate the mTOR pathway (Chi,
2012). In addition, environmental factors such as nutrient cues and growth factors can
also contribute to activation of the mTOR pathway (Chi, 2012). These stimuli normally
lead to the activation of upstream PI3K, which then results in the activation of AKT.
Activated AKT then phosphorylates tuberous sclerosis complex 2 (TSC2), inhibiting the
GTPase-activting protein (GAP) activity of the TSC complex. This further leads to the
activation of mTOR (Pollizzi and Powell, 2015). The activation of mTOR is important in
promoting glycolytic metabolism, the critical metabolic switch during T cell activation
(Duvel et al., 2010).
AMP-activated protein kinase (AMPK) is another key metabolic regulator in T
cells that acts as a metabolic stress sensor. AMPK is activated when the AMP to ATP
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ratio is increased (O'Sullivan and Pearce, 2015). AMPK works oppositely to the mTOR
pathway by promoting catabolic metabolism during metabolic stress (MacIver et al.,
2011). Specifically, in response to energy deprivation, AMPK phosphorylates the mTOR
binding partner Raptor, thereby inhibiting mTORC1 activities (Gwinn et al., 2008). Thus,
AMPK is critical in maintaining T cell metabolism under metabolic constraints (Blagih et
al., 2015).
The transcription factors hypoxia inducible factor 1α (HIF-1α) and c-Myc also
contribute to T cell metabolism (O'Sullivan and Pearce, 2015). Both HIF-1α and c-Myc
expression increase glucose uptake and divert glucose away from OXPHOS towards
aerobic glycolysis during T cell activation (Doedens et al., 2013; Wang et al., 2011).
HIF-1α is a transcription factor that stimulates the expression of multiple genes involved
in glycolysis. HIF-1α is usually induced by hypoxia; however, mTORC1 activation also
induces the expression of HIF-1α. The effects of HIF-1α on aerobic glycolysis during T
cell activation are likely dependent on the activation of mTOR. c-Myc deletion leads to a
marked impairment in glycolysis and glutaminolysis in T cells during activation. Myc
also drives a global reprogramming in T cell metabolism during activation (Wang et al.,
2011; Wang and Green, 2012). Therefore, all these distinct pathways orchestrate the
different metabolic states of CD4 T helper subsets.
Th1, Th2 and Th17 cells are highly dependent on aerobic glycolysis, but Treg
cells are primarily dependent on β-oxidation of lipids (Fig. 19) (Michalek et al., 2011).
85

Consistent with these findings, skewing cells to glycolysis by inhibiting the mTOR
pathway using rapamycin or genetic deletion of mTOR in T cells promotes the generation
of Treg cells even in Th17 polarizing conditions (Delgoffe et al., 2011; Kopf et al., 2007).
Among Th1, Th2 and Th17 cells, Th17 cells are in particular heavily dependent on
aerobic glycolysis for their differentiation and maintenance (Buck et al., 2015). This
relies on the activation and expression of the transcription factor HIF-1α downstream of
the mTOR pathway (Dang et al., 2011; Shi et al., 2011). Interestingly, the fatty acid
synthesis pathway is also suggested to be important in Th17 and Treg effector cell
function. Inhibition of acetyl-CoA carboxylase 1 (ACC1), an enzyme in fatty acid
synthesis, limits Th17 differentiation and promotes the development of Treg cells (Berod
et al., 2014). Th1 and Th2 differentiation also requires participation of the mTOR
pathways. Signaling through mTORC1 and mTORC2 selectively contributes to the
differentiation of CD4 T cells into Th1 and Th2 cells, respectively (Delgoffe et al., 2011;
Lee et al., 2010). Less is known about the role of metabolism in the differentiation and
maintenance of Tfh cells, but the master transcription factor of Tfh cells, Bcl6, has been
shown to suppress glycolysis through the regulation of c-Myc and HIF-1α (Johnston et
al., 2009; Nurieva et al., 2009; Oestreich et al., 2014).
Other than effector T cell differentiation, the effector function of T cells,
especially effector cytokine production, is also regulated by metabolic pathways.
Glyceraldehade 3-phosphate dehydrogenase (GAPDH), a critical metabolic enzyme in
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glycolysis is involved in the regulation of IFNγ and IL-2 production (Chang et al., 2013).
When aerobic glycolysis is less engaged, more intracellular GAPDH is freely available to
function as an RNA-binding protein that binds to the 3’-UTR of IFNγ and IL-2 mRNA.
This leads to an inhibition of IFNγ and IL-2 mRNA translation (Chang et al., 2013). In
this thesis, we show for the first time that mitochondrial membrane potential and
mitochondrial Ca2+ also contribute to the induction of IL-4 and IL-21 elicited by IL-6
signaling and mitochondrial Stat3.
3.4.4 Effector CD8 T cells. Although the cellular metabolism of effector CD8 T
cell is less studied, fatty acid synthesis has been suggested to be critical in regulating
effector T cell function. Sterol regulatory element binding protein 1 (SREBP1) is a
transcription factor that drives the expression of fatty acid synthesis genes. CD8 T cells in
mice deficient in SREBP1 are unable to blast during viral infection, leading to an
attenuated expansion and markedly reduced effector function (Kidani et al., 2013). In
addition, mice deficient in the fatty acid synthesis enzyme ACC1 do not show any defects
in effector T cell development after viral infection; however, in ACC-1 deficient CD8 T
cells, effector cell expansion is diminished due to increased cell death (Lee et al., 2014).
CD8 effector function has also recently been linked to mitochondrial OXPHOS
(Champagne et al., 2016). When an endogenous regulator of Complex I, methylationcontrolled J protein (MCJ or DNAJC15), is deleted, mitochondria in CD8 T cells are
more active in producing ATP through OXPHOS. The increased ATP contributes to the
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increased secretion of effector cytokines IFNγ and IL-2 (Champagne et al., 2016).
3.4.5 Memory T cells. At the end of an immune response, when most effector T
cells die, the cells that survive become memory cells. Similar to naïve and activated T
cells, memory T cell differentiation and function are also tightly regulated by metabolism
(Fig. 19 and 20). In contrast to T cells undergoing activation, memory cells revert back to
lipid oxidation and an increased capacity for efficient energy generation (Fig. 19 and 20).
Memory CD8 T cells preferentially use fatty acid oxidation as the energy source for their
metabolism (Buck et al., 2015; O'Sullivan and Pearce, 2015; Pearce et al., 2009; van der
Windt et al., 2012). Memory CD8 T cells express high levels of the mitochondrial lipid
transporter CPT1a, which facilitates the usage of lipids as the primary energy source (van
der Windt et al., 2012). Inhibition or knocking down of CTP1a diminishes mitochondrial
function and reduces memory cell stability and survival, suggesting that lipid β-oxidation
is critical in memory cell homeostasis (van der Windt et al., 2012). These metabolic
transitions eventually result in enhanced mitochondrial biogenesis and increased storage
of reserve energy as characterized by spare respiratory capacity (van der Windt et al.,
2012). This enables memory T cells to undergo rapid oxidative metabolism under
metabolic stress in response to secondary antigen challenge.
In contrast to IL-2, which supports effector function through promoting aerobic
glycolysis, cytokines such as IL-7 and IL-15 play an essential role in supporting memory
T cell survival by promoting mitochondrial biogenesis, fatty acid oxidation and spare
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respiratory capacity (Fraser et al., 2013; Pearce et al., 2013; van der Windt et al., 2012).
This is important for the maintenance of longevity of memory T cells. Surprisingly,
instead of acquiring free fatty acids (FFA) from extracellular sources for β-oxidation,
memory CD8 T cells take up significantly less FFA than effector T cells. They do not
show any functional defects even when cultured in lipid-free medium. Nevertheless, they
indeed synthesize their own triglycerides (TGs) in the ER that are further used in a selfreliance manner through lipolysis (O'Sullivan et al., 2014). In addition, glycerol is
imported into memory CD8 T cells to serve as the backbone for TG synthesis. It has been
recently identified that aquaporin 9 (AQP9) works as a glycerol importer, and IL-7
maintains memory CD8 T cell longevity through AQP9-mediated glycerol import and
TG synthesis (Cui et al., 2015).
In contrast, the role of metabolism in regulating memory CD4 T cells is less
understood. It has been suggested that glucose metabolism is important for memory CD4
T cell survival, and this is controlled by Notch signaling (Maekawa et al., 2015). In
summary, various metabolic pathways including both mitochondrial metabolism and
glycolytic metabolism are essential in many aspects of T cell function.
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4. Research Aims of Thesis

4.1 Aim 1
IL-6 plays critical roles in the regulation of immune responses as demonstrated
by numerous animal studies as well as clinical research using tocilizumab. As previously
noted, the role of IL-6 in CD4 T cell differentiation and effector CD4 T cell function has
been well-established. These were believed to be mediated largely through the
transcription factor Stat3 via gene regulation.
Stat3 has been found present in mitochondria where it regulates the ETC in
hepatocytes, heart and cancer cells, but it had not been described to be localized to the
mitochondria of T cells (Erlich et al., 2014a; Gough et al., 2009; Heusch et al., 2011;
Lachance et al., 2013; Wegrzyn et al., 2009; Zhang et al., 2013). However, whether IL-6
has an effect on mitochondrial function through the regulation of mitochondrial Stat3 or
whether this effect has an impact on the function of IL-6 on CD4 T cells is still unknown
(Fig. 21). In this thesis, we will address:

Specific Aim 1.1. whether IL-6-stimulated CD4 T cells can promote mitochondrial
function, including mitochondrial membrane potential and mitochondrial Ca2+.
Specific Aim 1.2. whether the effects of IL-6 on mitochondrial regulation are due to the
regulation of mitochondrial Stat3.
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Specific Aim 1.3. whether mitochondrial Stat3-mediated modulations in the mitochondria
of CD4 T cells can be the result of novel mechanisms, such as respiratory supercomplex
formation.
Specific Aim 1.4. whether the mitochondrial regulation elicited by IL-6 and
mitochondrial Stat3 could contribute to effector functions of effector CD4 T cells.

4.2 Aim 2
Although emerging studies and evidence strengthen the role of IL-6 in CD4 T
cell differentiation and effector function, little is known about the potential effect of IL-6
on CD8 T cells. We and others have shown that IL-6 promotes IL-21 production from
CD4 T cells and this leads to antibody production by B cells (Dienz et al., 2009; Nurieva
et al., 2007; Ozaki et al., 2002; Suto et al., 2008). This leads to our question of whether
IL-6 alone can contribute to CD8 T cell differentiation as it does in CD4 T cells (Fig. 22).
Furthermore, we propose that IL-21-producing CD8 T cells elicited by IL-6 also
contribute to antibody production during infection through the IL-6/IL-21 axis (Fig. 22).

Specific Aim 2.1. To test whether the addition of IL-6 or defects in IL-6 affect the
production of IL-21 by CD8 T cells in vitro and in vivo.
Specific Aim 2.2. To examine whether IL-6 affects the production of other effector
cytokines production and whether IL-6 leads to the differentiation of a unique CD8
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effector T subset.
Specific Aim 2.3. To test what determines the differentiation of CD8 T cells in response
to IL-6.
Specific Aim 2.4. To decipher whether the CD8 T cell-derived IL-21 can contribute to
antibody production by B cells in vitro.
Specific Aim 2.5. To investigate whether the CD8 T cell-derived IL-21 can contribute to
protective antibody response by B cells in vivo.
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Figure 21. Hypothetical model addressing role of IL-6 in effector CD4 functions
through the regulation of mitochondrial Stat3
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Figure 22. Hypothetical model addressing whether IL-6 can convert CD8 T cells to
B cell helpers by inducing IL-21 production
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SUMMARY
IL-6 plays an important role in determining the fate of effector CD4 cells and the
cytokines that these cells produce. Here we identify a novel molecular mechanism by
which IL-6 regulates CD4 cell effector function. We show that IL-6-dependent signal
facilitates the formation of mitochondrial respiratory chain supercomplexes to sustain
high mitochondrial membrane potential late during activation of CD4 cells.
Mitochondrial hyperpolarization caused by IL-6 is uncoupled from the production of
ATP by oxidative phosphorylation. However, it is a mechanism to raise the levels of
mitochondrial Ca2+ late during activation of CD4 cells. Increased levels of mitochondrial
Ca2+ in the presence of IL-6 are used to prolong Il4 and Il21 gene expression in effector
CD4 cells. Thus, the effect of IL-6 on mitochondrial membrane potential and
mitochondrial Ca2+ is an alternative pathway by which IL-6 regulates effector function of
CD4 cells and it could contribute to the pathogenesis of inflammatory diseases.
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INTRODUCTION
IL-6 is an inflammatory cytokine that is elevated in several autoimmune and
inflammatory disorders, including rheumatoid arthritis (RA) (Kishimoto, 2005).
Inhibition of IL-6 signaling by an anti-IL-6R antibody has been shown to be a highly
effective therapy in treating patients with RA (Tanaka and Kishimoto, 2012). IL-6 plays a
crucial role in regulating CD4 T helper cell differentiation and cytokine production
(Dienz and Rincon, 2009). It enhances Th2 differentiation through an auto-feedback loop
by upregulating autocrine IL-4 production (Diehl et al., 2002; Rincon et al., 1997). IL-6
inhibits IFNγ production and Th1 differentiation (Diehl et al., 2000). In combination with
TGFβ, IL-6 also contributes to the differentiation of Th17 cells (Bettelli et al., 2006;
Ivanov et al., 2006; Zhou et al., 2007). IL-6 inhibits regulatory T cell function and
downregulates Foxp3 expression (Dienz and Rincon, 2009; Pasare and Medzhitov, 2003).
In addition, IL-6 alone, without the need of TGFβ, induces IL-21 expression, a
mechanism by which it promotes the generation of follicular T helper (Tfh) cells (Diehl
et al., 2012; Dienz et al., 2009; Nurieva et al., 2008; Suto et al., 2008).
IL-6 binds to its membrane receptor, which triggers signaling through gp130, a
common transducer that activates Jak/Stat3 and Ras/MAPK pathways in T cells
(Boulanger et al., 2003; Heinrich et al., 2003; Kishimoto, 2005). Stat3 is a transcription
factor present in the cytosol but translocates to the nucleus upon stimulation where it
mediates the expression of numerous genes. Stat3 has been previously implicated in the
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regulation of genes involved in cell survival and proliferation by directly binding to
multiple survival genes, including Bcl2, Fos, Jun, Mcl1 and Fosl2 (Bourillot et al., 2009;
Carpenter and Lo, 2014; Durant et al., 2010; Hirano et al., 2000). Additionally, IL-6dependent Stat3 activation plays an important role in the expression of several cytokine
genes, including Il21 and Il17 (Dienz et al., 2009; Mathur et al., 2007; Zhou et al., 2007).
In addition to its role as a nuclear transcription factor, Stat3 has been found within
mitochondria in liver, heart and some cell lines where it enhances the mitochondrial
respiratory chain activity (Gough et al., 2009; Wegrzyn et al., 2009). However, no studies
have addressed whether IL-6 regulates mitochondrial function through Stat3.
IL-6 has for long been associated with metabolic changes and high levels of IL-6 in
serum have been correlated with BMI (Fried et al., 1998; Mohamed-Ali et al., 1997;
Vgontzas et al., 2000). Recent studies indicate that IL-6 is linked to glucose homeostasis
in adipose tissue and it participates in the switch from white to brown fat tissue in cancerinduced cachexia (Petruzzelli et al., 2014; Stanford et al., 2013). However, it remains
unclear whether IL-6 has a direct effect on the metabolism of cells. But in the context of
ischemia-reperfusion injury in cardiomyocytes, IL-6 has been shown to maintain
mitochondrial membrane potential in cardiomyocytes (Smart et al., 2006). Despite the
known role of IL-6 in CD4 cell effector function, no studies have addressed whether IL-6
has an effect on mitochondrial function in CD4 cells.
Here we show that IL-6 plays an important role in maintaining mitochondrial
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membrane potential (MMP) late during CD4 cell activation in a Stat3-dependent manner.
IL-6-mediated mitochondrial hyperpolarization is, however, uncoupled from oxidative
phosphorylation and ATP production. Instead, IL-6 uses the high MMP to raise
mitochondrial Ca2+ and, consequently, cytosolic Ca2+ levels to promote cytokine
expression late during activation. Thus, we have identified a previously undescribed
mechanism by which IL-6 regulates CD4 cell effector function.
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RESULTS
IL-6 is essential to sustain mitochondrial membrane potential during activation of
CD4 cells
Although the role of IL-6 in CD4 cell differentiation and cytokine gene expression is
well established, little is known about the role of this cytokine in mitochondrial function.
An essential function of the mitochondrial electron transport chain (ETC), in addition to
the transfer of electrons, is the generation of an electrochemical gradient across the
mitochondrial inner membrane by accumulating H+ at the intermembrane space. This
electrochemical gradient, known as mitochondrial membrane potential (MMP), is used as
a mechanism to generate ATP. Since IL-6 has been associated with maintaining MMP in
cardiomyocytes (Smart et al., 2006), we examined whether IL-6 regulates the MMP in
CD4 cells during activation. Fresh CD4 cells were activated with anti-CD3 and antiCD28 antibodies (Abs) in the presence or absence of IL-6 for different periods of times,
stained with TMRE (an MMP indicator), and analyzed by flow cytometry. Most freshly
isolated CD4 cells were hyperpolarized as shown by the high TMRE staining (Fig. 1A).
However, cells activated in the absence of IL-6 depolarized progressively during
activation (Fig. 1A). Interestingly, the presence of IL-6 prevents mitochondrial
depolarization during CD4 cell activation (Fig. 1A). After 48h of activation, most CD4
cells activated in the presence of IL-6 maintained a high MMP (TMREhigh) (Fig. 1B). In
contrast to IL-6, the presence of exogenous IL-2, the main growth factor of T cells, did
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not affect MMP in activated CD4 cells (Fig. 1C), supporting a selective role for IL-6 on
MMP.
To examine the effect of IL-6 on mitochondrial mass and levels of ETC complexes,
we performed Western blot analysis for subunits of these complexes using whole cell
extracts. IL-6 did not affect the overall mitochondrial mass as determined by the levels of
COX IV (Complex IV subunit of ETC), NDUFS3 and NDUFA9 (Complex I subunits)
(Fig. 1D). In addition, the frequency of live cells among those activated in the presence of
IL-6 was not significantly different from the frequency of live cells in the absence of IL-6
(Fig. 1E). Thus, the increase of MMP triggered by IL-6 is not a consequence of survival
or change in mitochondrial mass.
Antigen presenting cells (APCs) are one of the major sources of IL-6 during CD4
cell activation. To examine whether IL-6 was required to maintain the mitochondrial
hyperpolarization during antigen activation, naïve CD4 cells were obtained from OT-II
TCR transgenic mice (Barnden et al., 1998) and activated with OVA peptide and APCs
isolated from WT or IL-6 KO mice. Similar to CD4 cells activated with anti-CD3/CD28
Abs in the presence of IL-6, a large frequency of OT-II CD4 cells activated with WT
APC showed a high MMP (Fig. 1F and 1G). However, a blocking anti-IL-6 Ab
drastically decreased the frequency of cells with high MMP (Fig. 1F and 1G). In contrast
to WT APCs, very low frequency of activated CD4 cells showed high MMP when APC
from IL-6 KO mice were used (Fig. 1F and 1G). Remarkably, addition of exogenous IL-6
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to cells activated with IL-6 KO APCs restored high MMP (Fig. 1F and 1G). Thus, these
results indicate that IL-6 derived from APC during in vitro activation of CD4 cells is
essential to maintain mitochondrial hyperpolarization.
To address the role of IL-6 in regulating the MMP in CD4 cells during in vivo
activation, we performed adoptive transfer of OT-II CD4 cells into WT or IL-6 KO mice
as hosts. Mice were then immunized with ovalbumin, and after two days, cells were
harvested to examine their MMP. Similar to in vitro results, the fraction of OT-II cells
maintaining a high MMP was significantly greater in WT mice relative to IL-6 KO mice
(Fig. 1H). Together, these results indicate that IL-6 plays an essential role in maintaining
the MMP during activation of CD4 cells.

IL-6 facilitates the formation of respiratory chain supercomplexes in CD4 cells
during activation
Morphological states of highly pleomorphic inner membrane cristae reflect the
different mitochondrial metabolic stages. Mitochondrial cristae shape has been shown to
influence the efficiency of the respiratory chain in part by affecting the formation of
respiratory chain supercomplexes (RCS) (Cogliati et al., 2013; Gomes et al., 2011;
Hackenbrock, 1966), formed of Complex I together with Complex III and Complex IV.
The function of RCS is to facilitate the transfer of electrons between complexes and
increase Complex I activity while reducing the electron leak from ETC and mitigate the
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production of reactive oxygen species (ROS) (Acin-Perez et al., 2008; Althoff et al.,
2011; Schagger, 1995; Winge, 2012). To determine whether IL-6 could affect cristae
shape, we examined CD4 cells activated in the presence or absence of IL-6 by
transmission electron microscopy (TEM) imaging. No obvious differences in
mitochondrial integrity or mitochondrial mass were observed in cells activated with or
without IL-6 (Fig. 2A). Similarly, there was no increase in the number of mitochondria in
CD4 cells activated in the presence of IL-6 (Figure 2-figure supplement 1). However, the
morphology of the mitochondrial cristae in cells activated with IL-6 was different from
that of cells activated without IL-6 (Fig. 2A). The number of mitochondria with expanded
and disorganized cristae was greater in CD4 cells activated in the absence of IL-6
compared with CD4 cells activated with IL-6 (Fig. 2B). In contrast, the number of
mitochondria with tight and organized cristae was higher in cells activated in the
presence of IL-6 (Fig. 2C). Thus, IL-6 affects mitochondrial cristae shape during
activation of CD4 cells.
To determine whether the effect of IL-6 on mitochondrial cristae morphology could
be reflected in an altered formation of RCS as a mechanism to maintain a high MMP, we
examined the presence of RCS in activated CD4 cells. We performed blue-native gel
electrophoresis (BN-PAGE) using mitochondrial extracts generated in the presence of
digitonin to preserve the supercomplexes (Acin-Perez et al., 2008), followed by Western
blot analysis. The levels of RCS but not the levels of individual Complex I or Complex
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III were increased in mitochondria from IL-6-stimulated CD4 cells, as determined by the
presence of NDUFA9 (Complex I) and Core I (Complex III) within the RCS region (Fig.
2D).
Since the formation of RCS is associated with increased MMP but reduced
mitochondrial ROS (mROS) (Acin-Perez et al., 2008; Althoff et al., 2011; Schagger,
1995; Winge, 2012), we examined the production of mROS in CD4 cells activated with
or without IL-6 by flow cytometry using MitoSOX, a mitochondrial superoxide indicator.
Despite the increased MMP, IL-6 reduced the production of mROS (Fig. 2E and 2F).
Thus, the formation of RCS facilitated by IL-6 makes possible for this cytokine to sustain
mitochondrial hyperpolarization while minimizing the production of mROS during
activation of CD4 cells.

IL-6-mediated mitochondrial hyperpolarization is uncoupled from OXPHOS
The energy released from the transport of H+ from the mitochondrial intermembrane
space to the mitochondrial matrix through F0F1 ATP synthase, a subunit of Complex V, is
coupled to ATP generation. Thus, an increased MMP elicited by IL-6 could potentially
lead to an increase in mitochondrial ATP synthesis. We therefore examined ATP
production in CD4 cells activated in the presence or absence of IL-6. Surprisingly,
despite of the increased MMP, intracellular ATP levels were not affected by IL-6 (Fig.
3A). TCR stimulation has been shown to trigger rapid ATP release from CD4 cells (Yip
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et al., 2009). It was therefore possible that IL-6 increased ATP synthesis but also ATP
release. However, analysis of ATP levels in culture supernatants of activated cells
showed no difference in the levels of extracellular ATP (Fig. 3B). Since most ATP in
activated T cells is generated through glycolysis (Pearce et al., 2013), increased MMP by
IL-6 could enhance mitochondrial OXPHOS but have minimal effect on overall ATP
levels. To further address the effect of IL-6 on mitochondrial OXPHOS, we examined
oxygen consumption rate (OCR) using the Seahorse XF24 analyzer (Wu et al., 2007). No
statistically significant difference in basal mitochondrial OCR or maximal respiratory
capacity was detected (Fig. 3C). Thus, the effects of IL-6 on the MMP are uncoupled
from OXPHOS.
We also examined whether the mitochondrial hyperpolarization by IL-6 could
compromise anaerobic glycolysis during activation. Culture supernatants of activated
CD4 cells with or without IL-6 were assayed for lactate production. Lactate production
was not significantly different in cells activated with IL-6 (Fig. 3D). The Seahorse XF24
analyzer was also used to measure the extracellular acidification rate (ECAR), another
alternative approach to examine the rate of glycolysis. Consistent with the production of
lactate, there was no difference in anaerobic glycolysis in the presence of IL-6 during
CD4 cell activation (Fig. 3E). Thus, although IL-6 maintains high MMP late during the
activation of CD4 cells, it does not alter rates of OXPHOS or anaerobic glycolysis.
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IL-6-mediated high MMP results in elevated mitochondrial Ca2+ levels
Although the main function of the MMP is to drive the generation of ATP through
OXPHOS, MMP also plays an important role in mitochondrial Ca2+ homeostasis (Rizzuto
et al., 2012). Mitochondria are emerging as the primary subcellular Ca2+ store which
buffers cytosolic Ca2+ (Starkov, 2010). Mitochondrial Ca2+ uptake is modulated by
mitochondrial calcium uniporter (MCU) and it is dictated by the MMP (Baughman et al.,
2011; De Stefani et al., 2011; Mallilankaraman et al., 2012a; Mallilankaraman et al.,
2012b; Shanmughapriya et al., 2015), while Ca2+ release from mitochondria is mediated
by the mitochondrial Na+/Ca2+ exchanger (mNCLX) (Kirichok et al., 2004; Nita et al.,
2012; Palty et al., 2010; Rizzuto et al., 2012). Upon TCR engaging, it has been reported
that the formation of the immunological synapse triggers early store-dependent Ca2+
influx through mitochondrial Ca2+ buffering (Hoth et al., 1997; Quintana et al., 2007).
However, little is known about the mitochondrial Ca2+ signaling in activated effector
cells and how it may contribute to CD4 cell effector functions. We examined whether an
increased MMP regulated by IL-6 could affect mitochondrial Ca2+ homeostasis. CD4
cells activated in the presence or absence of IL-6 for 48 h were stained with Rhod-2 AM,
a selective indicator for mitochondrial Ca2+ (Brisac et al., 2010; Hajnoczky et al., 1995)
and analyzed by flow cytometry. Consistent with an increased MMP, there was a
significantly greater frequency of cells with high levels of mitochondrial Ca2+ (Rhod2high) in the presence of IL-6 (Fig. 4A and 4C). Short treatment of IL-6-activated CD4
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cells with the depolarizing agent CCCP significantly reduced the frequency of cells with
high levels of mitochondrial Ca2+ (Rhod-2high) (Fig. 4B and 4C), indicating that the
increased levels of mitochondrial Ca2+ are dependent on mitochondrial hyperpolarization.
Because of their dynamic characteristics and ability to redistribute within the cell,
mitochondria play an important role in cytoplasmic Ca2+ homeostasis. Mitochondria
uptake Ca2+ through MCU at the cytoplasmic membrane near the extracellular calcium
channels, as well as from ER storage, and serve as a delivery vehicle to increase cytosolic
Ca2+ (Rizzuto et al., 2012; Soboloff et al., 2012). Thus, early during T cell activation
mitochondria have been shown to relocate close to immune synapses and contribute to
increase cytosolic Ca2+ (Quintana et al., 2007; Schwindling et al., 2010). To determine
whether the increase in mitochondrial Ca2+ elicited by IL-6 could affect the levels of free
cytosolic Ca2+, we examined the basal level of cytosolic Ca2+ in CD4 cells using Fura-2
AM as a calcium indicator. The levels of cytosolic Ca2+, as determined by the
fluorometric ratio at 340nm/380nm (F340/380), in cells activated with IL-6 were higher
than in cells activated without IL-6 (Fig. 4D). It has been previously shown that TCR
stimulation fails to induce cytosolic Ca2+ flux in activated CD4 cells (Nagaleekar et al.,
2008). Similarly, no Ca2+ flux was triggered by TCR stimulation in CD4 cells activated in
the presence of IL-6 (data not shown). However, similar to the results with Fura-2
staining, analysis of the cytosolic Ca2+ baseline by Indo-1 staining and flow cytometry
analysis also revealed higher baseline in CD4 cells activated in the presence of IL-6
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relative to cells activated in the absence of IL-6 (Figure 4-figure supplement 1A).
Maximum cytosolic Ca2+ levels triggered by the calcium ionophore, ionomycin were
comparable between CD4 cells activated in the presence or absence of IL-6 (Figure 4figure supplement 1A). Thus, the presence of IL-6 during activation maintains increased
levels of cytosolic Ca2+.
To demonstrate that this increased cytosolic Ca2+ was dependent on high
mitochondrial Ca2+, we examined the effect of CGP-37157, a blocker of mitochondrial
Ca2+ efflux (Cox et al., 1993). As previously demonstrated (Delmotte et al., 2012),
treatment with CGP-37157 resulted in increased levels of mitochondrial Ca2+ (Figure 4figure supplement 1B). Importantly, the treatment with CGP-37157 lowered the cytosolic
Ca2+ levels in CD4 cells activated in the presence of IL-6 to the levels found in those
without IL-6 (Fig. 4D), indicating that this increase was dependent on mitochondrial
Ca2+. In addition, reducing the MMP in IL-6-stimulated cells by treatment with inhibitors
of Complex I (rotenone) and Complex III (antimycin) also lowered the levels of cytosolic
Ca2+ (Fig. 4D). Similar effects were found by the treatment with CCCP (Figure 4-figure
supplement 1C). IL-6 therefore provides a mechanism for CD4 cells to maintain elevated
levels of cytosolic Ca2+ through its effect on the MMP and mitochondrial Ca2+.

The regulation of the MMP and mitochondrial Ca2+ elicited by IL-6 is Stat3
dependent
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In addition to its role as a transcription factor, several studies have shown the
presence of Stat3 in mitochondria where it regulates the electron transport chain (ETC)
primarily in tissues with high mitochondria content (Erlich et al., 2014a; Gough et al.,
2009; Heusch et al., 2011; Lachance et al., 2013; Wegrzyn et al., 2009; Zhang et al.,
2013). Although IL-6 is a major activator of Stat3, no studies have previously addressed
the regulation of Stat3 in mitochondria by this cytokines. However, the maintenance of
high MMP late during activation of CD4 cells by IL-6 could possibly be mediated by
Stat3. We first examined whether Stat3 could also be present in mitochondria in activated
CD4 cells by Western blot analysis using extracts from different subcellular fractions. As
expected, Stat3 was present in both the nucleus and cytosol (Fig. 5A). Interestingly,
however, high levels of Stat3 were also present in mitochondria (Fig. 5A). GAPDH and
COX IV were used as cytosolic and mitochondrial fraction markers, respectively (Fig.
5A). To examine whether localization of Stat3 in mitochondria was influenced by IL-6
during CD4 cell activation, we performed Western blot analysis using mitochondrial
extracts from CD4 cells activated in the presence or absence of IL-6 as well as from
freshly isolated CD4 cells. Only low levels of Stat3 were present in the mitochondrial
fraction from freshly isolated CD4 cells (Fig. 5B). High levels of Stat3 were detected in
mitochondria from activated cells, but these levels were further upregulated by IL-6 (Fig.
5B). In contrast, as a control, the levels of NDUFA9 were not affected by IL-6 (Fig. 5B).
IL-6 did not have an effect on the total levels of Stat3 either, as determined by Western111

blot using whole cell lysates (Fig. 5C). We also examined whether Stat3 in mitochondria
was phosphorylated. No phospho-Stat3 was detected in mitochondria from freshly
isolated CD4 cells (Fig. 5B). Phospho-Stat3 was present in mitochondria of activated
CD4 cells, but the levels were substantially higher in the presence of IL-6 (Fig. 5B).
Thus, IL-6 promotes the accumulation of Stat3 in mitochondria during CD4 cell
activation.
We then investigated whether IL-6 increases MMP in activated CD4 cells through
Stat3. CD4 cells from wild-type (Stat3+/+) mice and T-cell conditional Stat3 knockout
(Stat3-/-) mice (Takeda et al., 1998) were activated in the absence or presence of IL-6, and
MMP was examined 48 h later. Interestingly, IL-6 failed to increase MMP in Stat3deficient CD4 cells during activation (Fig. 5D and 5E), indicating that effect of IL-6 on
MMP in CD4 cells is dependent on Stat3. To address whether this effect of Stat3
dissociates from its activity as a transcription factor, we used CD4 cells from mice
expressing a mutant Stat3 (mut-Stat3) carrying a deletion at V463 residue (Stat3-Δ463)
that prevents DNA binding but does not affect Stat3 phosphorylation (Steward-Tharp et
al., 2014). This mutation was found in autosomal dominant hyperimmunoglobulin E
syndrome (Holland et al., 2007; Jiao et al., 2008; Minegishi et al., 2007). Expression of
mut-Stat3 in mice has been shown to act as dominant-negative and inhibit Stat3 mediated
transcription (Steward-Tharp et al., 2014). CD4 cells from WT and mut-Stat3 mice were
activated with or without IL-6 and MMP was examined after 48 h. IL-6 was still able to
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increase MMP in CD4 cells from mut-Stat3 mice (Fig. 5F). In addition, we also tested the
effect of Stattic, a well characterized inhibitor of Stat3 that blocks dimerization of Stat3
through phosphor-Tyr705 (Schust et al., 2006). The presence of Stattic, even at a relatively
high concentration (Schust et al., 2006), did not affect the MMP in IL-6-treated CD4 cells
(Figure 5-figure supplement 1A and B). Thus, correlating with the accumulation of Stat3
in mitochondria, the increased mitochondrial membrane potential in CD4 cells activated
in the presence of IL-6 requires Stat3, but it is independent of Stat3-mediated
transcription.
Although the presence of Stat3 in mitochondria and its role as a regulator of ETC
activity has now been widely reported in different cell types, no previous studies have
addressed the role of Stat3 in mitochondrial Ca2+. To further determine whether IL-6
increases mitochondrial Ca2+ through Stat3, we examined mitochondrial Ca2+ in Stat3+/+
and Stat3-/- CD4 cells activated in the presence or absence of IL-6. Interestingly, in the
absence of Stat3, IL-6 failed to maintain elevated levels of mitochondrial Ca2+ (Fig. 5G
and 5H). To show that this effect was not dependent on Stat3 transcriptional activity we
also examined mitochondrial Ca2+ in CD4 cells from mut-Stat3 mice. Unlike Stat3
deficient CD4 cells, IL-6 was capable to increase mitochondrial Ca2+ in mut-Stat3 CD4
cells (Fig. 5I and 5J). To further examine whether Stat3 is necessary for the regulation of
cytosolic Ca2+ elicited by IL-6, cytosolic Ca2+ levels were measured in Stat3+/+ or Stat3-/CD4 cells activated in the presence or absence of IL-6 using the Fura-2 AM assay. Unlike
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Stat3+/+ CD4 cells, IL-6 failed to increase cytosolic Ca2+ in Stat3-/- CD4 cells (Figure 5figure supplement 2). Together, these data show for the first time that Stat3 contributes to
mitochondrial Ca2+ in response to IL-6 and, consequently, cytosolic Ca2+ homeostasis.
Previous studies have demonstrated the association of Stat3 with Complex I of the
ETC through GRIM-19, a component of Complex I (Gough et al., 2009; Lufei et al.,
2003; Tammineni et al., 2013; Wegrzyn et al., 2009). No studies have reported whether
Stat3 is present in the ETC supercomplexes. Our studies above (Fig. 2D) indicate that IL6 facilitates the formation of ETC supercomplexes in CD4 cells. We therefore examined
whether mitochondrial Stat3 could also be recruited to the supercomplexes. BN-PAGE
was performed using mitochondrial extracts generated with digitonin from CD4 cells
activated in the presence or absence of IL-6. Supercomplex region of BN-PAGE was
excised and resolved by Western blot analysis for Stat3. As described above, the levels of
supercomplexes were increased in CD4 cells activated in the presence of IL-6 as
determined by the levels of NDUFA9 and NDUFV1 subunits of Complex I (Fig. 5K).
Interestingly, Stat3 was also present in the supercomplex region isolated from IL-6treated CD4 cells (Fig. 5K). Thus, Stat3 is recruited to the ETC supercomplexes, where it
can regulate activity of Complex I through interaction with GRIM-19.

Mitochondrial Ca2+ is essential for IL-6 to sustain the production of IL-21 and IL-4
late during activation of CD4 cells
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IL-6, in the absence of other cytokines, is the major inducer of IL-21 production by
CD4 cells in mouse and human (Diehl et al., 2012; Dienz et al., 2009; Nurieva et al.,
2008; Suto et al., 2008). Stat3 is considered the main transcription factor that induces Il21
gene expression (Chen et al., 2006; Kaplan et al., 2011; Nurieva et al., 2007; Zhou et al.,
2007). However, since Stat3 but not its transcriptional activity is required for IL-6 to
sustain MMP and Ca2+ during the activation of CD4 cells, this could be an additional
mechanism by which IL-6 promotes the production of IL-21. We therefore examined the
ability of IL-6 to induce IL-21 production in CD4 cells from mut-Stat3 mice in which
Stat3 is present but its transcriptional activity is impaired. Similarly to human CD4 cells
from patients with Hyper IgE syndrome expressing mut-Stat3, CD4 cells from mut-Stat3
mice have been shown to fail to produce IL-17, another cytokine gene regulated by Stat3
(de Beaucoudrey et al., 2008; Durant et al., 2010; Ma et al., 2008; Milner et al., 2008;
Minegishi et al., 2009; Renner et al., 2008; Steward-Tharp et al., 2014). Although IL-6
totally failed to induce IL-21 production in Stat3-/- CD4 cells (Fig. 6A), it was able to
trigger the production of IL-21 in mut-Stat3 CD4 cells (Fig. 6B). Thus, correlating with
its role on MMP and mitochondrial Ca2+, Stat3 can contribute to the production of IL-21
in response to IL-6 independently of its function of transcription factor.
A recent study has reported that sustained elevated cytosolic Ca2+ levels are
associated with the increased expression of Il21 in CD4 cells in vivo (Shulman et al.,
2014). We therefore investigated whether the sustained high MMP elicited by IL-6 late
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during the activation of CD4 cells could contribute to the production of IL-21 triggered
by this cytokine. CD4 cells were activated in the presence or absence of IL-6 for 42 h and
treated with rotenone and antimycin (R/A) or CCCP (to depolarize mitochondria) for
another 6 h. IL-21 levels in the supernatants were determined by ELISA. Although there
were already substantial levels of IL-21 at 42 h in cells activated with IL-6, these levels
steeply rose in the next 6 hours (Fig. 6C). However, the increase in IL-21 levels was
prevented by the treatment with R/A or CCCP (Fig. 6C), indicating that the late
production of IL-21 was dependent on the increased MMP caused by IL-6. To further
address whether IL-6-mediated mitochondrial Ca2+ contributes to the late production of
IL-21, CD4 cells were activated in the presence or absence of IL-6 for 42 h, and treated
with CGP-37157 to inhibit mitochondrial Ca2+ export for another 6 h. The increase in IL21 production was also prevented by CGP-37157 (Fig. 6C), showing that the increased
mitochondrial Ca2+ elicited by IL-6 also contributes to the late production of IL-21.
Similarly, CGP-37157 prevented the increase in IL-21 production late during activation
in mut-Stat3 CD4 cells, without effecting IL-2 production (Figure 6-figure supplement
1A and B).
We and others have shown that IL-6 can also promote the production of IL-4 during
activation (Diehl et al., 2002; Heijink et al., 2002; Rincon et al., 1997). Like IL-21,
sustained elevated cytosolic Ca2+ levels have been associated with the increased
expression of Il4 in CD4 cells in vivo (Shulman et al., 2014). We therefore examined the
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effect that interfering with mitochondrial membrane potential or Ca2+ has on IL-4
production later during activation. Similar to IL-21, the levels of IL-4 were increased in
the last 6 h in IL-6-stimulated CD4 cells, however R/A, CCCP or CGP-37157 prevented
this increase (Fig. 6D), indicating that the increased MMP and cytosolic Ca2+ regulated
by mitochondrial Ca2+ caused by IL-6 also contributes to the late production of IL-4. In
contrast, IL-6 had no effect on IL-2 production and treatment with R/A, CCCP or CGP37157 had no effect (Fig. 6E). We also examined the relative contribution of
transcription-independent function of Stat3 in the regulation of these other cytokines by
IL-6. Similar to IL-21, IL-4 production was strongly reduced in in Stat3-/- CD4 cells, but
not in mut-Stat3 CD4 cells (Figure 6-figure supplement 2). In contrast, IL-2 production
was more affected in mut-Stat3 CD4 cells than in Stat3-/- CD4 cells (Figure 6-figure
supplement 2), further supporting a transcription-independent role of Stat3 in the
regulation of IL-21 and IL-4 by IL-6.
To address whether mitochondrial Ca2+ could contribute to the IL-6-mediated gene
expression of these cytokines, we also examined mRNA levels of Il21, Il4 and Il2. CD4
cells were activated in the presence of or absence of IL-6, and treated with CGP-37157 to
inhibit mitochondrial Ca2+ export. The levels of Il21 and Il4 mRNA were significantly
increased in cells treated with IL-6 but 6 h of CGP-37157 treatment was sufficient to
reduce these levels (Fig. 6F). In contrast, Il2 mRNA levels were not increased by IL-6,
and treatment with CGP-37157 did not have an effect. Thus, mitochondrial Ca2+
117

regulated by IL-6 is required for sustaining cytokine gene expression induced by IL-6 in
CD4 cells late during activation.
In addition, we also addressed the relevance of mitochondrial Ca2+ uptake in the
regulation of cytokines by IL-6 using the RU360 compound, a specific MCU inhibitor
(Matlib et al., 1998). We confirmed that the treatment with RU360 lowered the
mitochondrial Ca2+ levels in CD4 cells activated in the presence of IL-6 (Figure 6-figure
supplement 3). Importantly, the treatment with RU360 reduced the production of IL-21 in
CD4 cells activated with IL-6 (Fig. 6G). RU360 however had no effect on IL-2
production (Fig. 6G). Thus, both uptake and export of mitochondrial Ca2+ plays a role in
the regulation of cytokine production by IL-6 in CD4 cells.

Increased mitochondrial Ca2+ elicited by IL-6 is required to sustain nuclear NFAT
accumulation late during activation of CD4 cells
Il21 gene expression is regulated by Stat3, a Ca2+-independent transcription factor,
but it is also regulated by the NFAT transcription factor (Durant et al., 2010; Kim et al.,
2005). NFAT is also required for Il4 gene expression (Diehl et al., 2002; Rao, 1994;
Rengarajan et al., 2002). Nuclear translocation of NFAT is dependent on increased
cytosolic Ca2+ and activation of the Ca2+-dependent phosphatase, calcineurin.
Mitochondrial Ca2+ has been shown to contribute to NFAT activation in sensory neurons
(Kim and Usachev, 2009). Since we have shown IL-6 promotes NFATc2 nuclear
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accumulation (Diehl et al., 2002), we examined whether this could be dependent on
mitochondrial Ca2+. CD4 cells were activated in the presence of or absence of IL-6 for 42
h, and treated with CGP-37157 for another 6 h to inhibit mitochondrial Ca2+ export. The
addition of CGP disrupted the nuclear accumulation of NFATc2 in cells treated with IL-6
(Fig. 7A). Thus, mitochondrial Ca2+ regulated by IL-6 is required for IL-6 to sustain
NFATc2 in the nucleus late during activation.
To address whether NFAT contributes to the production of IL-21 and IL-4 induced
by IL-6 late during activation, CD4 cells were activated in the presence or absence of IL6 for 42 h, and treated for another 6 h with FK506, a NFAT inhibitor (FK). FK506
blocked the production of IL-21 and IL-4 induced by IL-6, as determined by ELISA (Fig.
7B). In addition, inhibition of NFAT late during activation also reduced Il21 and Il4
mRNA levels in cells exposed to IL-6 (Fig. 7C). Therefore, high mitochondrial Ca2+ and
nuclear accumulation of NFAT triggered by IL-6 late during activation in CD4 cells is
required to sustain expression of Il21 and Il4.
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DISCUSSION
Most of the functions of IL-6 in CD4 cells have been assigned to a regulatory role on
gene expression through Stat3 as a transcription factor. However, in the light of studies
indicating that Stat3 localizes in mitochondria where it regulates the mitochondrial
respiratory chain through association with Complex I (Gough et al., 2009; Wegrzyn et al.,
2009), it was also possible that IL-6 could have an effect on mitochondria in CD4 cells.
Our studies here show for the first time that IL-6 maintains mitochondrial
hyperpolarization late during activation of CD4 cells and this has an impact on
mitochondrial Ca2+ and, thereby cytosolic Ca2+. We also show that the effect of IL-6 on
mitochondrial Ca2+ and baseline cytosolic Ca2+ requires the presence of Stat3, but it is
independent of its role as a transcription factor.
In recent years, growing interest has been focused on mitochondrial biology in T
cells. Bioenergetic profiling of T cells has revealed that T cell metabolism changes
dynamically during activation (Pearce et al., 2013; Wang and Green, 2012). Naïve T cells
maintain low rates of glycolysis and predominantly oxidize glucose-derived pyruvate via
OXPHOS, or engage fatty acid oxidation (FAO). After activation, they rapidly switch to
anabolic growth and biomass accumulation. This adaption to aerobic glycolysis is
specifically required for effector functions in T cells (Chang et al., 2013). IL-2 and IL-15
have been reported to regulate mitochondrial respiration and the balance between
glycolysis and oxidative phosphorylation (van der Windt et al., 2012). IL-2 has been
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shown to support aerobic glycolysis, while IL-15 increases spared respiratory capacity
and oxidative metabolism by enhancing mitochondrial biogenesis and fatty acid oxidation
in CD8 cells (Pearce et al., 2009; van der Windt et al., 2012). IL-6 has been recently
shown to regulate glucose homeostasis in myeloid cells and induce the switch from white
adipose tissue to brown fat in cancer induced cachexia (Mauer et al., 2014; Petruzzelli et
al., 2014). Here we show that IL-6 enhances the MMP in CD4 cells. However, this is
uncoupled from oxidative phosphorylation (i.e. ATP synthesis). In addition, IL-6 does
not alter the balance between glycolysis and oxidative glycolysis during activation.
Instead, we show that a sustained MMP elicited by IL-6 leads to an effect on
mitochondrial Ca2+. No other studies have linked cytokine effects to mitochondrial Ca2+
in CD4 cells.
While endoplasmic reticulum (ER)-derived Ca2+ has been extensively studied in T
cells, less is known about mitochondrial Ca2+ homeostasis in T cells. Mitochondrial Ca2+
has been previously shown to modulate store-operated calcium signaling early upon T
cell activation at the immunological synapse (Hoth et al., 1997; Quintana et al., 2007).
Here we show that IL-6 uses MMP to sustain elevated levels of mitochondrial Ca2+ late
during activation and, consequently, elevated levels of cytosolic Ca2+. We have
previously shown that the expression of IP3Rs is downregulated during the activation of
CD4 cells (Nagaleekar et al., 2008). It is therefore possible that the source of Ca2+ in CD4
cells is reprogramed during activation. ER- IP3R is the main source of Ca2+ during early
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activation of naïve CD4 cells at the synapse. However, mitochondrial Ca2+ could be the
major source to sustain cytosolic Ca2+ in activated CD4 cells. Our data indicate that IL-6
sustains cytosolic Ca2+ late during activation by increasing the MMP and mitochondrial
Ca2+. This provides a potential mechanism by which Tfh cells have increased free
cytosolic calcium levels (Shulman et al., 2014). More importantly, we show here for the
first time that mitochondrial Ca2+ plays a key role in promoting increased production of
cytokine by effector CD4 cells. Although IP3R-mediated Ca2+ release is essential for the
initial induction of cytokine gene expression (Feske, 2007), we have previously shown
that IP3R-mediated Ca2+ is not responsible for late production of cytokines by activated
CD4 cells (Nagaleekar et al., 2008). Thus, the source of Ca2+ for cytokine production is
also reprogrammed during activation of CD4 cells. Although we cannot discard the effect
of other transcription factors, our study shows that mitochondrial Ca2+ is required for IL6 to keep NFATc2 in the nucleus, and that NFAT contributes to late expression of Il21
and Il4.
Mitochondrial respiration has been shown to lead to ROS production caused by
proton leaks and ROS can lead to oxidative injury. A number of recent studies have
shown that mitochondrial ROS (mROS) can function as signaling intermediates, and the
mROS signaling is required for antigen-specific T cell activation and subsequent IL-2
production (Byun et al., 2008; Schieke et al., 2008; Sena et al., 2013). Although IL-6
increases the MMP, we did not observe an increase in the levels of mROS correlating
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with the effect of IL-6 facilitating the formation of respiratory supercomplexes. The
presence of ETC Supercomplexes is emerging as a novel but highly relevant aspect of
mitochondrial function (Acin-Perez et al., 2008; Althoff et al., 2011). The function of
these supercomplexes is to facilitate the transfer of electrons between ETC complexes to
minimize the risk of electron leak and, thereby, the risk of producing harmful ROS. Our
study demonstrates for the first time the presence of ETC supercomplexes in CD4 cells,
and the effect that IL-6 has in promoting the formation of these supercomplexes during
activation of CD4 cells. This could be a mechanism by which IL-6 can sustain elevated
MMP and Ca2+ while minimizing the production of mROS. Although the association of
Stat3 with individual complexes of the ETC has been previously described in heart and
cancer cells (Gough et al., 2009; Wegrzyn et al., 2009), here we show for the first time
the presence of Stat3 in the ETC supercomplexes in CD4 cells. Stat3 may also be present
in mitochondrial supercomplexes in other tissues such as heart.
Thus, here we identify a novel mechanism by which IL-6 promotes the production of
IL-21 and IL-4 late during the activation of CD4 cells. This new mechanism involves
Stat3 but as a factor regulating mitochondrial membrane potential and Ca2+ instead of its
function as a mediator of transcription. Our studies also reveal a novel function of
mitochondrial respiration in the control of cytokine production through its effect on
mitochondrial Ca2+ homeostasis.
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EXPERIMENTAL PROCEDURES
Mice.
C57BL/6J mice were purchased from Jackson Laboratories. Null IL-6 deficient mice (IL6 KO) were previously described (Poli et al., 1994). Stat3 conditional knockout (Stat3-/-)
mice were generated by crossing the homozygous floxed Stat3 mice (Stat3loxp/loxp)
(Takeda et al., 1998) with T cell-specific Lck-Cre transgenic [B6.Cg-Tg(Lck-cre)1Cwi
N9] mice (Lee et al., 2001). Mutant-Stat3 (mut-Stat3) mice have been previously
described (Steward-Tharp et al., 2014). OT-II TCR transgenic mice have been previously
described (Barnden et al., 1998). All mice were housed under sterile conditions at the
animal care facility at the University of Vermont. All procedures performed on the mice
were approved by the University of Vermont Institutional Animal Care and Use
Committee.

Cell Purification and activation In Vitro.
CD4 cells were isolated from spleen and lymph nodes by negative selection as previously
described (Diehl et al., 2002). For Stat3+/+ and Stat3-/- mice, CD4 cells were purified by
cell sorting (FACS-Aria; Becton Dickinson). CD4 cells were activated with plate-bound
anti-CD3 (2C11) (5 µg/ml) and soluble anti-CD28 (1 µg/ml) (BD Pharmingen) mAbs in
the presence or absence of IL-6 (50 ng/mL) (Miltenyi). Pharmacological inhibitors were
added to culture 42 h after activation and supernatants were harvested 6 h later.APCs
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were purified by depleting CD4 and CD8 T cells using positive selection (Miltenyi), and
followed by irradiation treatment (2000 rad). APCs and OT-II CD4 cells were cocultured at 4:1 ratio in the presence of 5 µM OVA323-339 peptide (Barnden et al., 1998)
with or without IL-6 (50 ng /mL) (Miltenyi) or anti-IL-6 (2.5 µg /mL) (BD Pharmingen).
Pharmacological inhibitors used were CGP-37157 (Tocris Bioscience) (10 µM), CCCP (2
µM), rotenone (2 µM), antimycin (2 µM), Ru360 (10 µM), FK506 (InvivoGen) (10 nM),
Stattic (10 µM).
Immunization experiment in vivo.
OT-II CD4 cells were purified from OT-II TCR transgenic mice (Thy1.1+) by positive
selection using anti-CD4 MACS beads (Miltenyi Biotec). 2x106 naïve OT-II TCR Tg T
cells in 100 µL PBS were transferred i.v. into WT or IL-6 KO hosts (Thy1.2+). After
overnight, adoptive hosts were simultaneously immunized i.p. with 200 µL of 50 µg OVA
absorbed on alum (4.5%, w/v). After 2 d immunization, spleens from immunized mice
were harvested and stained with fluorescent conjugated Abs (anti-Thy1.1, anti-Vα2, antiCD69, anti-CD4, anti-CD44) and TMRE followed by flow cytometry analysis. For each
experiment, three to four hosts were used in each group.

Flow cytometry analysis.
Mitochondrial membrane potential analysis was performed by staining CD4 cells with
TMRE (Molecular Probes) as previously described (Hatle et al., 2013). Mitochondrial
127

calcium analysis was performed by staining with Rhod-2 AM (Invitrogen; 5 or 10 µM)
for 1 h at 37°C, as previously described (Brisac et al., 2010). Mitochondrial ROS
production was determined by 10 minutes staining of cells with 5 µM MitoSox Red
(Molecular Probes). Live/dead cell viability staining (Molecular Probes) was performed
as recommended by the manufacturer. All samples were examined by flow cytometry
analysis using an LSRII flow cytometer (BD Biosciences) and Flowjo software.

Western blot analysis.
Whole-cell extracts were prepared in Triton lysis buffer. Mitochondrial, nuclear and
cytosolic extracts were purified using the cell fractionation kit-standard (MitoScience) for
CD4 cells. Western blot analyses were performed as previously described (Hatle et al.,
2013). Anti-Stat3, anti-phospho-Stat3 (Tyr705) (Cell Signaling), anti-actin, anti-GAPDH,
anti-rabbit IgG, and anti-goat IgG (Santa Cruz Biotechnology); anti-mouse IgG (Jackson
Immunologicals); anti-CoxIV (Cell Signaling); anti-NDUFA9, anti-NDUFS3
(MitoScience) Abs were used.

Electron Microscopy Imaging.
Cells were suspended in fixative for 60 min at 4°C (2% glutaraldehyde, 0.05% CaCl2,
0.1% MgCl2, 22 mM betaine in 0.1M Pipes buffer). After rinsing in Pipes buffer, the cell
pellets were embedded in 2% SeaPrep agarose, crosslinked with above fixative and
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postfixed with 1% osmium tetroxide for 1 h at 4°C. The samples were again rinsed in
Pipes buffer, followed by dehydration through graded ethanol, cleared in propylene oxide
and embedded in Spurr’s epoxy resin. Semithin sections (1 µm) were cut with glass
knives on a Reichert ultracut microtome, stained with methylene blue-azure II, and
evaluated for areas of interest. Ultrathin sections (60-80 nm) were cut with a diamond
knife, retrieved onto 200 mesh thin bar nickel grids, contrasted with uranyl acetate (2% in
50% ethanol) and lead citrate, and examined with a JEOL 1400 TEM (JOEL USA, Inc,
Peabody, MA) operating at 60kV. Twenty-five digital images were acquired with an
AMT XR611 CCD camera by systemic uniform random sampling from each sample.
Number of mitochondria and mitochondria with tight or expanded cristae was counted
manually.

Confocal Microscopy Analysis.
Activated CD4 cells (48 h) were cytospun and immunostained as previously described
(Diehl et al., 2002) using a specific anti-NFATc2 Ab (Upstate Biotechnology), followed
by Alexa568-conjugated secondary Ab. Nuclei were stained with TOPRO (Molecular
Probes). Images were recorded using a Zeiss LSM 510 Meta confocal laser scanning
imaging system (Carl Zeiss Microimaging).

Blue-Native PAGE.
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Purified mitochondria were solubilized in Native PAGE loading buffer (Invitrogen)
containing 2% digitonin (Sigma). Complexes were resolved by native electrophoresis
through gradient 4-16% Native PAGE Novex Bis-Tris gels (Invitrogen) as previously
described (Hatle et al., 2013). Proteins were transferred to PVDF membrane for Western
blot analysis with anti-NDUFA9 (MitoScience) and anti-Core I (MitoScience).
Supercomplexes regions were also excised from BN-PAGE, eluted in SDS sample buffer
and resolved in SDS-PAGE. Proteins were then transferred to PVDF membrane for
Western blot analysis with anti-NDUFA9, anti-NDUFV1 and anti-Stat3 Abs.

Mitochondrial respiration and extracellular acidification.
Oxygen consumption rates (OCR) were measured, as previously described (van der
Windt et al., 2012) under basal conditions and in response to oligomycinv (1 µM), FCCP
(1 µM), and rotenone + antimycin A (1 µM) with the Seahorse XF-24 Extracellular Flux
Analyzer (Seahorse Bioscience) using the XF Cell Mito Stress Test Kit. Extracellular
acidification rates (ECAR) were measured as recommended by the manufacturer using
the XF Glycolysis Stress Test Kit.

RNA Isolation and RT-PCR.
Total RNA was isolated from CD4 cells using the Qiagen micro RNeasy kit, as
recommended by manufacture (Qiagen). cDNA synthesis was performed as previously
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described (Hatle et al., 2013). cDNA was used to quantify the relative mRNA levels for
mouse Il21, Il4 and Il2 (Assays-on-DemandTM by Applied Biosystems) by conventional
RT-PCR (Applied Biosystems) using β2-microglobulin as housekeeping gene. The
relative values were determined by the comparative CT analysis method.

ELISA.
Cytokine levels in cell culture supernatants were determined by ELISA as previously
described (Diehl et al., 2002; Dienz et al., 2009; Dienz et al., 2007).

ATP and Lactic acid measurement.
ATP was measured on 105 cells and/or 100µl of culture supernatants by using ATP Lite
kit (Perkin Elmer) as recommended by the manufacturer in a TD-20/20 single tube
luminometer (Holland et al.). Lactate production was examined in CD4 cells (2x106)
activated for 48 h, washed and incubated for 2 h in media. Measurement of lactate in
supernatants was done using the Lactate assay Kit II (BioVision).

Cytosolic calcium measurement
Cytosolic calcium was measured by staining with Fura-2 AM (Molecular Probes) (5 µM)
for 30 minutes, followed by fluorometrically measurement (340/380 exication, 510
emission) in a Synergy H4 plate reader (Bio-tek). F340/380 value was calculated by
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dividing the fluorescence reading at 340nm by the fluorescence at 380nm exication. Cells
were also loaded for 45 min at 37°C with 10 µM Indo-1 (Molecular probes)
(Grynkiewicz et al., 1985), harvested, washed and transferred to a standard extracellular
solution (140 mM NaCl, 4 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 1 mM KH2PO4, 10 mM
glucose, 10 mM HEPES (pH 7.4)). The ratio of Ca2+-bound Indo-1 fluorescence (405
nm) to unbound indo-1 fluorescence (480 nm) was then determined by flow cytometry
analysis.

Statistical Analysis.
Significance of differences between two groups was determined using GraphPad Prism v.
5.0, by standard Student t-test. Significance of differences among more than 2 groups was
determined by one-way or two-way ANOVA. Standard P< 0.05 was used as the cutoff
for significance. For flow cytometry analysis, percentages of compared samples under the
same gate were analyzed by t-test or ANOVA in Prism.
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Figure 1. IL-6 sustains high mitochondrial membrane potential (MMP) late during
activation.
(A) MMP during activation of CD4 cells with anti-CD3/CD28 Abs over time in the
presence or absence of IL-6, as determined by staining with TMRE and flow cytometry
analysis. (B) Percentage of CD4 cells with TMREhigh (defined by the gate displayed in
(A) at 48 h, after activation as in (A) (n= 3). (C) MMP during activation of CD4 cells in
the absence or presence of IL-2 was determined by staining with TMRE and flow
cytometry analysis. (D) Expression of NDUFA9, NDUFS3, COX IV and ACTIN
examined by Western blot analysis using whole-cell extracts from CD4 cells activated for
48 h. (E) Percentage of live CD4 cells activated as in (A) for 48 h, determined by flow
cytometry. (n=3) (F) MMP in OT-II CD4 cells activated by WT or IL-6 KO APCs with
OVA peptide in the presence or absence of the supplement of exogenous of IL-6 (IL-6)
or blocking anti-IL-6 antibody (αIL-6) for 48 h. (n=3) (G) Percentage of TMREhigh
population in OT-II CD4 cells from (F) (n=3). (H) OT-II CD4 cells were adoptively
transferred to WT or IL-6 KO recipient mice that were then immunized with ovalbumin
(and Alum). After 2 days, cells were harvested to examine for MMP. Percentage of
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TMREhigh population in activated OT-II T cells from WT or IL-6 KO mice were
determined by TMRE staining and flow cytometry analysis. Error bars represent the
mean±SD. * denotes p < 0.05, as determined by Student t test. Results are representative
of 2-3 experiments.
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Figure 2. IL-6 facilitates the formation of respiratory chain supercomplexes in CD4
cells during activation.
(A) Transmission electron microscopy analysis of mitochondria in CD4 cells activated in
the presence or absence of IL-6. Original magnification, X6,000. Bars represent 500 nm;
Blue arrows indicate mitochondria (B) Representative image of an “expanded cristae”
mitochondrion (Left). Number of mitochondria with expanded cristae in CD4 cells
activated in the presence or absence of IL-6 (right). (n=25) (C) Representative image of a
“tight cristae” mitochondrion (Left). Number of mitochondria with tight cristae in CD4
cells activated in the presence or absence of IL-6 (right). (n=23). Error bars represent the
mean±SD. * denotes p < 0.05, as determined by Student t test. Results are representative
of 2 experiments. (D) Digitonin-soluble mitochondrial extracts from CD4 cells were
resolved by BN-PAGE and transferred onto a membrane (Western blot) and
immunoblotted for NDUFA9 and Core1 protein. Immunoreactivity for the two proteins
within the supercomplex (SC) region is shown. Immunoreactivity for NDUFA9 with
monomeric complex I (Com I) and Core1 with dimeric complex III (Com III) are shown.
Lower panels display the densitometry of NDUFA9 (left) and Core I (right) subunits
135

within the supercomplex region (SC) and densitometry at the individual Complex I (Com
I) and Complex III (Com III) respectively. (E) Mitochondrial ROS during activation of
CD4 cells with anti-CD3/28 Abs in the presence or absence of IL-6 for 48 h was
determined by staining with MitoSox and flow cytometry analysis. (F) Percentage of
CD4 cells with mROShigh, defined by the gate displayed in (E) at 48 h, after activation as
in (E) (n= 4). Error bars represent the mean±SD. * denotes p < 0.05, as determined by
Student t-test. Results are representative of 2 experiments.
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Figure 3. IL-6-mediated increase in mitochondrial membrane potential in CD4 cells
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(A) Intracellular ATP levels (per 104 cells) in CD4 cells activated in the presence (IL-6)
of absence of IL-6 (Med) (n=5). (B) Extracellular ATP levels in supernatants of CD4
cells activated for 48 h (n= 3). (C) Oxygen consumption rates in CD4 cells activated with
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FCCP or rotenone plus antimycin (R/A). Average of basal level OCR (n= 3) and the
average of maximal OCR (n= 3) are shown. (D) Lactate levels in supernatant of CD4
cells activated for 48 h (n= 3). (E) Extracellular acidification rates (ECAR) were
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two-way ANOVA. Results are representative of 2-3 experiments.
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Figure 5. The regulation of the MMP and mitochondrial Ca2+ elicited by IL-6 is
Stat3 dependent.
(A) CD4 cells were activated with anti-CD3 and anti-CD28 mAbs. After 48 h, cytosolic,
nuclear and mitochondrial fractions were prepared and used to examine Stat3 by Western
blot analysis. GAPDH and COX IV were used as markers for cytosol and mitochondria,
respectively. (B) Mitochondrial fractions from freshly isolated CD4 cells, and CD4 cells
activated (48 h) with (IL-6) or without IL-6 (Media) were analyzed for Stat3, phosphoStat3 (p-Stat3) and the Complex I subunit NDUFA9, as mitochondrial loading control.
Relative densitometry ratios of p-Stat3 to NDUFA9 and total Stat3 to NDUFA9 in cells
activated in the presence and absence of IL-6 are shown. (C) Total Stat3 levels in CD4
cells activated (48 h) with or without IL-6 were examined by Western blot analysis using
whole cell extracts. GAPDH was used as loading control. (D) MMP in Stat3+/+ or Stat3-/CD4 cells activated with anti-CD3/28 Abs in the presence or absence of IL-6 for 48 h
(n=3). (E) Percentage of TMREhigh population in Stat3+/+ or Stat3-/- CD4 cells activated
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activated from (n=3). (G) Mitochondrial Ca2+ (Rhod-2 AM staining) in Stat3+/+ or Stat3-/CD4 cells activated as in (D). (H) Percentage of Rhod-2high population (gate shown in
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staining) in WT or mut-Stat3 CD4 cells activated as in (D). (J) Percentage of Rhod-2high
population (gate shown in panel I) in WT or mut-Stat3 CD4 cells activated as in (D) (n=
3). (K) Mitochondrial fractions of CD4 cells activated (48 h) with or without IL-6 were
resolved by BN-PAGE. Supercomplexes regions (SC region) of BN-PAGE were excised
and analyzed for Stat3, NDUFA9 and NDUFV1 by Western blot analysis. Error bars
represent the mean±SD. * denotes p < 0.05, as determined by Student t test and one-way
or two-way ANOVA test. Results are representative of 2-3 experiments.
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Figure 6. Mitochondrial Ca2+ is essential for IL-6 to sustain the production of IL-21
and IL-4 late during activation of CD4 cells.
(A) CD4 cells from Stat3+/+ or Stat3-/- mice were activated in the presence or absence of
IL-6 for 48 h. IL-21 production was measured by ELISA. (B) IL-21 production from WT
or mut-Stat3 CD4 cells with or without IL-6 during activation was measured as in (A)
CD4 cells were activated in the presence or absence of IL-6. After 42 h,
rotenone/antimycin (R/A), CCCP, GCP-37157 or vehicle were added to the cultures.
Supernatants were collected 6 h later. IL-21 (C), IL-4 (D), IL-2 (E) production was
measured by ELISA. (F) Relative mRNA levels for IL-21, IL-4 and IL-2 in activated in
CD4 cells (48 h) were measured by real-time PCR (RT-PCR). (G) CD4 cells were
activated in the presence of IL-6. After 24 h, Ru360 or vehicle control (Veh) were added
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determined by two-way ANOVA test. Results are representative of 2-3 experiments.
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ANOVA test. Results are representative of 2-3 experiments.
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Figure 4-figure supplement 1. IL-6 maintains elevated cytosolic Ca2+ through its
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(A) Cytosolic calcium of CD4 cells activated with anti-CD3/CD28 Abs for 48h in the
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IL-4 and IL-2 production in the supernatant was measured by ELISA. The percentage of
IL-4 and IL-2 levels in mut-Stat3 and Stat3-/- CD4 cells relative to the levels in WT CD4
cells are provided. n= 3. * denotes p <0.05 as determined by student t-test, showing
greater reduction in IL-4 production in Stat3-/- CD4 cells than in mut-Stat3 cells relative
to WT cells. # denotes p<0.05 as determined by student t-test, showing greater reduction
in IL-2 production in mut-Stat3 cells than in Stat3-/- cells relative to WT cells.
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Figure 6-figure supplement 3. Ru360 decreases mitochondrial Ca2+ in CD4 cells in
response to IL-6 during activation.
Mitochondrial Ca2+ determined by Rhod-2 AM staining and flow cytometry analysis in
CD4 cells activated with IL-6 and treated with vehicle (Veh) or Ru360 (10 µM) for the
last 24 h.

149

REFERENCES:
Acin-Perez, R., Fernandez-Silva, P., Peleato, M.L., Perez-Martos, A., and Enriquez, J.A.
(2008). Respiratory active mitochondrial supercomplexes. Mol. Cell 32, 529-539.
10.1016/j.molcel.2008.10.021.
Althoff, T., Mills, D.J., Popot, J.L., and Kuhlbrandt, W. (2011). Arrangement of electron
transport chain components in bovine mitochondrial supercomplex I1III2IV1. Embo J 30,
4652-4664. emboj2011324 [pii]
10.1038/emboj.2011.324.
Barnden, M.J., Allison, J., Heath, W.R., and Carbone, F.R. (1998). Defective TCR
expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes
under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34-40.
10.1046/j.1440-1711.1998.00709.x.
Baughman, J.M., Perocchi, F., Girgis, H.S., Plovanich, M., Belcher-Timme, C.A.,
Sancak, Y., Bao, X.R., Strittmatter, L., Goldberger, O., Bogorad, R.L., et al. (2011).
Integrative genomics identifies MCU as an essential component of the mitochondrial
calcium uniporter. Nature 476, 341-345. 10.1038/nature10234.
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., and
Kuchroo, V.K. (2006). Reciprocal developmental pathways for the generation of
pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238.
10.1038/nature04753.
Boulanger, M.J., Chow, D.C., Brevnova, E.E., and Garcia, K.C. (2003). Hexameric
structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science
300, 2101-2104. 10.1126/science.1083901.
Bourillot, P.Y., Aksoy, I., Schreiber, V., Wianny, F., Schulz, H., Hummel, O., Hubner, N.,
and Savatier, P. (2009). Novel STAT3 target genes exert distinct roles in the inhibition of
mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells 27, 17601771. 10.1002/stem.110.
Brisac, C., Teoule, F., Autret, A., Pelletier, I., Colbere-Garapin, F., Brenner, C., Lemaire,
C., and Blondel, B. (2010). Calcium flux between the endoplasmic reticulum and
mitochondrion contributes to poliovirus-induced apoptosis. J. Virol. 84, 12226-12235.
10.1128/JVI.00994-10.
Byun, H.O., Kim, H.Y., Lim, J.J., Seo, Y.H., and Yoon, G. (2008). Mitochondrial
dysfunction by complex II inhibition delays overall cell cycle progression via reactive
oxygen species production. J. Cell. Biochem. 104, 1747-1759. 10.1002/jcb.21741.
Carpenter, R.L., and Lo, H.W. (2014). STAT3 Target Genes Relevant to Human Cancers.
Cancers 6, 897-925. 10.3390/cancers6020897.
Chang, C.H., Curtis, J.D., Maggi, L.B., Jr., Faubert, B., Villarino, A.V., O'Sullivan, D.,
150

Huang, S.C., van der Windt, G.J., Blagih, J., Qiu, J., et al. (2013). Posttranscriptional
control of T cell effector function by aerobic glycolysis. Cell 153, 1239-1251.
10.1016/j.cell.2013.05.016.
Chen, Z., Laurence, A., Kanno, Y., Pacher-Zavisin, M., Zhu, B.M., Tato, C., Yoshimura,
A., Hennighausen, L., and O'Shea, J.J. (2006). Selective regulatory function of Socs3 in
the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. USA 103, 8137-8142.
10.1073/pnas.0600666103.
Cogliati, S., Frezza, C., Soriano, M.E., Varanita, T., Quintana-Cabrera, R., Corrado, M.,
Cipolat, S., Costa, V., Casarin, A., Gomes, L.C., et al. (2013). Mitochondrial cristae shape
determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell
155, 160-171. 10.1016/j.cell.2013.08.032.
Cox, D.A., Conforti, L., Sperelakis, N., and Matlib, M.A. (1993). Selectivity of inhibition
of Na(+)-Ca2+ exchange of heart mitochondria by benzothiazepine CGP-37157. J
Cardiovasc Pharmacol 21, 595-599
de Beaucoudrey, L., Puel, A., Filipe-Santos, O., Cobat, A., Ghandil, P., Chrabieh, M.,
Feinberg, J., von Bernuth, H., Samarina, A., Janniere, L., et al. (2008). Mutations in
STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp.
Med. 205, 1543-1550. 10.1084/jem.20080321.
De Stefani, D., Raffaello, A., Teardo, E., Szabo, I., and Rizzuto, R. (2011). A fortykilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature
476, 336-340. 10.1038/nature10230.
Delmotte, P., Yang, B., Thompson, M.A., Pabelick, C.M., Prakash, Y.S., and Sieck, G.C.
(2012). Inflammation alters regional mitochondrial Ca(2)+ in human airway smooth
muscle cells. Am. J. Physiol. Cell Physiol 303, C244-256. 10.1152/ajpcell.00414.2011.
Diehl, S., Anguita, J., Hoffmeyer, A., Zapton, T., Ihle, J.N., Fikrig, E., and Rincon, M.
(2000). Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 13,
805-815
Diehl, S., Chow, C.W., Weiss, L., Palmetshofer, A., Twardzik, T., Rounds, L., Serfling, E.,
Davis, R.J., Anguita, J., and Rincon, M. (2002). Induction of NFATc2 expression by
interleukin 6 promotes T helper type 2 differentiation. J. Exp. Med. 196, 39-49
Diehl, S.A., Schmidlin, H., Nagasawa, M., Blom, B., and Spits, H. (2012). IL-6 triggers
IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell
differentiation in B cells. Immunol. Cell Biol. 90, 802-811. 10.1038/icb.2012.17.
Dienz, O., Eaton, S.M., Bond, J.P., Neveu, W., Moquin, D., Noubade, R., Briso, E.M.,
Charland, C., Leonard, W.J., Ciliberto, G., et al. (2009). The induction of antibody
production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J. Exp.
Med. 206, 69-78. 10.1084/jem.20081571.
151

Dienz, O., Eaton, S.M., Krahl, T.J., Diehl, S., Charland, C., Dodge, J., Swain, S.L., Budd,
R.C., Haynes, L., and Rincon, M. (2007). Accumulation of NFAT mediates IL-2
expression in memory, but not naive, CD4+ T cells. Proc. Natl. Acad. Sci. USA 104,
7175-7180. 10.1073/pnas.0610442104.
Dienz, O., and Rincon, M. (2009). The effects of IL-6 on CD4 T cell responses. Clin.
Immunol 130, 27-33. 10.1016/j.clim.2008.08.018.
Durant, L., Watford, W.T., Ramos, H.L., Laurence, A., Vahedi, G., Wei, L., Takahashi, H.,
Sun, H.W., Kanno, Y., Powrie, F., and O'Shea, J.J. (2010). Diverse targets of the
transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity
32, 605-615. 10.1016/j.immuni.2010.05.003.
Erlich, T.H., Yagil, Z., Kay, G., Peretz, A., Migalovich-Sheikhet, H., Tshori, S.,
Nechushtan, H., Levi-Schaffer, F., Saada, A., and Razin, E. (2014). Mitochondrial STAT3
plays a major role in IgE-antigen-mediated mast cell exocytosis. J. Allergy Clin.
Immunol. 10.1016/j.jaci.2013.12.1075.
Feske, S. (2007). Calcium signalling in lymphocyte activation and disease. Nat. Rev.
Immunol. 7, 690-702. 10.1038/nri2152.
Fried, S.K., Bunkin, D.A., and Greenberg, A.S. (1998). Omental and subcutaneous
adipose tissues of obese subjects release interleukin-6: depot difference and regulation by
glucocorticoid. J Clin Endocrinol Metab 83, 847-850. 10.1210/jcem.83.3.4660.
Gomes, L.C., Di Benedetto, G., and Scorrano, L. (2011). During autophagy mitochondria
elongate, are spared from degradation and sustain cell viability. Nat. Cell Biol. 13, 589598. 10.1038/ncb2220.
Gough, D.J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A.C., and Levy, D.E.
(2009). Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science
324, 1713-1716. 10.1126/science.1171721.
Grynkiewicz, G., Poenie, M., and Tsien, R.Y. (1985). A new generation of Ca2+
indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450
Hackenbrock, C.R. (1966). Ultrastructural bases for metabolically linked mechanical
activity in mitochondria. I. Reversible ultrastructural changes with change in metabolic
steady state in isolated liver mitochondria. J. Cell. Biol. 30, 269-297
Hajnoczky, G., Robb-Gaspers, L.D., Seitz, M.B., and Thomas, A.P. (1995). Decoding of
cytosolic calcium oscillations in the mitochondria. Cell 82, 415-424
Hatle, K.M., Gummadidala, P., Navasa, N., Bernardo, E., Dodge, J., Silverstrim, B.,
Fortner, K., Burg, E., Suratt, B.T., Hammer, J., et al. (2013). MCJ/DnaJC15, an
endogenous mitochondrial repressor of the respiratory chain that controls metabolic
alterations. Mol. Cell. Biol. 33, 2302-2314. 10.1128/MCB.00189-13.
Heijink, I.H., Vellenga, E., Borger, P., Postma, D.S., de Monchy, J.G., and Kauffman,
152

H.F. (2002). Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by
interleukin-2-dependent and -independent mechanisms in freshly isolated human T cells.
Immunology 107, 316-324
Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Muller-Newen, G., and Schaper,
F. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation.
Biochem. J 374, 1-20. 10.1042/BJ20030407.
Heusch, G., Musiolik, J., Gedik, N., and Skyschally, A. (2011). Mitochondrial STAT3
activation and cardioprotection by ischemic postconditioning in pigs with regional
myocardial
ischemia/reperfusion.
Circ.
Res
109,
1302-1308.
10.1161/CIRCRESAHA.111.255604.
Hirano, T., Ishihara, K., and Hibi, M. (2000). Roles of STAT3 in mediating the cell
growth, differentiation and survival signals relayed through the IL-6 family of cytokine
receptors. Oncogene 19, 2548-2556. 10.1038/sj.onc.1203551.
Holland, S.M., DeLeo, F.R., Elloumi, H.Z., Hsu, A.P., Uzel, G., Brodsky, N., Freeman,
A.F., Demidowich, A., Davis, J., Turner, M.L., et al. (2007). STAT3 mutations in the
hyper-IgE syndrome. N Engl J Med 357, 1608-1619. 10.1056/NEJMoa073687.
Hoth, M., Fanger, C.M., and Lewis, R.S. (1997). Mitochondrial regulation of storeoperated calcium signaling in T lymphocytes. J. Cell. Biol. 137, 633-648
Ivanov, II, McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., Cua,
D.J., and Littman, D.R. (2006). The orphan nuclear receptor RORgammat directs the
differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121-1133.
10.1016/j.cell.2006.07.035.
Jiao, H., Toth, B., Erdos, M., Fransson, I., Rakoczi, E., Balogh, I., Magyarics, Z.,
Derfalvi, B., Csorba, G., Szaflarska, A., et al. (2008). Novel and recurrent STAT3
mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol 46,
202-206. 10.1016/j.molimm.2008.07.001.
Kaplan, M.H., Glosson, N.L., Stritesky, G.L., Yeh, N., Kinzfogl, J., Rohrabaugh, S.L.,
Goswami, R., Pham, D., Levy, D.E., Brutkiewicz, R.R., et al. (2011). STAT3-dependent
IL-21 production from T helper cells regulates hematopoietic progenitor cell homeostasis.
Blood 117, 6198-6201. 10.1182/blood-2011-02-334367.
Kim, H.P., Korn, L.L., Gamero, A.M., and Leonard, W.J. (2005). Calcium-dependent
activation of interleukin-21 gene expression in T cells. J. Biol. Chem. 280, 25291-25297.
10.1074/jbc.M501459200.
Kim, M.S., and Usachev, Y.M. (2009). Mitochondrial Ca2+ cycling facilitates activation
of the transcription factor NFAT in sensory neurons. J. Neurosci. 29, 12101-12114.
10.1523/JNEUROSCI.3384-09.2009.
Kirichok, Y., Krapivinsky, G., and Clapham, D.E. (2004). The mitochondrial calcium
153

uniporter is a highly selective ion channel. Nature 427, 360-364. 10.1038/nature02246.
Kishimoto, T. (2005). Interleukin-6: from basic science to medicine--40 years in
immunology.
Annu.
Rev.
Immunol
23,
1-21.
10.1146/annurev.immunol.23.021704.115806.
Lachance, C., Goupil, S., and Leclerc, P. (2013). Stattic V, a STAT3 inhibitor, affects
human spermatozoa through regulation of mitochondrial activity. J. Cell Physiol. 228,
704-713. 10.1002/jcp.24215.
Lee, P.P., Fitzpatrick, D.R., Beard, C., Jessup, H.K., Lehar, S., Makar, K.W., PerezMelgosa, M., Sweetser, M.T., Schlissel, M.S., Nguyen, S., et al. (2001). A critical role for
Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity
15, 763-774
Lufei, C., Ma, J., Huang, G., Zhang, T., Novotny-Diermayr, V., Ong, C.T., and Cao, X.
(2003). GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via
functional interaction. EMBO J. 22, 1325-1335. 10.1093/emboj/cdg135.
Ma, C.S., Chew, G.Y., Simpson, N., Priyadarshi, A., Wong, M., Grimbacher, B., Fulcher,
D.A., Tangye, S.G., and Cook, M.C. (2008). Deficiency of Th17 cells in hyper IgE
syndrome due to mutations in STAT3. J. Exp. Med. 205, 1551-1557.
10.1084/jem.20080218.
Mallilankaraman, K., Cardenas, C., Doonan, P.J., Chandramoorthy, H.C., Irrinki, K.M.,
Golenar, T., Csordas, G., Madireddi, P., Yang, J., Muller, M., et al. (2012a). MCUR1 is an
essential component of mitochondrial Ca2+ uptake that regulates cellular metabolism.
Nat. Cell Biol. 14, 1336-1343. 10.1038/ncb2622.
Mallilankaraman, K., Doonan, P., Cardenas, C., Chandramoorthy, H.C., Muller, M.,
Miller, R., Hoffman, N.E., Gandhirajan, R.K., Molgo, J., Birnbaum, M.J., et al. (2012b).
MICU1 is an essential gatekeeper for MCU-mediated mitochondrial Ca(2+) uptake that
regulates cell survival. Cell 151, 630-644. 10.1016/j.cell.2012.10.011.
Mathur, A.N., Chang, H.C., Zisoulis, D.G., Stritesky, G.L., Yu, Q., O'Malley, J.T., Kapur,
R., Levy, D.E., Kansas, G.S., and Kaplan, M.H. (2007). Stat3 and Stat4 direct
development of IL-17-secreting Th cells. J. Immunol. 178, 4901-4907
Matlib, M.A., Zhou, Z., Knight, S., Ahmed, S., Choi, K.M., Krause-Bauer, J., Phillips, R.,
Altschuld, R., Katsube, Y., Sperelakis, N., and Bers, D.M. (1998). Oxygen-bridged
dinuclear ruthenium amine complex specifically inhibits Ca2+ uptake into mitochondria
in vitro and in situ in single cardiac myocytes. J. Biol. Chem. 273, 10223-10231
Mauer, J., Chaurasia, B., Goldau, J., Vogt, M.C., Ruud, J., Nguyen, K.D., Theurich, S.,
Hausen, A.C., Schmitz, J., Bronneke, H.S., et al. (2014). Signaling by IL-6 promotes
alternative activation of macrophages to limit endotoxemia and obesity-associated
resistance to insulin. Nat. Immunol. 15, 423-430. 10.1038/ni.2865.
154

Milner, J.D., Brenchley, J.M., Laurence, A., Freeman, A.F., Hill, B.J., Elias, K.M.,
Kanno, Y., Spalding, C., Elloumi, H.Z., Paulson, M.L., et al. (2008). Impaired T(H)17
cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature
452, 773-776. 10.1038/nature06764.
Minegishi, Y., Saito, M., Nagasawa, M., Takada, H., Hara, T., Tsuchiya, S., Agematsu, K.,
Yamada, M., Kawamura, N., Ariga, T., et al. (2009). Molecular explanation for the
contradiction between systemic Th17 defect and localized bacterial infection in hyperIgE syndrome. J. Exp. Med. 206, 1291-1301. 10.1084/jem.20082767.
Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N.,
Ariga, T., Pasic, S., Stojkovic, O., et al. (2007). Dominant-negative mutations in the
DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448, 1058-1062.
10.1038/nature06096.
Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D.R., Miles, J.M., Yudkin, J.S., Klein,
S., and Coppack, S.W. (1997). Subcutaneous adipose tissue releases interleukin-6, but not
tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82, 4196-4200.
10.1210/jcem.82.12.4450.
Nagaleekar, V.K., Diehl, S.A., Juncadella, I., Charland, C., Muthusamy, N., Eaton, S.,
Haynes, L., Garrett-Sinha, L.A., Anguita, J., and Rincon, M. (2008). IP3 receptormediated Ca2+ release in naive CD4 T cells dictates their cytokine program. J. Immunol.
181, 8315-8322
Nita, II, Hershfinkel, M., Fishman, D., Ozeri, E., Rutter, G.A., Sensi, S.L., Khananshvili,
D., Lewis, E.C., and Sekler, I. (2012). The mitochondrial Na+/Ca2+ exchanger
upregulates glucose dependent Ca2+ signalling linked to insulin secretion. PLoS One 7,
e46649. 10.1371/journal.pone.0046649.
Nurieva, R., Yang, X.O., Martinez, G., Zhang, Y., Panopoulos, A.D., Ma, L., Schluns, K.,
Tian, Q., Watowich, S.S., Jetten, A.M., and Dong, C. (2007). Essential autocrine
regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480-483.
10.1038/nature05969.
Nurieva, R.I., Chung, Y., Hwang, D., Yang, X.O., Kang, H.S., Ma, L., Wang, Y.H.,
Watowich, S.S., Jetten, A.M., Tian, Q., and Dong, C. (2008). Generation of T follicular
helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell
lineages. Immunity 29, 138-149. 10.1016/j.immuni.2008.05.009.
Palty, R., Silverman, W.F., Hershfinkel, M., Caporale, T., Sensi, S.L., Parnis, J., Nolte, C.,
Fishman, D., Shoshan-Barmatz, V., Herrmann, S., et al. (2010). NCLX is an essential
component of mitochondrial Na+/Ca2+ exchange. Proc. Natl. Acad. Sci. USA 107, 436441. 10.1073/pnas.0908099107.
Pasare, C., and Medzhitov, R. (2003). Toll pathway-dependent blockade of CD4+CD25+
T cell-mediated suppression by dendritic cells. Science 299, 1033-1036.
155

10.1126/science.1078231.
Pearce, E.L., Poffenberger, M.C., Chang, C.H., and Jones, R.G. (2013). Fueling
immunity: insights into metabolism and lymphocyte function. Science 342, 1242454.
10.1126/science.1242454.
Pearce, E.L., Walsh, M.C., Cejas, P.J., Harms, G.M., Shen, H., Wang, L.S., Jones, R.G.,
and Choi, Y. (2009). Enhancing CD8 T-cell memory by modulating fatty acid
metabolism. Nature 460, 103-107. 10.1038/nature08097.
Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J.,
Swarbrick, M., Rose-John, S., Rincon, M., Robertson, G., et al. (2014). A switch from
white to brown fat increases energy expenditure in cancer-associated cachexia. Cell
Metab 20, 433-447. 10.1016/j.cmet.2014.06.011.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G.,
Rodan, G.A., and Costantini, F. (1994). Interleukin-6 deficient mice are protected from
bone loss caused by estrogen depletion. EMBO J. 13, 1189-1196
Quintana, A., Schwindling, C., Wenning, A.S., Becherer, U., Rettig, J., Schwarz, E.C.,
and Hoth, M. (2007). T cell activation requires mitochondrial translocation to the
immunological synapse. Proc. Natl. Acad. Sci. USA 104, 14418-14423.
10.1073/pnas.0703126104.
Rao, A. (1994). NF-ATp: a transcription factor required for the co-ordinate induction of
several cytokine genes. Immunol. Today, 15, 274-281. 10.1016/0167-5699(94)90007-8.
Rengarajan, J., Mowen, K.A., McBride, K.D., Smith, E.D., Singh, H., and Glimcher, L.H.
(2002). Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate
interleukin 4 gene expression. J. Exp. Med. 195, 1003-1012
Renner, E.D., Rylaarsdam, S., Anover-Sombke, S., Rack, A.L., Reichenbach, J., Carey,
J.C., Zhu, Q., Jansson, A.F., Barboza, J., Schimke, L.F., et al. (2008). Novel signal
transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell
numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J.
Allergy Clin. Immunol. 122, 181-187. 10.1016/j.jaci.2008.04.037.
Rincon, M., Anguita, J., Nakamura, T., Fikrig, E., and Flavell, R.A. (1997). Interleukin
(IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J. Exp. Med. 185, 461469
Rizzuto, R., De Stefani, D., Raffaello, A., and Mammucari, C. (2012). Mitochondria as
sensors and regulators of calcium signalling. Nat. Rev. Mol. Cell Biol. 13, 566-578.
10.1038/nrm3412.
Schagger, H. (1995). Native electrophoresis for isolation of mitochondrial oxidative
phosphorylation protein complexes. Methods Enzymol. 260, 190-202
Schieke, S.M., McCoy, J.P., Jr., and Finkel, T. (2008). Coordination of mitochondrial
156

bioenergetics with G1 phase cell cycle progression. Cell Cycle 7, 1782-1787
Schust, J., Sperl, B., Hollis, A., Mayer, T.U., and Berg, T. (2006). Stattic: a smallmolecule inhibitor of STAT3 activation and dimerization. Chem Biol 13, 1235-1242.
10.1016/j.chembiol.2006.09.018.
Schwindling, C., Quintana, A., Krause, E., and Hoth, M. (2010). Mitochondria
positioning controls local calcium influx in T cells. J. Immunol. 184, 184-190.
10.4049/jimmunol.0902872.
Sena, L.A., Li, S., Jairaman, A., Prakriya, M., Ezponda, T., Hildeman, D.A., Wang, C.R.,
Schumacker, P.T., Licht, J.D., Perlman, H., et al. (2013). Mitochondria are required for
antigen-specific T cell activation through reactive oxygen species signaling. Immunity
38, 225-236. 10.1016/j.immuni.2012.10.020.
Shanmughapriya, S., Rajan, S., Hoffman, N.E., Zhang, X., Guo, S., Kolesar, J.E., Hines,
K.J., Ragheb, J., Jog, N.R., Caricchio, R., et al. (2015). Ca2+ signals regulate
mitochondrial metabolism by stimulating CREB-mediated expression of the
mitochondrial Ca2+ uniporter gene MCU. Sci Signal 8, ra23. 10.1126/scisignal.2005673.
Shulman, Z., Gitlin, A.D., Weinstein, J.S., Lainez, B., Esplugues, E., Flavell, R.A., Craft,
J.E., and Nussenzweig, M.C. (2014). Dynamic signaling by T follicular helper cells
during
germinal
center
B
cell
selection.
Science 345,
1058-1062.
10.1126/science.1257861.
Smart, N., Mojet, M.H., Latchman, D.S., Marber, M.S., Duchen, M.R., and Heads, R.J.
(2006). IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves
mitochondrial function in cardiomyocytes. Cardiovasc. Res 69, 164-177.
10.1016/j.cardiores.2005.08.017.
Soboloff, J., Rothberg, B.S., Madesh, M., and Gill, D.L. (2012). STIM proteins: dynamic
calcium signal transducers. Nat. Rev. Mol. Cell Biol. 13, 549-565. 10.1038/nrm3414.
Stanford, K.I., Middelbeek, R.J., Townsend, K.L., An, D., Nygaard, E.B., Hitchcox,
K.M., Markan, K.R., Nakano, K., Hirshman, M.F., Tseng, Y.H., and Goodyear, L.J.
(2013). Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin
Invest 123, 215-223. 10.1172/JCI62308.
Starkov, A.A. (2010). The molecular identity of the mitochondrial Ca2+ sequestration
system. FEBS J 277, 3652-3663. EJB7756 [pii]
10.1111/j.1742-4658.2010.07756.x.
Steward-Tharp, S.M., Laurence, A., Kanno, Y., Kotlyar, A., Villarino, A.V., Sciume, G.,
Kuchen, S., Resch, W., Wohlfert, E.A., Jiang, K., et al. (2014). A mouse model of HIES
reveals pro- and anti-inflammatory functions of STAT3. Blood 123, 2978-2987.
10.1182/blood-2013-09-523167.
Suto, A., Kashiwakuma, D., Kagami, S., Hirose, K., Watanabe, N., Yokote, K., Saito, Y.,
157

Nakayama, T., Grusby, M.J., Iwamoto, I., and Nakajima, H. (2008). Development and
characterization of IL-21-producing CD4+ T cells. J. Exp. Med. 205, 1369-1379.
10.1084/jem.20072057.
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., and Akira, S. (1998). Stat3
activation is responsible for IL-6-dependent T cell proliferation through preventing
apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J.
Immunol. 161, 4652-4660
Tammineni, P., Anugula, C., Mohammed, F., Anjaneyulu, M., Larner, A.C., and Sepuri,
N.B. (2013). The import of the transcription factor STAT3 into mitochondria depends on
GRIM-19, a component of the electron transport chain. J. Biol. Chem. 288, 4723-4732.
10.1074/jbc.M112.378984.
Tanaka, T., and Kishimoto, T. (2012). Targeting interleukin-6: all the way to treat
autoimmune and inflammatory diseases. Int. J. Biol. Sci. 8, 1227-1236.
10.7150/ijbs.4666.
van der Windt, G.J., Everts, B., Chang, C.H., Curtis, J.D., Freitas, T.C., Amiel, E., Pearce,
E.J., and Pearce, E.L. (2012). Mitochondrial respiratory capacity is a critical regulator of
CD8+ T cell memory development. Immunity 36, 68-78. 10.1016/j.immuni.2011.12.007.
Vgontzas, A.N., Papanicolaou, D.A., Bixler, E.O., Hopper, K., Lotsikas, A., Lin, H.M.,
Kales, A., and Chrousos, G.P. (2000). Sleep apnea and daytime sleepiness and fatigue:
relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol
Metab 85, 1151-1158. 10.1210/jcem.85.3.6484.
Wang, R., and Green, D.R. (2012). Metabolic checkpoints in activated T cells. Nat.
Immunol. 13, 907-915. 10.1038/ni.2386.
Wegrzyn, J., Potla, R., Chwae, Y.J., Sepuri, N.B., Zhang, Q., Koeck, T., Derecka, M.,
Szczepanek, K., Szelag, M., Gornicka, A., et al. (2009). Function of mitochondrial Stat3
in cellular respiration. Science 323, 793-797. 10.1126/science.1164551.
Winge, D.R. (2012). Sealing the mitochondrial respirasome. Mol. Cell. Biol. 32, 26472652. 10.1128/MCB.00573-12.
Yip, L., Woehrle, T., Corriden, R., Hirsh, M., Chen, Y., Inoue, Y., Ferrari, V., Insel, P.A.,
and Junger, W.G. (2009). Autocrine regulation of T-cell activation by ATP release and
P2X7 receptors. FASEB J 23, 1685-1693. 10.1096/fj.08-126458.
Zhang, Q., Raje, V., Yakovlev, V.A., Yacoub, A., Szczepanek, K., Meier, J., Derecka, M.,
Chen, Q., Hu, Y., Sisler, J., et al. (2013). Mitochondrial localized Stat3 promotes breast
cancer growth via phosphorylation of serine 727. J. Biol. Chem. 288, 31280-31288.
10.1074/jbc.M113.505057.
Zhou, L., Ivanov, II, Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D.E., Leonard,
W.J., and Littman, D.R. (2007). IL-6 programs T(H)-17 cell differentiation by promoting
158

sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967-974.
10.1038/ni1488.

159

CHAPTER 3

160

Mitochondrial Stat3, the need for design thinking

Rui Yang, Mercedes Rincon1
Department of Medicine/Immunobiology Program, University of Vermont, Burlington,
VT, USA, 05405
1

To whom correspondence may be addressed.

Address: University of Vermont College of Medicine, Given Medical Building Room
C331, 89 Beaumont Ave., Burlington, VT 05405-0068, USA. Phone: 802-656-0937;
email: mrincon@uvm.edu

161

Abstract
Stat3 has been studied extensively as a transcription factor; however, the finding that
Stat3 also localizes to mitochondria has opened a new area to discover non-classical
functions. Here we review the current knowledge of mitochondrial Stat3 as a regulator of
the electron transport chain (ETC) and its impact on mitochondrial production of ATP
and ROS. We also describe recent findings identifying Stat3 as a regulator of
mitochondrial Ca2+ homeostasis through its effect on the ETC. It is becoming evident that
these non-classical functions of Stat3 can have a major impact on cancer progression,
cardiovascular diseases, and inflammatory diseases. Therefore, mitochondrial Stat3
functions challenge the current design of therapies that solely target Stat3 as a
transcription factor and suggest the need for “design thinking,” which leads to the
development of novel strategies, to intervene in the Stat3 pathway.
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1. Introduction
Signal Transducers and Activators of Transcription family 3 (Stat3) plays a crucial
role in normal development, acute phase response, chronic inflammation, autoimmunity,
metabolism and cancer progression (Levy and Lee, 2002). Stat3 was first identified as an
acute phase response factor (APRF) which selectively interacts with the promoter regions
of acute phase genes in IL-6-stimulated hepatocytes (Akira et al., 1994; Lutticken et al.,
1994; Raz et al., 1994; Zhong et al., 1994b). Stat3 is activated by a family of cytokines
which share the same signal transducer gp130, including IL-6, IL-11, LIF (leukaemia
inhibitory factor), OSM (oncostatin M), ciliary neurotrophic factor (CNTF),
cardiotrophin-1 and cardiotrophin-like cytokines (Heinrich et al., 2003). Several gp130
independent stimuli including epidermal growth factor (EGF), hepatocyte growth factor
(HGF), IL-10, leptin also activate Stat3 (Heinrich et al., 2003). Stat3 is abundantly
expressed in most tissues. Stat3 is structurally similar to other Stat proteins, containing a
conserved N-terminal domain involved in tetramerization and cooperativity, a Src
homology 2 (SH2) domain for homodimerization, a DNA-binding domain and a Cterminal transactivating domain (Becker et al., 1998; Xu et al., 1996). There are two
alternatively spliced Stat3 isoforms: the full-length Stat3α (a 770 amino acid protein) and
truncated isoform Stat3β (containing amino acid 1-715 and 7 unique amino acids due to a
frame-shift) (Caldenhoven et al., 1996; Maritano et al., 2004; Schaefer et al., 1995; Yoo
et al., 2002). While Stat3α and Stat3β share most features in cellular signaling and
functions, Stat3α has some non-redundant features in regulating IL-6 signaling, including
the upregulation of the negative feeback protein SOCS3 in response to IL-6 (Maritano et
al., 2004).
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As a major stimulus of Stat3, engagement of IL-6 with IL-6 receptor α (IL-6Rα)
recruits the ubiquitously expressed signal transducer gp130. Engagement of gp130 by IL6 and other cytokines that signal through Stat3 leads to the activation of Jak1, Jak2 and
Tyk2 (Lutticken et al., 1994; Narazaki et al., 1994; Stahl et al., 1994). Activation of Jak
family kinases stimulates downstream transcription factor Stat3 (Boulanger et al., 2003;
Heinrich et al., 1998). Stat3 is phosphorylated at two well-studied phosphorylation sites,
Tyr705 and Ser727. Tyr705 phosphorylation in response to cytokine stimulation is mediated
by Janus kinases, Jak1, Jak2 and Tyk2, with Jak1 being the preferential kinase (Guschin
et al., 1995). Phosphorylation of Tyr705 leads to Stat3 homodimerization, nuclear
translocation, DNA binding and downstream transcriptional activities (Fig. 1). The Ser727
phosphorylation is more complex because different activation signals lead to serine
phosphorylation by different kinases, including ERK1, ERK2, p38, JNK and MAP
kinases (Decker and Kovarik, 2000). Ser727 phosphorylation at the transcativating domain
is considered a secondary event after Tyr705 phosphorylation (Fig. 1). This is required for
the maximal transcriptional activity of Stat3 (Wen et al., 1995). In addition, Stat3 has also
been shown to form a heterodimer with Stat1 in response to IL-6 stimulation (Zhong et
al., 1994a).
Although Stat3 has been studied as a transcription factor for decades, a small pool of
Stat3 (mitoStat3) was found localized in mitochondria, where it functions as a positive
regulator of mitochondrial electron transport chain (ETC) (Gough et al., 2009; Wegrzyn
et al., 2009). A number of follow up studies have further confirmed the presence of Stat3
in mitochondria in different cells and tissues. Besides the pivotal role in cellular
metabolism, the functions of mitoStat3 have been expanded to include cell death,
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development, cancer transformation, ischemia/reperfusion (I/R) heart injury, sperm
motility, T cell immunity and others (Boengler et al., 2010; Gough et al., 2009; Heusch et
al., 2011; Lachance et al., 2013; Shulga and Pastorino, 2012; Szczepanek et al., 2011;
Wegrzyn et al., 2009; Yang et al., 2015b; Zhang et al., 2013; Zhou and Too, 2011).
In light of the recent findings supporting new aspects of mitoStat3 in regulating
mitochondrial metabolism and cellular function, and the rapidly growing interest in
mitoStat3 from the therapeutical point of view, the goal of this review is to summarize
these new discoveries and provide an overview of where the field is heading.
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2. Regulation of mitochondrial function by mitochondrial Stat3
As a transcription factor, the role of Stat3 in the regulation of genes from acute phase
response, chronic inflammation, and cancer development has been well characterized
(Levy and Lee, 2002; Yu et al., 2014). Null disruption of Stat3 gene in mice leads to
early embryonic degeneration and lethality (Takeda et al., 1997). Interestingly, however,
many autosomal-dominant Hyper-IgE syndrome patients who bear a dominant negative
mutation in Stat3 that disrupts its DNA binding transcriptional activity do not exhibit
major developmental defects (de Beaucoudrey et al., 2008; Milner et al., 2008; Minegishi
et al., 2009). These findings posed the question whether some of the initial Stat3
functions might be independent of its activity as a transcription factor. While it was
generally believed that Stat3 was just a transcription factor, several studies observed that
GRIM-19, a component of Complex I of ETC, binds to Stat3 directly (Lufei et al., 2003;
Zhang et al., 2003). These studies paved the way for later revolutionary findings that
some Stat3 localizes in mitochondria (Gough et al., 2009; Wegrzyn et al., 2009). Despite
several studies reporting controversial results that GFP tagged Stat3 is excluded from
mitochondria (Cimica et al., 2011) and disproportioned stoichiometry analysis (Phillips et
al., 2010) between Stat3 and ETC complexes, growing evidences have confirmed the
presence of mitoStat3 and its role in regulating cellular metabolism and various
functions.
•

2.1 The role of mitoStat3 in the regulation of electron transport chain and

mitochondrial ATP synthesis.
MitoStat3 is associated with the inner mitochondrial membrane where Complex I
resides (Tammineni et al., 2013). As with most mitochondrial proteins encoded by
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nuclear genes, the mechanisms by which Stat3 is transported to the mitochondria remain
unclear. Although the C-terminus of Stat3 has been shown to be required for
mitochondrial transport no specific mitochondrial targeting signal has been identified.
Since Stat3 associates with GRIM-19, a component of the ETC Complex I, most likely
Stat3 transport to mitochondria is mediated by GRIM-19 through the mitochondrial
importer Tom20 (Boengler et al., 2010; Lufei et al., 2003; Shulga and Pastorino, 2012;
Tammineni et al., 2013; Zhang et al., 2003) (Fig. 1). In addition, heat shock protein 22
(Hsp22) has also been suggested to be an alternative shuttle for mitoStat3 (Qiu et al.,
2011) (Fig. 1). MitoStat3 is not required for mitochondrial maintenance or formation
(Gough et al., 2009). However, it enhances the activities of complex I and complex II of
ETC (Wegrzyn et al., 2009). In Stat3 deficient pro-B cells, the activities of Complex I
and Complex II are reduced, but expression of a mitochondrial-targeted Stat3 (MLSStat3) rescues the ETC Complex I and II activities (Wegrzyn et al., 2009). This shows
that mitoStat3 maintains ETC activities independent of nuclear activities. MitoStat3 has
also been shown to enhance the activity of Complex V in cells undergoing oncogenic
transformation (Gough et al., 2009). Intriguingly, mitoStat3 also enhances ETC Complex
IV activity in FGFR-R388 single nucleotide polymorphic variant cells (Tateno et al.,
2011). The biochemical mechanisms by which mitoStat3 regulates ETC complex
activities have been investigated by several groups. MitoStat3 directly interacts with
Complex I and possibily Complex II of ETC (Wegrzyn et al., 2009), suggesting that
mitoStat3 cooperatively enhances the enzyme activities of Complex I and II of ETC.
Interestingly, both Tyr705 and Ser727 phosphorylation of Stat3 have been found in
mitochondria (Heusch et al., 2011; Wegrzyn et al., 2009; Yang et al., 2015b; Zhang et al.,
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2013). However, Stat3 Tyr705 phosphorylation does not seem to be required for the
optimal activities of ETC in several cell types (Wegrzyn et al., 2009). In contrast, Ser727
phosphorylation is critical for mitoStat3 to enhance ETC Complex I and Complex II
activities (Gough et al., 2009; Wegrzyn et al., 2009).
Complex I largely contributes to establishing the mitochondrial membrane potential
(MMP) across the inner membrane by pumping protons to the intermembrane space. The
contribution of Stat3 to the maintenance of MMP appears to be dependent on cell types
or metabolic requirements of cells. In H-ras transformed fibroblasts, Stat3 does not seem
to be required for MMP (Gough et al., 2009). In contrast, disruption of Stat3 reduces
MMP in other conditions, such as astrocytes (Sarafian et al., 2010). While naïve CD4 T
lymphocytes prior activation have high MMP, we have shown that upon activation MMP
decreases over time (Yang et al., 2015b). However, if IL-6 is present during the
activation of CD4 T cells, MMP remains high (Yang et al., 2015b). The effect of IL-6 on
preventing mitochondrial depolarization in these cells is Stat3-dependent (Yang et al.,
2015b). Furthermore, we have shown that the effect of Stat3 on MMP is independent of
its transcription-mediated activities (Yang et al., 2015b). Thus, the contribution of
mitoStat3 to MMP is most likely determined by the metabolic state of the cells and
specific requirements of mitochondrial respiration. Alternatively, since in addition to
Complex I both Complex III and IV contribute to the generation of MMP, the role of
mitoStat3 in MMP could be determined by the relative proportion of contribution by
Complex I.
MMP is primarily used for ATP synthesis by Complex V of the ETC. This process is
defined as oxidative phosphorylation (OXPHOS) because it is coupled to oxygen
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consumption. The lack of mitoStat3 lowers the levels of ATP in cells undergoing
oncogenic transformation (Gough et al., 2009). Tissue specific disruption of Stat3 also
reduces ATP production in astrocytes (Sarafian et al., 2010). IL-6 promotes mitoStat3
translocation in pancreatic cancer cell lines panc02 and panc02.03, and leads to a
significant increase in the levels of ATP (Kang et al., 2012a). Together, in most tissues
and cells, mitoStat3 positively regulates ETC activities and this results in elevated ATP
production (Fig. 2).
Interestingly, we have recently reported that IL-6 also facilitates mitoStat3
translocation in activated mouse CD4 T cells. However, the increase in mitoStat3 does
not result in any changes in ATP levels (Yang et al., 2015b). This suggests that the effect
of mitoStat3 in the regulation of ATP production could be cell type and tissue type
specific.
•

2.2. Exploring the role of mitoStat3 in calcium homeostasis

While a major function of the mitochondrial membrane potential is to drive the
synthesis of ATP by OXPHOS, it is also used to regulate Ca2+ uptake into the
mitochondria (Rizzuto et al., 2012) (Fig. 2). Mitochondria were one of the first
intracellular organelles to be associated with Ca2+ storage. In recent years, mitochondria
are emerging as a critical organelle in buffering cytosolic Ca2+. The uptake of Ca2+ into
the mitochondrial matrix through the ion impermeable inner mitochondrial membrane is
mediated by the recently identified mitochondrial calcium uniporter (MCU), using the
mitochondrial membrane potential gradient (Baughman et al., 2011; De Stefani et al.,
2011; Shanmughapriya et al., 2015). Mitochondrial Ca2+ is then released to the cytosol by
the mitochondrial Na+/Ca+ exchanger (mNCX) and mitochondrial H+/Ca2+ exchanger

169

(mHCX) (Crompton et al., 1977; Palty et al., 2010; Rizzuto et al., 2012) (Fig. 2). The
uptake and release of Ca2+ by mitochondria contributes to the cytosolic Ca2+ homeostasis.
Although mitoStat3 is known to regulate ETC activity and contribute to establishment of
MMP, no studies had revealed its role in mitochondrial Ca2+ homeostasis until recently.
We have recently shown that IL-6 sustains mitochondrial membrane polarization during
the activation of CD4 cells, and that this effect is mediated by Stat3 independently of its
transcriptional activity (Yang et al., 2015b). Surprisingly, despite its effect on
mitochondrial membrane potential, we found that IL-6 does not affect ATP synthesis,
oxygen consumption rate or glycolytic rate (Yang et al., 2015b). However, we discovered
that the sustained mitochondrial polarization triggered by IL-6 is essential to promote
mitochondrial Ca2+ influx through MCU, and requires Stat3 but not its transcriptional
activity (Yang et al., 2015b). Thus, in addition of its role in modulating mitochondrial
respiration, mitoStat3 can also regulate mitochondrial Ca2+ through its effect on the ETC
and mitochondrial membrane potential (Fig. 2). While endoplasmic reticulum (ER) is the
best characterized intracellular Ca2+ storage that regulates cytosolic Ca2+, a number of
studies have now proposed that mitochondria could be even more essential since it serves
as a vehicle to deliver Ca2+ from ER to the cytosol (Billups and Forsythe, 2002; Medler
and Gleason, 2002; Rizzuto et al., 2012; Tang and Zucker, 1997) (Fig. 2). We have
shown that CD4 cells activated with IL-6 through mitoStat3 maintain higher cytosolic
Ca2+ levels using mitochondrial Ca2+ as a source (Yang et al., 2015b). In addition,
mitoStat3 can also regulate cytosolic Ca2+ through the mitochondrial permeability
transition pore (MPTP), a Ca2+-dependent nonselective pore that is opened to release Ca2+
and cytochrome C from mitochondria matrix to cytosol, leading to cell death (Fig. 2).

170

Therefore, in addition to the regulation of mitochondrial ATP production, mitoStat3 also
plays a role in Ca2+ homeostasis.
•

2.3. MitoStat3 in the regulation of ROS

In mitochondria, ETC Complex I, II and III shuttle electrons for Complex IV
(cytochrome c oxidase) to complete reduction of O2 to H2O. However, electron leakage
also occurs when electrons passed down the respiratory chain exit prior to the reduction
of O2 to H2O at Complex IV, forming reactive oxygen species (ROS). Accumulation of
ROS has been linked to multiple pathological conditions, including neurodegenerative
diseases, ischemia/reperfusion injuries, diabetes, cancer and aging (Murphy, 2009; Sena
and Chandel, 2012). Although mitoStat3 enhances ETC activity, the role of mitoStat3 in
the regulation of mitochondrial ROS is less clear. TNFα induces Ser727 phosphorylation
of Stat3 in L929 cells. This leads to increased Stat3-GRIM-19 interaction, which results
in increased mitoStat3 translocation (Shulga and Pastorino, 2012, 2014). Increased ROS
production by TNFα could be mediated by mitoStat3 (Shulga and Pastorino, 2012, 2014;
Zouein et al., 2014). Similarly, increased ROS production by nerve growth factor (NGF)
in PC12 cells has also been associated with increased Stat3 mitochondrial localization
(Zhou and Too, 2011). In contrast to these studies suggesting that mitoStat3 promotes
ROS production, several other studies suggest that mitoStat3 prevents ROS production.
Stat3 deficient astrocytes produce high levels of ROS, leading to increased cell death
(Sarafian et al., 2010). The levels of ROS are also higher in several mouse bone marrow
subtype cells of Stat3 deficient mice relative to wild-type (Mantel et al., 2012). Upon
induction of cardiac ischemia, expression of transcriptionally inactive mitochondriatargeted Stat3 in heart in a transgenic mouse model (MLS-STAT3E mice) significantly
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reduces the production of ROS, preserving heart tissues during ischemia/reperfusion
injuries (Szczepanek et al., 2011). Similarly, expression of MLS-Stat3 also reduces ROS
production in the murine breast cancer 4T1 cells (Zhang et al., 2013). We have also
shown that IL-6 increases MMP by mitoStat3 in mouse CD4 cells, but this effect is
associated with a reduced ROS production (Yang et al., 2015b). Therefore, although not
yet clear, there is growing evidence to suggest that while mitoStat3 can promote ETC
activity in mitochondria, it can also suppress the production of mitochondrial ROS (Fig.
2).
The mechanisms by which mitoStat3 could minimize the production of mitochondrial
ROS while increasing electron transport at the ETC also remain unclear. However, a
recent metabolomics study has revealed that mitoStat3 is required for the functions of
gamma-glutamyl cycle, and the formation of glutathione, which can balance the normal
redox stage (Garama et al., 2015). Thus, while electron leaks may still occur, mitoStat3
could neutralize the ROS through this mechanism.
Alternatively, it is also possible that mitoStat3 can directly reduce the production of
electron leak from ETC. Historically, respiratory ETC complexes were thought to be
randomly distributed as independent entities (Hackenbrock et al., 1986). However, this
view has been challenged based on both functional and structural analyses that support a
model where the individual ETC complexes interact to form stable supramolecular
structures, called respiratory chain supercomplexes (RCS) or respirasome (Acin-Perez et
al., 2008; Eubel et al., 2004a; Eubel et al., 2004b) (Fig. 3). RCS containing Complex I
and III, or Complex I, III and IV have been the most studied (Winge, 2012). The
objective of RCS is to facilitate electron transfer within the individual complexes in RCS
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and to minimize the generation of ROS. Our recent study has revealed the presence of
Stat3 in RCS in CD4 cells activated in the presence of IL-6 (Yang et al., 2015b).
Increased levels of mitoStat3 containing RCS correlates with decreased mitochondrial
ROS levels in these cells (Yang et al., 2015b) (Fig. 3). Similar to this study, Stat3 also
plays a protective role against ROS production in heart, astrocytes and sperm as reviewed
above. Because RCS minimize the formation of ROS while facilitating normal ETC
functions, the presence of mitoStat3 in RCS could be a mechanism by which mitoStat3
can promote ETC activity while still preventing ROS formation (Fig. 3). Although more
studies are needed to address whether Stat3 regulates the formation of respiratory
supercomplexes, the formation of RCS elicited by mitoStat3 could be another mechanism
for mitoStat3 to mediate a very efficient mitochondrial respiration in other tissues, such
as heart and cancer cells.
3. Regulation of cellular function by mitochondrial Stat3
As such an important positive regulator in mitochondrial ETC, as described above,
mitoStat3 results in various major physiological consequences in the following areas,
cardioprotection, cancer progression and immunological regulation.
•

3.1. Cardioprotective role of mitochondrial Stat3

Reperfusion of an ischaemic heart (I/R) may exacerbate the damage caused by
ischaemia itself, as reflected in increased necrosis and release of cellular enzymes,
accompanied by dysfunction in mitochondria (Honda et al., 2005). Upon reperfusion,
rapid accumulation of mitochondrial Ca2+ is accompanied by increased mitochondrial
membrane potential, extensive production of ROS and adenine nucleotide depletion.
These lead to opening of the MPTP, which enables free passage across the mitochondrial
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membranes of molecules of less than 1.5 kDa (Halestrap, 2009; Halestrap et al., 2004) to
release protons, accumulated Ca2+ and pro-apoptotic proteins like cytochrome c to initiate
downstream apoptosis (Doran and Halestrap, 2000; Halestrap, 2009; Petronilli et al.,
1994). The presence of Stat3 in mitochondria was first discovered in heart (Wegrzyn et
al., 2009), specifically in the mitochondrial of subsarcolemmal and interfibrillar
cardiomyocytes (Boengler et al., 2010). Importantly, mitoStat3 provides cardioprotection
during heart I/R injury (Boengler et al., 2010; Heusch et al., 2011; Szczepanek et al.,
2011; Szczepanek et al., 2015). For instance, expression of a transcriptional inactive
mitochondria-targeted Stat3 with a mutation in DNA-binding domain in a transgenic
mouse model (MLS-STAT3E mice) leads to better cardiac tissue preservation during
heart I/R injury (Szczepanek et al., 2011; Szczepanek et al., 2015). It is believed that the
cardioprotection elicited by mitoStat3 is mediated by delaying MPTP opening (Boengler
et al., 2010; Boengler et al., 2013; Heusch et al., 2011; Szczepanek et al., 2011;
Szczepanek et al., 2015). Several studies have proposed that this is an indirect effect of
mitoStat3 on ETC, primarily through the suppression of ROS (Boengler et al., 2010;
Boengler et al., 2013; Heusch et al., 2011; Szczepanek et al., 2011; Szczepanek et al.,
2015). Alternatively, it has also been suggested that mitoStat3 delays MPTP opening
during heart I/R injury through direct interaction with cyclophilin D, one of the MPTP
components (Boengler et al., 2010). Therefore, mitoStat3 provides cardioprotective
effects, although additional studies will be needed to dissect the specific mechanisms.
•

3.2. MitoStat3 promotes cancer progression

Unlike most other cells, cancer cells produce most of their ATP through glycolysis,
even under aerobic conditions, instead of mitochondrial OXPHOS, known as the
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Warburg effect (Warburg et al., 1927). However, mitochondria still play a role in ROS
production and Ca2+ homeostasis in cancer cells (Gogvadze et al., 2008). The nuclear role
of Stat3 in cancer progression has been studied extensively (Yu et al., 2014), but the
findings of Stat3 being present in mitochondria opened a new area in cancer research in
terms of how mitoStat3 might regulate cancer physiology.
Malignant transformation of mouse embryonic fibroblasts using RAS requires the
presence of mitoStat3, and blocking mitoStat3 halts tumor growth (Gough et al., 2009;
Gough et al., 2013). Similarly, mitoStat3 is also critical to the oncogenesis in
precancerous Barrett’s epithelial cells, especially during Ras-dependent transformation
(Yu et al., 2015). This is dependent on the Ser727 phosphorylation of mitoStat3.
MitoStat3 contributes to the Ras-dependent oncogenic transformation by augmenting
ETC complex activities (Gough et al., 2009). MitoStat3 is also required for optimal
gamma-glutathione cycle activities. This restrains ROS levels in cells undergoing
oncogenic transformation. In the absence of mitoStat3, significant cell death
accompanied by decreased reducing GSH and increased mitochondrial ROS is observed
(Garama et al., 2015). Importantly, the actions of mitoStat3 in controlling respiration and
Ras transformation are mediated by the phosphorylation of Ser727. In addition, expression
of MLS-Stat3 in Stat3 null background promotes breast cancer cell growth, and Ser727
phosphorylation is required for the effects (Zhang et al., 2013). Moreover, in pancreatic
cells, IL-6 induces mitoStat3 translocation to mitochondria. This leads to an enhanced
ETC complex I activity and ATP production, suggesting that mitoStat3 could accelerate
early neoplastic lesions through enhanced bioenergetics (Kang et al., 2012a; Kang and
Tang, 2012; Kang et al., 2012b). Interestingly, mitoStat3 has also been shown to induce
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autophagy in pancreatic cancer cells, which is a common strategy for cancer cell growth,
survival and therapeutic resistance. This suggests another mechanism for mitoStat3 to
promote carcinogenesis (Kang et al., 2012a). FGFR4-R388 variant cells rely on mitoStat3
to enhance cytochrome c oxidase (complex IV) activities. This leads to pituitary
tumorigenesis (Tateno et al., 2011). MitoStat3 has also been proposed to contribute to the
tumorigenesis in keratinocytes through the regulation of mitochondrial gene expression
by binding to mitochondrial DNA (Macias et al., 2014), however this effect on
mitochondrial gene expression has not been corroborated by any other study. Therefore,
mitoStat3 holds critical functions in promoting tumorigenesis and cancer progression, but
the mechanism remains to be clarified.
A number of studies have also linked Stat3 to chemoresistance and metastasis in
cancer (Bhardwaj et al., 2007; Chen et al., 2010; Du et al., 2012a; Guo et al., 2013; Han
et al., 2013; Real et al., 2002; Wen et al., 2013). However, no study has reported a direct
effect of mitoStat3 in these important aspects of cancer biology.
•

3.3. Perspective of mitoStat3 in Immune Regulation

As a transcription factor, Stat3 has a pleiotropic function in the immune response.
Stat3 is a key regulator in T cell differentiation. Naïve CD4 cells can differentiate into T
helper 1 (Th1), Th2, Th17, regulatory T helper cells (Treg) and follicular T helper cells
(Tfh). The balance of these T helper subsets is critical for maintainance of host immune
response and preservation of immune tolerance (Stockinger and Veldhoen, 2007; Weaver
et al., 2007; Yang et al., 2008). Stat3 is required for Th17 cell differentiation, which is
primarily driven by IL-6, and also mediates autoimmune diseases (Bettelli et al., 2006;
Bettelli et al., 2008; Flanagan et al., 2014; Lee et al., 2009; Milner et al., 2015; Nishihara
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et al., 2007; Weaver et al., 2013). Stat3 is also required for the differentiation of Tfh cells
which produce IL-21 and help B cell antibody production (Crotty, 2011; Ma et al., 2012;
Nurieva et al., 2008). Stat3 binds to regulatory regions of genes including Il17 and Il21 to
regulate important immune gene expression (Durant et al., 2010). Patients with Stat3
dominant-negative mutation develop Job’s Syndrome or Hyper IgE syndrome (HIES) in
which patients have defective Th17 responses and defective IL-6 response with increased
IgE levels (de Beaucoudrey et al., 2008; Milner et al., 2008; Minegishi et al., 2009;
Steward-Tharp et al., 2014). Patients with gain-of-function Stat3 mutations develop
early-onset autoimmune disorders (Flanagan et al., 2014; Milner et al., 2015; Walker et
al., 2015).
Although the function of Stat3 as a transcription factor in immune response has been
well studied, how mitoStat3 may contribute to some aspects previously assigned to Stat3
as a transcription factor had remained unknown until recently. Our study was the first
identifying Stat3 in mitochondria in CD4 cells activated with IL-6 (Yang et al., 2015b).
IL-6 promotes the production of IL-4 and IL-21 by CD4 cells (Diehl et al., 2002; Dienz et
al., 2009; Zhou et al., 2007). Stat3, as a transcription factor, has been shown to induce
early expression IL-21 by IL-6 (Dienz et al., 2009). Instead, we have shown that Stat3
also contributes to sustaining late production of IL-21 and IL-4 independently of its
transcription activity (Yang et al., 2015b). Increased mitochondrial Ca2+ mediated by
Stat3 contributes to sustained NFAT activities and this further sustains the expression of
IL-4 and IL-21 by IL-6 (Yang et al., 2015b). This correlates with the finding that Tfh
cells have higher Ca2+ to help expressing IL-4 and IL-21 in vivo (Shulman et al., 2014).
Moreover, although mitochondria play a key role in the metabolism of memory CD8
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cells, and Stat3 is critical in the development and maintenance of memory T cells (Cui et
al., 2011; Siegel et al., 2011; van der Windt et al., 2012), no studies have reported a role
for mitoStat3 in this process. Investigating how mitoStat3 contributes to other T cell
differentiation and effector functions could be a promising field in future immune
research. Mitochondria are also essential in leukocyte chemotaxis due to their dynamic
characteristics and their ability to relocate using coupled microtubules to the adhesion
zone where they can provide both ATP and Ca2+ needed for migration (Campello et al.,
2006; Morlino et al., 2014; Sanchez-Madrid and Serrador, 2007). Since mitoStat3
promotes the increase in both mitochondrial ATP and Ca2+, it could also contribute to
migration of immune cells in inflammatory response, as well as migration of cancer cells
in metastasis (Fig. 2).
Other than T cells, Stat3 regulates the functions of other immune cells including
macrophages, dendritic cells, and mast cells. Interestingly, a recent study has shown that
mitoStat3 directly contributes to mast cell degranulation in response to stimuli (Erlich et
al., 2014b). Regulation of mitochondrial activities by mitoStat3 could also be involved in
cytokine secretion.
4. Targeting mitochondrial Stat3 for treatment of cancer
As reviewed above, mitoStat3 is crucial in cancer progression and immunological
effector function. Targeting nuclear functions of Stat3 has been studied extensively in
treating cancer and autoimmune diseases experimentally (Jing and Tweardy, 2005; Yu et
al., 2012; Yue and Turkson, 2009). As a successful experimental target, Stat3 is currently
targeted by cancer therapies in several clinical trials, including cyclic Stat3 decoy in head
and neck cancer, AZD9150 anti-sense oligonucleotide in malignant ascites, OPB-51602
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in advanced solid tumors and WP1066 in central nervous system melanoma and recurrent
glioblastoma multiforme. Although many drugs were developed to target nuclear
function of Stat3, the potential therapeutic values of targeting mitoStat3 have not been
carefully investigated. In addition, several recent studies imply the significance of
targeting mitoStat3. Importantly, several known Stat3 inhibitors have been demonstrated
to have promising mitochondrial effects, suggesting that Stat3 inhibitors might have
inhibitory effects on mitoStat3. The findings of these inhibitors, the potential therapeutic
values of targeting mitoStat3 and perspectives of targeting mitoStat3 as a new R&D
strategy are summarized below.
Aberrant activation of Stat3 occurs commonly in human tumors. It leads to elevated
anti-apoptotic mechanisms and cell cycle regulating proteins. Many cancers express
constitutively active Stat3 for better resistance to cell death (Yu et al., 2014). Importantly,
mitoStat3 holds critical functions in tumorigenesis and cancer progression. MitoStat3 is
required for metabolic switch during cancer cell oncogenic transformation and
tumorigenesis (Gough et al., 2009; Gough et al., 2013; Tateno et al., 2011). MitoStat3
promotes ETC complex activities in cancer cells. This leads to increased ATP production
(Kang et al., 2012a; Kang and Tang, 2012; Kang et al., 2012b). MitoStat3 suppresses
ROS production during canceriogenesis (Garama et al., 2015). A number of
pharmacological Stat3 inhibitors have been developed by directly targeting Stat3. Most of
these Stat3 inhibitors target either Stat3 dimerization or Stat3 DNA binding activities
(Yue and Turkson, 2009). Interestingly, some of these inhibitors have shown promising
effects in inhibiting mitoStat3. Moreover, specific mitoStat3 inhibitors have been
discovered recently. These Stat3 inhibitors are selectively described below.
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Several DNA-based Stat3 inhibitors have been already tested in cancer treatment in
clinical trials in US. AZD9150 or ISIS481464 is a synthetic bicyclic nucleic acidcontaining antisense oligonucleotide that is complementary to the mRNA for Stat3.
AZD9150 down-regulates Stat3 expression. AZD9150 was first found effective in
inhibiting growth in human lymphoma cell lines and tumor xenografts and primary
human tumor explants (Hong et al., 2015). AZD9150 is currently tested clinically in
patients with diffused large B cell lymphoma or advanced/metastatic hepatocellular
carcinoma. Cyclic stat3 decoy is another DNA-based Stat3 inhibitor. Cyclic Stat3 decoy
contains double-stranded oligonucleotides that correspond to the Stat3 response element.
This effectively blocks Stat3 DNA binding activities (Leong et al., 2003). Cyclic Stat3
decoy has demonstrated selective binding for Stat3 protein and inhibited the growth of
head and neck squamous cell carcinoma cells in vitro and in xenograft models (Leong et
al., 2003; Sen et al., 2012). Cyclic Stat3 decoy is now being tested clinically in patients
with head and neck squamous cell carcinoma. Although targeting Stat3 using DNAbased inhibitors has shown promising preclinical anti-tumor effects, whether they could
interfere with mitoStat3 function is still unknown.
Peptide-based Stat3 inhibitors have been shown very effective in experimental cancer
treatment. Peptide derivatives block Stat3 dimerization and downstream Stat3 functions
by mimicking Stat3 SH2 domain. PY*LKTK (Y* represents phosphorylated tyrosine
residue) peptide is one of the Stat3 SH2 domain binding peptides. Tagging a membrane
translocation sequence to the PY*LKTK peptide suppresses cancer transformation and
cancer growth (Turkson et al., 2001; Vultur et al., 2004). ISS 610, another peptide
derivative inhibitor, is more potent in disrupting Stat3 dimerization (Turkson et al.,
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2004). ISS 610 induces cancer cell growth inhibition and apoptosis. S3I-M2001, an
oxazole-based peptide inhibitor, also inhibits cancer growth by blocking Stat3
dimerization (Zhang et al., 2012b). Although peptidomimetics of Stat3 have been
effective in inhibiting cancer progression in experimental models, none of them have
been tested in clinical trials so far in the US and the effect of peptidomimetics on
mitoStat3 has not been investigated.
The majority of Stat3 inhibitors are small molecule inhibitors. Stat3 protein consists
of six structural domains, including N-terminal, coiled-coil, DNA binding domain, Src
homology 2 (SH2) domain for dimerization, transactivation domain and C-terminal end.
Most Stat3 small molecule inhibitors were designed to target SH2 and DNA binding
domains. Intriguingly, some small molecule Stat3 inhibitors have been suggested to
inhibit mitoStat3. However, the molecular mechanisms and demonstrations of how these
inhibitors interact with mitoStat3 need further investigations. Stattic, a common Stat3
inhibitor which first developed to target Stat3 phosphorylation and dimerization, is
effective in experimental cancer therapies. Cells treated with Stattic have reduced Tyr
phosphorylation and decreased Stat3 homodimerization. Stattic induces cancer cell
apoptosis and inhibits cancer cell growth and progression experimentally (Adachi et al.,
2012; Pan et al., 2013; Schust et al., 2006; Zhang et al., 2015). More interestingly, Stattic
is implied to target mitochondrial function by inhibiting mitoStat3 in several tissues other
than cancers (Table 1). In isolated mitochondria from heart, Stattic increases ROS
generation and facilitates MPTP opening (Boengler et al., 2013). This suggests that
Stattic has direct effects on mitoStat3. Stattic causes exacerbated myocardial I/R cellular
injuries due to increased MPTP opening during myocardial I/R injuries (Boengler et al.,
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2010; Boengler et al., 2013; Heusch et al., 2011) (Table 1). Similar to cells lacking
mitoStat3, Stattic reduces mitochondrial ETC activities, mitochondrial membrane
potential, ATP production and increases ROS production (Boengler et al., 2013;
Lachance et al., 2013). Since Stattic is well known to inhibit cancer cell growth and
promote apoptosis, the relative contribution of its effects on mitoStat3 could be
substantial to Stattic’s anti-tumor functions. However, more efforts are needed to
distinguish its effects on mitoStat3 from nuclear Stat3. In addition, FLLL32, a new small
molecule inhibitor, selectively inhibits Stat3 Tyr705 phosphorylation (Bill et al., 2010; Lin
et al., 2010). FLLL32 has promising anti-tumor effects by facilitating cancer cell
apoptosis (Bill et al., 2010; Lin et al., 2010). Similar to experimental models lacking
mitoStat3, FLLL32 significantly depolarizes mitochondrial membrane potential in
melanoma cells (Bill et al., 2010) (Table 1). However, the specific molecular interactions
need further investigation. Recently, the first mitoStat3 inhibitor has been demonstrated
recently. MDC-1112 or Phospho-valproic acid was first found to inhibit pancreatic cancer
cell growth in xenograft model (Table 1). Antibody pathway screening reveals that
MDC-1112 targets the phosphorylation of Stat3. Besides inhibiting IL-6-stimulated Stat3
phosphorylation and nuclear DNA binding, surprisingly, MDC-1112 also inhibits the
mitochondrial accumulation of mitoStat3. This leads to depolarized mitochondrial
membrane potential and increased ROS production, and subsequent apoptotic cell death
(Mackenzie et al., 2013), which can be reversed by overexpression of transcriptional
inactive Stat3 (Stat3Y705F) or mitochondrial localized Stat3 (MLS-Stat3). This indicates
that MDC-1112 inhibits pancreatic cancer growth by potentially inhibiting mitoStat3
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activity. Further investigations into the functions of MDC-1112, as a novel inhibitor, may
lead to new understanding of mitoStat3 activities as well as novel cancer therapies.
A number of small molecules targeting upstream JAKs have also been proposed as
potential modulators of Stat3. JSI-124 or cucurbitacin I inhibits Stat3 phosphorylation by
suppressing levels of Janus kinases and also activities of Janus kinases (Blaskovich et al.,
2003). JSI-124 inhibits growth, invasion and induces apoptotic cell death in multiple
cancer cells, including leukemia, lymphoma, lung cancer, breast cancer, glioma,
glioblastoma, endometrial cancer and cervical cancers (Blaskovich et al., 2003; Chen et
al., 2007; Ishdorj et al., 2010; Premkumar et al., 2010; Shi et al., 2006; Su et al., 2008;
Zhang et al., 2012a). Interestingly, JSI-124 also inhibits mitochondria-related functions
(Table 1). JSI-124 leads to a significant reduction in mitochondrial membrane potential
in SW480 colon cancer cells (Kim et al., 2014). In addition, JSI-124 induces
mitochondrial ROS production in a Stat3 dependent manner, and subsequently,
downstream activation of autophagy (Zhang et al., 2012a). Although JSI-124 contributes
to multiple aspects of mitochondrial function, whether the effects of JSI-124 are due to
direct modulation of mitoStat3 needs further investigation. Another small molecule
inhibitor AG490 selectively inhibits Janus kinases, especially Jak2 to suppress Stat3
phosphorylation (Levitzki and Gazit, 1995; Wang et al., 1999). AG490 induces cancer
cell apoptosis and inhibits malignant cell growth and invasion in multiple cancer cells
(De Vos et al., 2000; Du et al., 2012b; Huang et al., 2006; Miyamoto et al., 2001).
Intriguingly, recent studies have revealed that AG490 also elicits many functions by
targeting mitochondria in various cell and tissue models (Table 1). AG490 has been
implied to inhibit mitoStat3 pathway directly and abolish the cardioprotective effects
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elicited by mitoStat3 in myocardial I/R injury by postconditioning treatment (Heusch et
al., 2011). AG490 induces apoptosis in astrocytes by inhibiting mitochondrial membrane
potential and increasing ROS generation (Sarafian et al., 2010), and also blocks Stat3mediated lectin neuroprotection by destabilizing mitochondrial function (Guo et al.,
2008). Thus, some of the anti-tumor effects of AG490 might be in part due to its effects
on mitoStat3. Thus, these JAKs inhibitors have shown promising effects in inhibiting
mitoStat3, however, the specificity of these inhibitors for Stat3 relative to other
downstream factors requires more careful investigation.
In summary, in many of conventional Stat3 inhibitors, some of them have shown
significant direct effects on mitoStat3. Others have shown evidence suggesting their
inhibitory effects on mitochondria. New screening systems have also discovered novel
mitoStat3 inhibitors. Although the direct mitoStat3 inhibition effect of many of these
inhibitors needs to be validated, further investigation into this topic may shed light into
new targets in anti-tumor therapies.
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Remarks
In summary, in addition to the well-characterized role of Stat3 as a transcription factor,
we have described here the molecular mechanisms and functions of mitochondrial Stat3
as well as promising ways to target mitoStat3 as a strategy to modulate biological
functions. Distinct from several other important review papers (Meier and Larner, 2014;
Szczepanek et al., 2012a; Szczepanek et al., 2012b; Zouein et al., 2015), this review
summarizes several recent findings related to mitoStat3, including calcium homeostasis,
respiratory supercomplexes, regulation of immune system and the inhibitors that might
modulate mitoStat3 activities. The role of mitoStat3 in the regulation of supercomplex
and calcium should be also confirmed in other tissues. As mentioned above, additional
studies exploring the mechanisms by which mitoStat3 could regulate supercomplexes
formation and mitochondrial calcium homeostasis are urgently needed to understand
broader aspects of mitoStat3. Moreover, testing existing Stat3 inhibitors with their
inhibitory effects on mitoStat3, as well as developing novel mitoStat3 specific inhibitors,
are of great therapeutic and research values.
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Inhibitor
AG490

Target Site
JAK2 kinases,
Stat3 tyr phosphorylation
(Levitzki and Gazit,
1995; Wang et al., 1999)

Function
↑ malignant cells apoptosis, ↓ malignant
cell growth, ↓ malignant cell invasion
(De Vos et al., 2000; Du et al., 2012b;
Huang et al., 2006; Miyamoto et al.,
2001)

Mitochondrial Effects

·
·
·

·
·
·

·

Stattic

Stat3 phosphorylation,
SH2 domain (Boengler et
al., 2013)

↑ malignant cells apoptosis, ↓ malignant
cell growth, ↑ tumor chemo- and
radiosensitivity (Adachi et al., 2012;
Pan et al., 2013; Zhang et al., 2015)

·

·
·

·
·
·

·

·

·
CucurbitacinI/JSI-124

MDC1112/phosph
o-valproic
acid

Stat3 tyr phosphorylation
(Blaskovich et al., 2003)

Stat3 phosphorylation,
mitochondrial Stat3
accumulation (Mackenzie
et al., 2013)

↑ malignant cells apoptosis, ↓ malignant
cell growth (Blaskovich et al., 2003;
Chen et al., 2007; Ishdorj et al., 2010;
Premkumar et al., 2010; Shi et al.,
2006; Su et al., 2008; Zhang et al.,
2012a)

·

↑ malignant cells apoptosis, ↓ malignant
cell growth (Mackenzie et al., 2013)

·

·
·

·
·

FLLL32

Stat3 tyr phosphorylation
(Bill et al., 2010; Lin et
al., 2010)

↑ malignant cells apoptosis (Bill et al.,
2010; Lin et al., 2010)

·
·

↓ mitochondrial membrane potential in
astrocytes (Sarafian et al., 2010)
↑ ROS production in astrocytes
(Sarafian et al., 2010)
↓ cardioprotective preservation of
mitochondrial function by inhibition of
mitoStat3 in myocardial I/R injury
(Heusch et al., 2011)
↑ MPTP opening (Lemoine et al.,
2013; Smith et al., 2010)
↓ neuroprotective effects by leptinmediated mitochondrial stabilization
(Guo et al., 2008)
↓ cardioprotective effects by
melatonin-mediated mitochondrial
preservation in myocardial I/R injury
(Yang et al., 2013)
↓ cardioprotective effects by the
reduced MPTP opening elicited by
leptin and atorvastatin in myocardial
I/R injury (Lemoine et al., 2013;
Smith et al., 2010)
↓ mitochondrial ADP-stimulated
oxygen consumption in
cardiomyocytes (Boengler et al.,
2010)
↓ ATP production in human sperms
and mast cells (Erlich et al., 2014b;
Lachance et al., 2013)
↓ oxygen consumption rates and ↓
ETC complex II and complex III
activities in mast cells (Erlich et al.,
2014b)
↓ mitochondrial membrane potential in
human sperms (Lachance et al., 2013)
↑ ROS production in human sperms
(Lachance et al., 2013)
↓ cardioprotective preservation of
mitochondrial function by mitoStat3
activation in myocardial I/R injury
(Heusch et al., 2011)
↑ ROS production in cardiomyocytes,
and subsequent ↑ MPTP opening and ↓
ATP production (Boengler et al.,
2013)
↑ cellular injuries due to ↑ MPTP
opening by mitoStat3 inhibition in
myocardial I/R injury (Boengler et al.,
2010)
↓ mast cell degranulation through the
inhibition of mitochondrial function
(Erlich et al., 2014b)
↓ mitochondrial membrane potential
(Kim et al., 2014)
↑ ROS production and subsequent ↑
autophagy (Zhang et al., 2012a)
↑ mitochondrial apoptotic cell death in
cancer cells (Ishdorj et al., 2010;
Premkumar et al., 2010; Su et al.,
2008)
↓ mitoStat3 mitochondrial
accumulation (Mackenzie et al.,
2013)
↓ mitochondrial membrane potential
(Mackenzie et al., 2013)
↑ mitochondrial apoptotic cell death
(Mackenzie et al., 2013)
↓ mitochondrial membrane potential
(Bill et al., 2010)
↑ mitochondrial apoptotic cell death in
cancer cells (Bill et al., 2010; Lin et
al., 2010)

Table 1. Promising anti-tumor Stat3 inhibitors that target mitochondrial functions
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pathway
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Gene
transcripIon
mitochondrion

Figure 1. Classical and non-classical pathways of Stat3.
Classical pathway where Stat3 translocates to the nucleus and mediates gene
transcription. Non-classical pathway where Stat3 is recruited to mitochondria and
regulates functions alternative to transcription.
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(A). MitoStat3 in mitochondrial
respira@on

(B). MitoStat3 in mitochondrial Ca2+
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Figure 2. mitoStat3 as a regulator of mitochondria functions.
(A) mitoStat3 promotes mitochondrial respiration (ATP synthesis) by increasing ETC
activity and MMP. (B) mitoStat3 regulates mitochondrial Ca2+ and cytosolic Ca2+
through the regulation of ETC and MPTP.
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Figure 3. mitoStat3 as a regulator of respiratory supercomplexes.
Stat3 can be recruited to respiratory supercomplexes to promote ETC activity and ATP
synthesis without increasing ROS production.
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ABSTRACT
IL-6 is known to contribute to the differentiation of CD4 T cells into different subsets
of effector T helper cells. Less is known about the potential of IL-6 in regulating CD8
cell effector function. Here, we identify IL-6 as a master regulator of IL-21 in effector
CD8 cells. IL-6 promotes the differentiation of a subset of naïve CD8 cells that express
IL-6R into a unique population of effector CD8 cells characterized by the production of
high levels of IL-21 and low levels of IFNγ. Similar to CD4 T follicular helper (Tfh)
cells, IL-21-producing CD8 cells generated in the presence of IL-6 directly provide help
to B cells to induce isotype switching. CD8 cell-derived IL-21 contributes to the
production of protective virus-specific IgG antibodies during influenza virus infection.
Thus, this study reveals the presence of a new mechanism by which IL-6 regulates
antibody production during viral infection, and a novel function of effector CD8 cells in
the protection against viruses.
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INTRODUCTION
Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by multiple cell types in
response to external stimuli including trauma, stress and infection (Kishimoto, 2005). IL6 plays a crucial role in regulating CD4 T helper cell (Th) differentiation and effector
functions (Dienz and Rincon, 2009). It enhances Th2 differentiation through an autofeedback by upregulating IL-4 production (Diehl et al., 2002). IL-6 also inhibits IFNγ
production and Th1 differentiation through an independent mechanism (Diehl et al.,
2000). In combination with TGF-β, IL-6 contributes to the differentiation of Th17 cells
(Bettelli et al., 2006; Ivanov et al., 2006). Importantly, IL-6 by itself also induces IL-21
production in CD4 cells (Diehl et al., 2012; Dienz et al., 2009; Suto et al., 2008) and is
required for the generation of T follicular helper (Tfh) cells (Nurieva et al., 2008). IL-6
indirectly promotes the production of antibodies by B cells by acting on CD4 Tfh cells
inducing the production of IL-21 (Dienz et al., 2009).
In contrast to CD4 cells, little is known about the potential effect of IL-6 on CD8
cells. Effector CD8 cells are high producers of IFNγ and they are also cytotoxic through
the production of granzyme and perforin, the two major functions by which these cells
protect from virus infections (Russell and Ley, 2002). However, CD8 Tc2 and Tc17
subsets have also been identified when placed in a complex cytokine environment (Croft
et al., 1994; Hamada et al., 2009). No effect of IL-6 on Tc2 has been reported. Similar to
CD4 Th17 cells, IL-6 in combination with multiple other cytokines contributes to the
generation of CD8 Tc17 cells (Hamada et al., 2009). Tc17 cells also play an important
role in protecting against lethal influenza infection (Hamada et al., 2009). Indirect
evidence through the use of class I deficient mice suggested that CD8 cells may provide
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help for IgG and IgA production by B cells (Christianson et al., 1997; Cronin et al., 1995;
Franco and Greenberg, 1995; Spriggs et al., 1992). IL-4-producing CD8 cell clones have
also been shown to promote B cell antibody production in vitro (Cronin et al., 1995).
However, there is no direct evidence that CD8 cells promote antibody production.
Here we show that IL-6 alone induces the differentiation of CD8 cells into a unique
effector cell population that produces high levels of IL-21, with minimal production of
IFNγ, and is capable of providing B cell help to promote antibody production.
Furthermore, IL-21 production by effector CD8 cells is required for an antibody response
to influenza virus. Thus, through the IL-6/IL-21 axis, CD8 cells emerge as regulators of
the anti-viral antibody response.
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RESULTS AND DISCUSSION
IL-6 induces the production of IL-21 in CD8 cells through Stat3
IL-6 is known to be major inducer of IL-21 in CD4 cells (Diehl et al., 2012; Dienz et
al., 2009; Suto et al., 2008), but no previous studies have reported the effect of IL-6 on
CD8 cells. To determine whether CD8 cells also produce IL-21 in response to IL-6, CD8
cells were activated with anti-CD3 and anti-CD28 Abs in the presence or absence of IL-6
for different periods of time. The levels of IL-21 produced by CD8 cells activated
without IL-6 were almost undetectable at any time point (Fig. 1A). In contrast, high
levels of IL-21 were produced by CD8 cells activated in the presence of IL-6 (Fig. 1A).
The IL-21 levels induced by IL-6 in CD8 cells were comparable to those produced by
CD4 cells (Fig. 1B), although the kinetics were slightly delayed in CD8 cells (Fig. 1A
and 1B). We have shown that IL-6 can also promote the production of IL-4 during
activation in CD4 cells (Diehl et al., 2002). However, IL-6 failed to induce IL-4 in CD8
cells (Fig. 1C). In addition, IL-6 had no effect on the expression of activation markers
such as CD69 (Fig. 1D) or cell proliferation (data not shown), and had only a marginal
effect on cell survival (Fig. 1E) of CD8 cells during activation. Together, these results
indicate a selective effect of IL-6 on IL-21 production.
To determine the dose-dependent response of IL-6 on IL-21 production, CD8 cells
were activated in the presence of different concentrations of IL-6. The induction of IL-21
by IL-6 during activation of CD8 cells was dose-dependent, and low doses (e.g. 6.25
ng/ml) of IL-6 were sufficient to trigger IL-21 production in CD8 cells (Fig. 1F),
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demonstrating the efficacy of IL-6 in inducing IL-21 production by CD8 cells.
We also examined the effect of other cytokines on IL-21 production by CD8 cells.
Although IL-2 and IL-15 are critical regulators of CD8 cell proliferation, survival and
differentiation (Waldmann, 2006), neither IL-2 nor IL-15 induced IL-21 production in
CD8 cells (Fig. 1G). IL-12 has also been shown to promote activation, survival and
effector functions in CD8 cells (Valenzuela et al., 2002). However, similar to IL-2 and
IL-15, IL-12 did not trigger the production of IL-21 (Fig. 1G), but it enhanced the
production of IFNγ (Fig. 1H), as expected. In contrast to IL-21, IFNγ production was
reduced in CD8 cells activated with IL-6 (Fig. 1H). None of the combinations of IL-2,
IL-15 and IL-12 were capable of inducing IL-21 production in CD8 cells, or had any
effect on the induction of IL-21 by IL-6 (data not shown). Thus, induction of IL-21
production in CD8 cells during activation is relatively selective to IL-6.
To examine whether IL-21 production in CD8 cells by IL-6 was due to the induction
of IL-21 gene expression, Il21 mRNA levels were measured by real-time RT-PCR. The
levels of IL-21 mRNA were markedly higher in CD8 cells activated in the presence of
IL-6 (Fig. 1I). In contrast, the presence of exogenous IL-2 as a growth factor during
activation failed to regulate Il21 gene expression (Fig. 1I). Stat3 is a transcription factor
that is required for Il21 gene expression in CD4 cells (Nurieva et al., 2007; Ray et al.,
2014). Analysis of Stat3 phosphorylation by Western blot in CD8 cells activated in the
absence or presence of IL-6 showed a clear activation of Stat3 by IL-6 in these cells (Fig.
1J). To determine whether Il21 expression in CD8 cells was also dependent on Stat3,
CD8 cells from WT and T-cell conditional Stat3 knockout (Stat3 KO) mice (Takeda et al.,
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1998) were activated in the absence or presence of IL-6. No Il21 mRNA was detected in
Stat3 KO CD8 cells activated in the presence of IL-6 (Fig. 1K). Accordingly, IL-6 failed
to induce IL-21 production in Stat3 deficient CD8 cells (Fig. 1L). Thus, IL-6 is a
selective and powerful inducer of IL-21 in CD8 cells via a Stat3 dependent mechanism.
IL-6 differentiates CD8 cells into IL-21-producing effector cells
The data above show that high levels of IL-21, but low levels of IFNγ, are produced
by CD8 cells activated in the presence of IL-6 relative to those activated without IL-6.
Similar to IFNγ, the levels of IL-2 produced by CD8 cells activated in the presence of IL6 were also lower (Fig. 2A). To determine whether the reduced levels of these cytokines
in the supernatant was due to a negative effect of IL-6 or to an increased consumption,
we examined the levels of IL-2 and IFNγ mRNA by real-time RT-PCR in activated CD8
cells. Interestingly, IL-6 reduced the levels of Ifng (Fig. 2B) and Il2 mRNA (Fig. 2C).
Thus, while IL-6 induces IL-21, it also has a negative effect on the expression of IFNγ
and IL-2 in CD8 cells.
These results suggested that IL-6 could promote the differentiation of CD8 cells into
effector CD8 cells characterized by high IL-21, low IFNγ and low IL-2 production. To
further address this question, we examined cytokine production at the single cell level by
flow cytometry analysis. IL-2 and IFNγ were detected by intracellular staining. Since it is
known that the intracellular staining for IL-21 with antibodies is not highly effective, we
used IL-21-reporter mice in which a truncated human CD4 (hCD4) reporter gene is
expressed from a bicistronic transcript produced from the Il21 locus (Silberger et al.,
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manuscript in preparation). Thus, hCD4 expression on the cell surface is a surrogate for
IL-21 gene expression. CD8 cells from IL-21 reporter mice were activated in the absence
or presence of IL-6. After 3 d, activated cells (>99% CD8 cells) were stained for IL-2,
IFNγ, and hCD4. No hCD4 was detected in CD8 cells activated in the absence of IL-6
(Fig. 2D). However, a subset of hCD4 (IL-21)-expressing CD8 cells was present when
CD8 cells were activated in the presence of IL-6 (Fig. 2D). Consistent with the results
obtained by ELISA of supernatants (Fig. 1), the percentage of IFNγ-producing cells as
well as IL-2-producing cells were markedly reduced in CD8 cells activated with IL-6
(Fig. 2D). Importantly, most IL-21-producing cells did not make IL-2 (Fig. 2E) or IFNγ
(Fig. 2F). These results show that IL-6 promotes the generation of an effector CD8 cell
subpopulation that produces high levels of IL-21 but minimal levels of IFNγ and IL-2.
We then investigated whether this IL-21–producing subset of effector CD8 cells
represented a relatively committed subset. CD8 cells were activated for 2 d with antiCD3/CD28 Abs in the presence or absence of IL-6 (primary activation), extensively
washed and an equal number of cells was then restimulated with anti-CD3 Ab only or
anti-CD3 Ab plus IL-6. IL-21 levels were determined in the supernatant 24 h later. CD8
cells in which primary activation was done in the absence of IL-6 did not produce IL-21
after restimulation even when IL-6 was added during the restimulation phase (Fig. 2G).
In contrast, high levels of IL-21 were induced after restimulation with anti-CD3 Abs
alone if effector CD8 cells were initially activated in the presence of IL-6 (Fig. 2G).
Similar results were obtained when Il21 mRNA levels were assayed (Fig. 2 H),
indicating that the absence of IL-21 was not due to increased consumption. Moreover,
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CD8 cells that received IL-6 during the primary activation still produced low levels of IL2 after restimulation (Fig. 2I). These data show that the presence of IL-6 during the
primary activation promotes the differentiation of CD8 cells into a unique effector CD8
cell subset that remains capable of producing IL-21 upon activation.
To better dissect the period of time during activation when CD8 cells remain
responsive to IL-6 and produce IL-21, CD8 cells were activated with anti-CD3/CD28
Abs, and IL-6 was administered at different periods of time after stimulation. IL-21 levels
were measured 3 d after the stimulation. The maximum production of IL-21 was achieved
when IL-6 was added at the initiation of stimulation (Fig. 2J). Delayed addition of IL-6
resulted in progressively decreased production of IL-21 by CD8 cells (Fig. 2J). Addition
of IL-6 48 h after activation did not induce IL-21 production when examined a day later
(Fig. 2J) or even when cells were incubated for 3 more days post-addition of IL-6 (Fig.
2K). Furthermore, normalizing cell number prior to administrating IL-6 after 48 h of
activation did not restore IL-21 production (data not shown). Thus, the differentiation of
CD8 cells into IL-21–producing effector cells requires IL-6 signaling early during
differentiation.
IL-6R defines a CD8 subset capable of producing IL-21
IL-6 induces signals by binding to its membrane IL-6 receptor (IL-6R), which then
associates with gp130, a common signal transducer that activates the Jak/Stat3 pathway
(Heinrich et al., 2003). Although gp130 is ubiquitously expressed, the expression of IL6R is more restricted to hematopietic cells and hepatocytes, and varies among different
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cell types (Rose-John, 2012). To determine the fraction of CD8 cells that could produce
IL-21 by responding to IL-6, we analyzed the cell surface levels of IL-6R by flow
cytometry. Only a subset of CD8 cells had detectable levels of IL-6R (IL-6Rhigh) (Fig.
3A). The levels of surface expression of IL-6R in CD8 cells were lower than in CD4 cells,
both in intensity (Fig. 3B) and frequency of expressing cells (Fig. 3C). The lower
frequency of IL-6R-expressing CD8 cells could explain the delayed kinetics for IL-21
production relative to CD4 cells (Fig. 1A and 1B). Analysis of IL-6R expression during
thymocyte development showed that single positive CD4 thymocytes already expressed
higher levels of IL-6R than single positive CD8 thymocytes (Fig. 3D), while no IL-6R
expression could be found in double positive thymocytes (Fig. 3D). Thus, the difference
in the expression of IL-6R between CD8 and CD4 cells seemed to be determined already
during thymocyte development. Expression of IL-6R on the cell surface has been shown
to be downregulated in CD4 cells during activation (Rincon et al., 1997). Analysis of IL6R during activation of CD8 cells also showed a downregulation with only minimal
levels of IL-6R after 48 h of activation (Fig. 3E). Accordingly, treatment of activated
CD8 cells (48 h) with IL-6 during restimulation had minimal effect on Stat3
phosphorylation (data not shown). These results correlate with the failure of IL-6 to
induce IL-21 in CD8 cells when administrated 48 h after activation (Fig. 2J) or during
restimulation of effector CD8 cells (Fig. 2K).
To characterize the subset of freshly isolated CD8 cells that could produce IL-21 in
response to IL-6, we performed a phenotypic analysis of the CD8 cells expressing
detectable IL-6R (IL-6Rhi) and CD8 cells with levels of IL-6R under the background
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levels (IL-6Rlo) prior to activation. No CD25 (IL-2Rα) expression could be detected in
either of the two subsets (Fig. 3F). Only minimal KLRG1 (short-lived effector cell
marker) and low levels of CD127 (IL-7R) were detected but there was no difference
between the two subsets (Fig. 3F). The levels of CD44 were however different between
IL-6Rhi and IL-6Rlo CD8 subsets (Fig. 3F). The IL-6Rhi CD8 cell subset contained a
lower frequency of cells expressing high levels of CD44 (CD44high) (Fig. 3G). Similarly,
analysis of IL-6R expression in gated CD44low (“naïve”) and CD44high (memory/activated)
CD8 cells also showed higher expression of IL-6R in naïve CD8 cells (Fig. 3H). These
results suggested that naïve CD8 cells are capable of producing IL-21 if IL-6 is present.
We examined IL-21 production in FACS sorted CD44high CD8 cells and CD44low CD8
cells after activation in the absence or presence of IL-6. Correlating with expression of
IL-6R, higher levels of IL-21 were found in CD44low CD8 cells (Fig. 3I). To further
confirm the production of IL-21 in naïve CD8 cells, we used CD8 cells from OT-I mice
that express a TCR recognizing ovalbumin (OVA), as bona fide naïve CD8 cells. Similar
to WT CD8 cells, IL-6R was expressed on most OT-I CD8 cells (Fig. 3J). We then
examined IL-21 production in OT-I CD8 cells activated with or without IL-6. While no
IL-21 was detected in the absence of IL-6, OT-I CD8 cells activated with IL-6 produced
high levels of IL-21 (Fig. 3K). Thus, naïve CD8 cells express IL-6R and can produce
high levels of IL-21 during activation if IL-6 is present.
To determine whether the cell surface expression of IL-6R could be used as a marker
to identify the subset of CD8 cells that can differentiate into IL-21 producing cells, we
performed cell sorting of IL-6Rhi and IL-6Rlo CD8 cells. As a negative control to define
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the gates for IL-6R, we used IL-6R KO CD8 cells. Sorted IL-6Rhi and IL-6Rlo CD8 cells
were activated with anti-CD3/CD28 Abs in the presence or absence of IL-6. IL-6Rhi CD8
cells produced high levels of IL-21 in response to IL-6 (Fig. 3L). In contrast, IL-21 was
almost undetectable in IL-6Rlo CD8 cells activated in the presence of IL-6 (Fig. 3L).
Thus, the expression of IL-6R defines the subset of CD8 cells capable of producing IL-21.
IL-21-producing CD8 cells promote IgG isotype switching in B cells in vitro
IL-21 has an essential role in B cell antibody responses (Ozaki et al., 2002; Pene et al.,
2004). IL-21 induces isotype switching in both human and mouse B cells, and is critical
for germinal center formation and B cell differentiation into plasma cells for long-term
antibody production (Diehl et al., 2012; Ettinger et al., 2005; Ozaki et al., 2004). IL-21
has been considered the major cytokine produced by CD4 Tfh cells that mediates the
function of these cells (Eto et al., 2011; Linterman et al., 2010). Since the results above
show that CD8 cells produce IL-21 if IL-6 is present during activation, it was possible
that CD8 cells could also acquire a B cell helper function. To address this possibility, we
first asked whether cell culture supernatant obtained from activated CD8 cells could
promote antibody production by B cells in vitro. WT and IL-21 receptor (IL-21R) KO B
cells were activated with LPS and an anti-CD40 Ab in the absence or presence of
supernatant from WT or IL-21 KO CD8 cells previously activated with or without IL-6.
Interestingly, culture supernatants from WT CD8 cells activated with IL-6 significantly
increased the production of IgG1 in WT B cells (Fig. 4A). In contrast, supernatants from
IL-21 KO CD8 cells had no effect on IgG1 production (Fig. 4A). In addition,
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supernatants from WT CD8 cells activated with IL-6 had no effect on IgG1 production in
IL-21R KO B cells (Fig. 4A), although these B cells still could produce IgG1 in response
to IL-4 (Fig. 4B) indicating that there is not an intrinsic defect in IL-21R KO B cells.
Thus, IL-21 produced by CD8 cells in vitro is sufficient to promote IgG1 production by B
cells when activated through LPS and CD40 pathway. Similar results were found when B
cells were activated with LPS alone (Fig. 4C), with an anti-IgM Ab alone (Fig. 4D), or
an anti-CD40 Ab alone (Fig. 4E), indicating that CD8 cells can provide help to B cells
activated through different mechanisms.
To further demonstrate that CD8 cells differentiated in the presence of IL-6 have the
capacity to promote isotype switching by B cells, we established co-cultures of CD8 cells
with B cells where CD8 cells were activated with anti-CD3/CD28 Abs and B cells with
LPS. The co-cultures were performed in the presence or absence of IL-6. After 6 d, the
levels of IgG1 in the co-culture supernatants were determined. First, we used WT CD8
cells and B cells from WT or IL-21R KO mice. B cells co-cultured with CD8 cells in the
presence of IL-6 produced higher levels of IgG1 than those co-cultured in the absence of
IL-6 cells (Fig. 4F). However, IL-21R KO B cells co-cultured with CD8 cells failed to
produce IgG1 even in the presence of IL-6 (Fig. 4F), indicating that the effect of IL-6 on
IgG1 production was dependent on IL-21 acting on B cells. IL-21 promotes isotype
switching to IgG isotypes, but has no effect on the production of IgM (Ozaki et al., 2002).
Analysis of IgM in the co-cultures showed that IgM levels were comparable between WT
and IL-21R KO B cells co-cultured with CD8 cells either in the presence or absence of
IL-6 (Fig. 4G), showing that IL-21R KO and WT B cells were equally activated. We also
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noticed that co-cultures of IL-21R KO B cells activated through TLR signaling pathway
in the presence of CD8 cells contained less baseline IgG1 than WT B cells even in the
absence of IL-6 (Fig 4F). Since TLR ligands can trigger IL-6 production in B cells (Barr
et al., 2007), this could be due to endogenous B cell-derived IL-6 inducing IL-21 in CD8
cells, and IL-21 acting on B cells. To address this question, we established co-cultures
using WT and IL-6 KO B cells. While there was some IgG1 being produced in cocultures with WT B cells even in the absence of exogenous IL-6, the levels of IgG1 were
practically undetectable in co-cultures containing IL-6 KO B cells (Fig. 4H). Addition of
IL-6 to those co-cultures was able to restore the effect of CD8 cells in promoting
antibody production by B cells (Fig. 4H). Moreover, addition of IL-6 to co-cultures with
IL-6R KO CD8 cells failed to promote the production of IgG1 in those co-cultures (Fig.
4I). Thus, together these results demonstrate that IL-6 is essential for CD8 cells to be able
to promote isotype switching in B cells.
In addition to TLR4 (LPS receptor), a number of recent studies have shown the
contribution of other TLR pathways in B cell antibody response such as TLR9 (He et al.,
2004). We found that in the presence of IL-6, CD8 cells also enhanced IgG isotype
switching in B cells activated with an anti-IgM Ab and the TLR9 ligand unmethylated
CpG (Fig. 4J), and this CD8 cell help was dependent on their ability to produce IL-21
(Fig. 4K). Thus, CD8 cells activated in the presence of IL-6 promote IgG isotype
switching of B cells in vitro through their ability to produce IL-21.
IL-21-producing CD8 cells promote IgG isotype switching in B cells in vivo during
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influenza infection
To determine whether CD8 cells can act as helper B cells in vivo during virus
infection where antibody response is critical for protection, we first investigated whether
CD8 cells produce IL-21 in response to IL-6 in vivo. WT mice and IL-6 KO mice were
i.n. infected with a sublethal dose of the PR8 influenza A virus. The levels of IL-21
mRNA expression in CD8 cells isolated from the spleen and mediastinal lymph node
(MLN) 7 d post-infection were measured by real time RT-PCR, but Il21 expression was
nearly undetectable (Fig. 5A). Similar to CD4 cells and B cells, CD8 cells were also
recruited to the lung during influenza virus infection (data not shown). We therefore
examined Il21 expression in CD8 cells isolated from lung of infected mice. In contrast to
spleen/MLN CD8 cells, lung CD8 cells from WT mice expressed high levels of IL-21
(Fig. 5A). Unlike WT mice, Il21 expression was almost undetectable in CD8 cells from
lungs of infected IL-6 KO mice indicating that IL-21 expression is dependent on IL-6
(Fig. 5A). Analysis at 14 days post-infection further showed IL-21 expression in CD8
cells from the WT lung but practically undetectable in CD8 from WT spleen/MLN (Fig.
5A). To show in vivo IL-21 production by CD8 cells from infected mice, we performed
ELISPOT assays using isolated CD8 cells from lung or spleen/MLN. Analysis based on
the number of producing cells as well as the overall intensity showed higher levels of IL21 being produced by CD8 cells from the lungs than CD8 cells from spleen/MLN (Fig.
5B). Thus, similar to the in vitro studies, during influenza infection in vivo, CD8 cells
recruited to the lungs produce IL-21 but only if IL-6 is present.
It is known that IgG antibody response against influenza virus is strongly attenuated
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in IL-21 KO mice while IgM antibody response is not affected (Dienz et al., 2009;
Rasheed et al., 2013). To investigate whether IL-21-producing CD8 cells could restore
antibody response, we performed adoptive transfer of WT CD8 cells into IL-21 KO mice.
As control, we also performed adoptive transfer of IL-21 KO CD8 cells into IL-21 KO
mice. Recipient mice were then infected with a sublethal dose of PR8 influenza virus.
Two weeks post-infection, mice were harvested and activated germinal center (GC) B
cells from the spleen and lung were analyzed. Activated GC B cells in the spleen were
identified by flow cytometry based on PNA and Fas (PNAhi Fashi), or PNA, Fas, IgD and
CD24 expression (PNAhi Fashi IgD- CD24hi) (Supplementary Fig. S1A). There was no
difference in the frequency of activated GC B cells in the spleen between recipient mice
reconstituted with WT or IL-21 KO CD8 cells (Supplementary Fig. S1A). Activated GC
B cells in lungs were detected by GL-7 expression analyzed by confocal microscopy in
lung tissue sections (Supplementary Fig. S1B). There was an increased frequency of
activated GC B cells in lungs of IL-21 KO mice reconstituted with WT CD8 cells
compared with those that received IL-21 KO CD8 cells (Fig. 5C). To further demonstrate
the contribution of IL-21 derived from CD8 cells to the development of lung GC B cells
and to compare this with IL-21 derived from CD4 cells, similar adoptive transfer
experiments were performed with WT or IL-21 KO CD4 and CD8 cells. To facilitate the
quantification, GC B cells in the lungs of infected mice were examined by flow
cytometry as PNAhi Fashi IgD- cells as described above, using lung cell homogenates
(Supplementary Fig. S1C). A higher frequency of lung GC B cells was found in mice
that received WT CD8 cells than in mice that had received IL-21 KO CD8 cells (Fig. 5D).
220

Interestingly, WT CD8 cells were as efficient in promoting GC B cells in the lung as WT
CD4 cells (Fig. 5D). Together these data show the relevant role that CD8 cells have on
GC B cells in the lung through IL-21 production during influenza virus infection.
To determine whether this had an effect on antibody production, we measured the
levels of PR8 virus-specific antibodies in serum using ELISA. As expected, IgM
response to influenza virus was comparable between the two groups of IL-21 KO
recipient mice (Fig. 5E). In contrast, significantly higher levels of PR8-specific total IgG
were found in IL-21 KO mice that received WT CD8 cells relative to IL-21 KO mice that
received IL-21 KO CD8 cells (Fig. 5F). Therefore, IL-21 produced by CD8 cells
contributes to virus specific IgG response. Analysis of the different virus specific IgG
isotypes showed no statistically significant difference in IgG1 titers (Fig. 5G). However,
the levels of virus-specific IgG2c (Fig. 5H) and IgG3 (Fig. 5I) were markedly decreased
in mice that received IL-21 KO CD8 cells. Thus, through their production of IL-21, CD8
cells have an important role in B cell isotype switching and in shaping antibody response
against influenza virus. To determine whether this antibody response promoted by CD8
cells also provide protection, sera from infected IL-21 KO recipients that received WT or
IL-21 KO CD8 cells were tested for protective efficacy in WT mice following a lethal
dose of H1N1 PR8 virus infection. The sera from IL-21 KO mice that had received WT
CD8 cells conferred more protection than the sera from IL-21 KO mice that had received
IL-21 KO CD8 cells (Fig. 5J). Thus, CD8 cells contribute to antibody mediated
protection in virus infection through their ability to produce IL-21.
The presence of inducible bronchus associated lymphoid tissue (iBALT) has been
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reported as a secondary lymphoid tissue in the lungs of influenza virus infected mice
(Moyron-Quiroz et al., 2006; Moyron-Quiroz et al., 2004; Rangel-Moreno et al., 2007).
Interestingly, in addition to CD4 cells and B cells, immunostaining analysis in influenza
virus infected lungs also showed the presence of CD8 cells in close contact with B cells
and GC B cells (GL-7 cells) in these lymphoid structures (Fig. 5K and Supplementary
Fig. S2), further supporting that CD8 cells can provide help to B cells in the lung.

In summary, our studies here reveal that CD8 cells can produce high levels of IL-21
when IL-6 is present during their activation both in vitro and in vivo. More importantly,
in addition to their known cytotoxic effector functions, here we demonstrate a novel
function of CD8 cells as helpers of B cells in antibody production.
B cells are most commonly activated by antigen in the presence of CD40 ligand
provided by activated CD4 cells (Banchereau et al., 1994). However, CD4 cells or
CD40/CD40L are not essential for Ab production and virus clearance during influenza
virus infection (Lee et al., 2005), suggesting another source of B cell help. In contrast to
CD4 cells, CD8 cells have not been considered as cognate B cell helpers because they
express only low levels of CD40L (Sad et al., 1997). CD4 cells have been shown to
provide B cell help in an antigen specific manner, while B cells have been shown to
cross-present to CD4 cells. The ability of B cells in cross-presenting to CD8 cells through
MHC class I is less clear (Keller et al., 2009; Lee Szeto et al., 2015). Nevertheless, B
cells can also be activated directly by different TLR agonists independently of CD40.
TLR4 (recognizing LPS), TLR3 (recognizing dsRNA produced during viral replication),
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TLR7 (recognizing viral ssRNA), and TLR9 (recognizing hypomethylated DNA from
bacteria and viruses) have been reported to be expressed in B cells and contribute to B
cell activation and Ab production (Clingan and Matloubian, 2013; Genestier et al., 2007;
Heer et al., 2007; Kasturi et al., 2011; Simchoni and Cunningham-Rundles, 2015; Xu et
al., 2008). However, while TLRs can synergize with BCR for activation of B cells, TLR
signaling is not highly efficient in inducing Ig class switching without additional T cellderived cytokines. Here we reveal that CD8 cells can promote Ig class switching and
production of antibodies in B cells activated by TLR signals through the production of
IL-21 when IL-6 is present.
Interestingly, our studies here in influenza virus infection also reveal that CD8 cells in
the lung produce IL-21, but IL-21 expression could not be detected in CD8 cells from
spleen and draining lymph node of infected mice. Similarly, no IL-21 expression could
be detected in CD8 cells from spleens or lymph nodes in mice immunized with antigens
and different adjuvants (data not shown). Since CD4 cells are abundantly present in the
follicles (Tfh cells) in these lymphoid tissues, this raises the possibility that CD8 cells act
as B cell helpers primarily in the non-lymphoid tissues while CD4 Tfh cells are the
predominant B cell helpers in spleen or lymph node follicles. Thus, in the case of
influenza virus infection, lung B cells stimulated through specific TLRs (e.g. TLR3 or
TLR7) may receive help from IL-21-producing CD8 cells activated in the lung through
virus recognition on lung epithelial cells. Similarly, IL-21-producing CD8 cells present in
tissues with chronic inflammation may also provide help to the inflammatory B cells in
these tissues. For example, CD8 cells have been found in kidney in lupus, an
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inflammatory disease in which B cells and antibodies contribute to the pathogenesis
(Couzi et al., 2007). Alternatively, since we have shown that lung epithelial cells are a
major source of IL-6 in the lung (Neveu et al., 2011), it is possible that CD8 cellmediated help to B cells is more prevalent in lung due to the IL-6-rich environment that
promotes the production of IL-21 by CD8 cells. In this regard, our studies here
demonstrate that IL-21 production by CD8 cells in vivo in the lung is dependent on the
presence of IL-6. Overall, our studies provide new insight for the role of CD8 cells in the
immune response and they can have a major clinical impact in the vaccine development
and cancer immunology fields.
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MATERIALS AND METHODS
Mice and influenza virus Infection
Null IL-6 knockout (KO) and IL-21 KO mice were previously described (Dienz et al.,
2009; Poli et al., 1994). IL-21 hCD4 reporter mice were generated by Drs. Casey Weaver
and David Randolph (University of Alabama at Birmingham; manuscript in preparation).
T cell specific-Stat3 conditional knockout (Stat3 KO) mice were generated by crossing
the homozygous floxed Stat3 mice (Stat3loxp/loxp) (Takeda et al., 1998) with T cell-specific
Lck-Cre transgenic [B6.Cg-Tg(Lck-cre)1Cwi N9] mice (Lee et al., 2001). OT-I TCR
transgenic mice were previously described (Hogquist et al., 1994). All the mice were
fully back-crossed into the C57BL/6J background. WT C57BL/6J mice were purchased
from Jackson Laboratories.
For adoptive transfer experiments, 12x106 WT or IL-21 KO CD8 cells were
adoptively transferred to IL-21 KO recipient mice. For influenza A virus infection, mice
were infected intranasally (i.n.) with a sublethal doses (3×103 EIU) of Puerto Rico
A/PR/8/34 H1N1 (PR8) influenza A virus as previously described (Dienz et al., 2012).
Mice were euthanized 7 or 14 days post infection for real-time RT-PCR analysis and 13
days post infection for PR8 specific antibody analysis. For analysis of serum-mediated
protection, 13 days after sublethal influenza virus infection of IL-21 KO mice that had
received WT or IL-21 KO CD8 cells, sera were harvested. Sera were intraperitoneally
administered (30 µl) into WT mice one day after infection with a lethal dose (104 EIU) of
Puerto Rico A/PR/8/34 H1N1 (PR8) influenza A virus. Weight lost and survival were
followed up for 17 days post-infection. All mice were housed under sterile conditions at
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the AAALAC-approved animal care facility at the University of Vermont. All procedures
performed on the mice were approved by the University of Vermont Institutional Animal
Care and Use Committee.

Cell Purification and activation in vitro.
In most experiments, CD8 cells were isolated from spleen and lymph nodes by
negative selection as previously described (Diehl et al., 2002). CD8 cells isolated by
negative selection are typically >85% in purity and have <2% CD4 contaminants. CD8
cells from Stat3 conditional KO mice and IL-21 reporter mice and their corresponding
WT controls as well as CD8 cells from WT and IL-21 KO mice for adoptive transfer
experiments were purified by positive selection using anti-CD8 magnetic microbeads
(Miltenyi). Positive selection resulted in >92% CD8 cell purity, with less than 0.5% CD4
cell contamination (data not shown). CD8 cells from the lung were isolated using the
lung dissociation kit (Miltenyi) as recommended by the manufacturer, followed by
positive selection (Miltenyi). B cells from WT or IL-21R KO mice were purified by
positive selection (Miltenyi) (typically >92% in purity). IL-6Rhi and IL-6Rlo CD8 cells,
and CD44high and CD44low CD8 cells were isolated by immunostaining and cell sorting
(FACS-Aria; Becton Dickinson). IL-6R KO cells stained with anti-IL-6R Abs were used
as the negative control for IL-6Rhi and IL-6Rlo CD8 gating.
CD8 cells were activated with plate-bound anti-CD3 (145-2C11) (5 µg/ml) and
soluble anti-CD28 (1 µg/ml) (BioXCell) Abs in the presence or absence of IL-6 (50
ng/mL) (Miltenyi) except where indicated. Human recombinant IL-2 (50 U/mL)
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(Biolegend), mouse recombinant IL-12 (5 ng/mL) and IL-15 (20 ng/mL) (Amgen) were
used. B cells were activated as listed below: 1). LPS (1 µg/mL) (Sigma); 2). anti-IgM
F(ab’)2 (10 µg/mL) (Jackson ImmunoResearch) alone; 3). anti-CD40 Ab (1 µg/mL) (BD
Pharmingen) alone; 4). LPS (1 µg/mL) and IL-4 (100 U/mL); 5). anti-CD40 Ab (1
µg/mL) with LPS (1 µg/mL); 6). anti-IgM F(ab’)2 (10 µg/mL) with CpG (1 µg/mL)
(Sigma).

Flow Cytometry Analysis
For IL-6R staining experiments, splenocytes were stained with anti-CD4 Ab
(Biolegend), anti-CD8 Ab (Miltenyi), anti-CD44 Ab (Biolegend), anti-IL-6Rα Ab (BD
pharmingen), anti-KLRG1 Ab (eBiosciences), anti-CD25 Ab (Biolegend), anti-CD127
Ab (BD pharmingen). For germinal center B cell staining, lung cell homogenates were
generated using the lung dissociation kit (Miltenyi), as recommended by the
manufactorer. Lung cells or spleen cells were stained with anti-CD8 Ab (Miltenyi), antiFas Ab (BD pharmingen), anti-B220 Ab (Biolegend), anti-CD24 Ab (Biolegend), antiIgD Ab (BD pharmingen) and biotin-PNA (Vector laboratories) followed by secondary
staining using Strepavidin staining Abs (BD pharmingen). The immunostaining was
always performed in the presence of Fc block (BD pharmingen). For intracellular
cytokine staining experiments, CD8 cells from IL-21 hCD4 reporter mice were activated
for 3 days with or without IL-6. Cells were harvested, stained with anti-CD8 Ab
(Miltenyi), anti-hCD4 Ab (Biolegend) and life-dead staining (Invitrogen). Cells were
then fixed, permeabilized using saponin buffer (Sigma) as described (Yang et al., 1998a),
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and stained with anti-IFNγ Ab (Biolegend) or anti-IL-2 Ab (Biolegend). Expression of
CD69 on activated cells was determined by immunostaining with an anti-CD69 Ab
(Biolegend) and flow cytometry analysis. CD8 cell survival was determined by
LIVE/Dead Viability kit, as recommended by the manufacturer (Molecular Probes) and
flow cytometry analysis. CD8 cell proliferation was determined by CFSE staining
(Molecular Probes) and flow cytometry analysis. All flow samples were run on FACSLSR II (BD biosciences) and FlowJo Version 10.1.

RNA Isolation and real time RT-PCR.
Total RNA was isolated using the Qiagen micro RNeasy kit, as recommended by
manufacture (Qiagen). cDNA synthesis was performed as previously described (Yang et
al., 2015a). cDNA was used for real time RT-PCR assay using specific probe/primer sets
for mouse Il21, Il2, Ifng and b-microglobulin (Assays-on-DemandTM, Applied
Biosystems). We followed the comparative CT method (2-∆∆CT) as described by the
manufacture (Applied Biosystems) (Livak and Schmittgen, 2001). Briefly, Il21, Il2 and
Ifng mRNA levels relative to the expression of b-microglobulin as housekeeping gene
were obtained (∆CT). ∆∆CT values were then obtained by subtracting the ∆Ct value from
a given reference sample (Fig. 1I, 1K, 2B, 2C and 2H) as calibrator to the rest of the
samples. For Fig. 5A the average of the ∆CT value for the 5 individual mice in the
WT/Lung CD8 group was used as calibrator. The final relative expression data are
provided as 2-∆∆CT, defined as RQ value (relative quantitation).

228

ELISPOT assay.
The detection of IL-21-producing CD8 cells by ELISPOT was performed as we
previously published (Dienz et al., 2009). Briefly, purified CD8 cells (5 x 104 cells/well)
were plated in an anti-IL-21 Ab-coated ELISPOT plate and incubated (9 h) in the
presence of PMA (20ng/ml) and ionomycin (1 µg/ml). Plates were developed as
previously described (Dienz et al., 2009). The number of spots (number of IL-21producing cells) per well as well as the total area of spots (overall IL-21 production) per
well were measured.

Western-blot analysis.
Western blot analysis were performed as we previously reported (Yang et al., 2015a),
using the following antibodies: anti-actin (Santa Cruz), anti-pSTAT3 Tyr705 (Cell
Signaling Transduction) and anti-STAT3 (Cell Signaling Transduction) and anti-rabbit
HRP (Jackson ImmunoResearch Laboratories) and anti-goat HRP (Santa Cruz).

Lung Imaging.
Lungs frozen in Tissue-Tek O.C.T. compound (Sakura Finetek) were sectioned using
a CM1850 cryostat (Leica). 30-µm frozen sections were blocked for 30 minutes with
Background Buster (Innovex Biosciences) at room temperature, stained 6 hours at 4oC in
a humidified chamber with anti-CD8a (BD Biosciences), anti-GL-7 (Biolegend) and antiB220 (Biolegend) in PBS with 2% goat serum. Alternatively (for lymphoid structures in
the lung), whole mount imaging was performed on 250µm scalpel cut lung sections that
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were then fixed with 2% PFA (1 hour at 4oC), blocked and stained with the antibody
cocktail mentioned above and anti-CD4 Ab (BD Biosciences). Immunofluorescence
confocal microscopy was performed with the Zeiss 780 laser scanning microscope (Carl
Zeiss; air objective 20× Plan-Apochromat with NA (Numerical aperture) 0.5 or water
objective 10x Plan- Apochromat with NA 0.30) using multichannel frame scans. Image
processing was performed using Imaris 8.1 software. Images were analyzed using LSM5
image browser and cells in 3-4 images from each mouse were counted using ImageJ cell
counter plugin.

ELISA.
IL-21, IL-2, IL-4 and IFNγ levels in cell culture supernatants were determined by
ELISA as previously described (Diehl et al., 2000; Yang et al., 2015a). IgG1 levels in cell
culture supernatants were determined by ELISA as previously described (Dienz et al.,
2009). Levels of Influenza A PR8-specific IgG, IgM, IgG1, IgG2c and IgG3 were
determined using UV-inactivated influenza PR8 as antigen as previously described
(Dienz et al., 2009). Antibody levels in serially diluted serum samples were analyzed
using HRP-conjugated Abs specific for mouse IgM, IgG, IgG1, IgG2c and IgG3
(SouthernBiotech).
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Figure 1. IL-6 induces the production of IL-21 in CD8 cells through Stat3. (A and B)
CD8 and CD4 cells were activated using anti-CD3/CD28 Abs in the absence (Med) or
presence (IL-6) of IL-6 (50 ng/mL) for 24, 48 or 72 h. IL-21 production from CD8 cells
(A) and CD4 cells (B) were determined by ELISA (n=3). (C) IL-4 production by CD8 or
CD4 cells during activation as in (A) for 72 h was determined by ELISA (n=3). (D)
CD69 expression by flow cytometry analysis in freshly isolated CD8 cells (shaded) or
activated as in (A) in the absence (blue) or presence (red) or IL-6. (E) Percentage of live
CD8 cells activated as in (A) for 2 d was determined by flow cytometry (n=3). (F) CD8
cells were activated as in (A) for 72 h with or without (Med) different concentrations of
IL-6 as indicated. IL-21 production in culture supernatants was determined by ELISA
(n=3). (G and H) CD8 cells were activated as in (A) in the absence (Med) or presence of
IL-6, IL-2, IL-15 or IL-12 for 72 h. IL-21 (G) and IFNγ (H) production in culture
supernatants were determined by ELISA (n=3). (I) Relative mRNA levels for IL-21 in
CD8 cells activated as in (A) in the absence (Med) or presence of IL-6 or IL-2 were
determined by real-time RT-PCR. (J) CD8 cells were activated as in (A) in the absence
or presence of IL-6 for 0’ (Uns), 15’, 30’, 1 h or 3 h. The levels of Tyr705-phosphorylated
STAT3 (P-STAT3), total STAT3 or actin were determined Western blot analysis. (K and
L) WT or Stat3 T-cell conditional KO (Stat3 KO) CD8 cells were activated as in (A) in
the presence (IL-6) or absence (Med) of IL-6 for 72 h. Relative IL-21 mRNA levels were
determined by real-time RT-PCR (K), and IL-21 levels in cell culture supernatants were
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determined by ELISA (L), (n=3). Error bars represent the mean±SD. * denotes p < 0.05,
as determined by Student t test or two-way ANOVA. u.d denotes undetectable levels.
Results are representative of 2-3 experiments.
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Figure 2. IL-6 reprograms effector CD8 cells into IL-21-producing effector cells. (A)
CD8 cells were activated using anti-CD3/CD28 Abs in the absence (Med) or presence
(IL-6) of IL-6 (50 ng/mL) for 72 h. IL-2 production in culture supernantants was
determined by ELISA (n=3). (B and C) CD8 cells were activated as in (A) in the absence
(Med) or presence of IL-6 or IL-2. Relative mRNA levels for IFNγ (B) and IL-2 (C) in
CD8 cells were determined by real-time RT-PCR. (D) CD8 cells from IL-21-hCD4
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supernatants was determined by ELISA (n=3) (I). (J) CD8 cells were activated with antiCD3/CD28 Abs in the absence (Med) or presence of IL-6 that was added to the cultures
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at the indicated periods of time after activation. IL-21 production in supernatants after 72
h of activation was determined by ELISA (n=3). (K) CD8 cells were activated using antiCD3/CD28 Abs in the absence of IL-6 (Med) or in the presence of IL-6 added at the time
of activation (0 h), 24 h or 48 h post-activation. 72 h after the addition of IL-6, IL-21
production was determined by ELISA (n=3). Error bars represent the mean±SD. *
denotes p < 0.05, as determined by Student t-test, one-way ANOVA or two-way
ANOVA. Results are representative of 2-3 experiments.
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Figure 3. IL-6R defines a CD8 subset capable of producing IL-21. (A) IL-6R
expression in freshly isolated CD4 and CD8 cells was examined by flow cytometry
analysis. IL-6R KO CD4 or CD8 cells were used as negative controls (shaded). The gate
defining the IL-6Rhigh (IL-6Rhi) cell population is shown. (B and C) IL-6R MFI (B) and
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(D) IL-6R expression on CD4/CD8 double positive (DP), single CD4 positive (CD4 SP),
and single CD8 positive (CD8 SP) thymocytes was analyzed by flow cytometry.
Unstained DP thymocytes were used as negative control (shaded). (E) IL-6R expression
(blue) on freshly isolated CD8 cells (0 h) or after activation for the indicated periods of
time was determined by flow cytometry. The unstained corresponding population was
used as negative controls (shaded histograms). (F) Expression of CD25, KLRG1, CD127
and CD44 on CD8 IL-6Rhigh (IL-6Rhi) and CD8 IL-6Rlow (IL-6Rlo) cells was determined
by flow cytometry. The gate based on a negative control is shown. (G) Percentage of
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supernatants (72 h) was determined by ELISA (n=3). (J) Expression of IL-6R on OT-I
CD8 cells as determined by flow cytometry. As a negative control (shaded histogram),
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unstained cells are shown. (K) OT-I CD8 cells were activated using anti-CD3/CD28 Abs
in the absence (Med) or presence (IL-6) of IL-6. After 72 h, production of IL-21 in
culture supernatants was determined by ELISA (n=3). (L) FACS sorted CD8 IL-6Rhi and
CD8 IL-6Rlo cells from WT mice were activated using anti-CD3/CD28 Abs in the
absence (Med) or presence of IL-6. Production of IL-21 in culture supernatants after 72 h
was determined by ELISA (n=3). Error bars represent mean±SD. * denotes p < 0.05, as
determined by Student t-test and two-way ANOVA. Results are representative of 2-3
experiments.
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Figure 4. IL-6 reprograms CD8 cells to become B cell-helpers through their
production of IL-21 in vitro. (A) Culture supernatants (SN) were collected from WT and
IL-21 KO CD8 cells activated with anti-CD3/CD28 Abs in absence (Med SN – CD8) or
presence (IL-6 SN – CD8) of IL-6 for 3 days. WT and IL-21R KO B cells were activated
with LPS and anti-CD40 Abs in the presence of the culture supernatants (SN) from the
specified activated CD8 cells. IgG1 production by B cells after 6 days was determined by
ELISA (n=3). (B) WT or IL-21R KO B cells were activated using LPS+IL-4 for 6 d in
culture supernatants from WT CD8 cells activated for 3 d in the presence of IL-6. IgG1
production in culture supernatants was determined by ELISA (n=3). (C) WT or IL-21R
KO B cells were activated LPS in the presence of culture supernatants (SN) obtained
from WT CD8 cells activated as in (A). After 6 days, IgG1 production by B cells was
determined by ELISA (n=3). (D and E) WT or IL-21R KO B cells were activated with an
anti-IgM Ab (D) or anti-CD40 Ab (E) in the presence of activated-CD8 cell supernatant
(SN) as described in (C). IgG1 production by B cells after 6 days was determined by
ELISA (n=3). (F and G) WT or IL-21R KO B cells were co-cultured with WT CD8 cells.
B cells in the co-cultures were activated with LPS while CD8 cells were activated with
anti-CD3/CD28 Abs in the absence (Med) or presence (IL-6) of IL-6. After 6 days, the
levels of IgG1 (F) and IgM (G) in the co-cultures were determined by ELISA (n=3). (H)
IgG1 levels measured by ELISA in 6 d co-cultures of WT or IL-6 KO B cells (activated
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by LPS) with WT CD8 cells (activated by anti-CD3/CD28 Abs in the presence or
absence of IL-6), (n=3). (I) IgG1 levels measured by ELISA in 6 d co-cultures of IL-6
KO B cells (activated by LPS) with WT or IL-6R KO CD8 cells (activated with antiCD3/CD28 Abs in the presence or absence of IL-6) as indicated, (n=3). (J) Co-cultures of
B cells and CD8 cells were established as described in (F), but a combination of an antiIgM Ab and CpG was used (instead of LPS) to activate B cells. IgG1 levels in the cocultures after 6 days were determined by ELISA (n=3). (K) WT B cells were co-cultured
with WT or IL-21 KO CD8 cells. B cells in the co-cultures were activated with a
combination of an anti-IgM Ab and CpG, while CD8 cells were activated with antiCD3/CD28 Abs in absence (Med) or presence (IL-6) of IL-6. After 6 days, the levels of
IgG1 in culture supernatants were measured by ELISA (n=3). Error bars represent the
mean±SD. * denotes p < 0.05, as determined by Student t test, one-way ANOVA or twoway ANOVA test. Results are representative of 2-3 experiments.
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Figure 5. IL-21-producing CD8 cells promote isotype switching in B cells in vivo
during influenza virus infection. (A) WT or IL-6 KO mice were infected with a
sublethal dose of H1N1 PR8 virus. 7 days (d 7) or 14 days (d 14) post-infection, CD8
cells were isolated from lung or spleen/MLN (S/M) and relative IL-21 mRNA levels
were determined by real-time RT-PCR. For 7 days, WT and IL-6 KO lungs, n=5 and WT
S/M, n=3; For 14 days, WT lungs and S/M, n=3. (B) CD8 cells (5 x 104 cells/well) from
lungs or spleen/MLN (S/M) of mice infected with influenza virus as in (A) for 14 days
were assayed for IL-21 production by ELISPOT assay. Number of IL-21 producing cells
(number of spots) and the total area of spots (area) per well were measured, (n=3). (C)
IL-21 KO mice as host mice received WT CD8 or IL-21 KO CD8 cells and were infected
with a sublethal dose of H1N1 PR8 virus. After 14 days, lung tissue was immunostained
and imaged. Percentage of GL-7+ cells relative to the number of B220+ cells in lungs of
these mice was determined. (D) Percentage of GC B cells (PNAhi FAShi IgD-) within the
B220 population in lungs from influenza virus infected (day 14) IL-21 KO mice that had
received WT CD8, WT CD4, IL-21 KO CD8 or IL-21 KO CD4 cells, (n=4). (E - I) Sera
from IL-21 KO recipients that received WT CD8 cells or IL-21 KO CD8 cells and were
infected with influenza virus as described in (C) were analyzed for influenza specific IgM
(E) (p=0.5703), IgG (F) (p=0.0012), IgG1 (G) (p=0.2278), IgG2c (H) (p<0.0001) and
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IgG3 (I) (p=0.0002) levels by ELISA. (J) Purified CD8 cells from WT or IL-21 KO mice
were adoptively transferred to IL-21 KO recipient mice, and these mice were
subsequently infected with a sublethal dose of influenza virus. 13 days postinfection, sera
was collected and administered i.p. to WT mice 1 d after infection with a lethal dose of
influenza virus. n=9, for WT mice that received serum from WT CD8 cell-reconstituted
IL-21 KO mice (WT-CD8, blue), n=10, for WT mice that received serum from IL-21 KO
CD8 cells-reconstitute IL-21 KO mice (IL-21 KO-CD8, red). Kaplan-Meier survival
curve is shown, p= 0.05 by log-rank test. (K) Confocal microscopy images of lungs from
influenza virus infected mice (day 12) showing the staining for B220 (Red), GL-7 (Blue)
and CD8 (green) individually or as a merged image in lymphoid structures. Scale bars
(50 µm) are shown. Error bars represent the mean±SD. * denotes p < 0.05, as determined
by Student t test, two-way ANOVA or log-rank test. Results are representative of 2-3
experiments.
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Supplemental Figure S1. (A) WT or IL-21 KO CD8 cells were transferred to IL-21 KO
recipients, and these mice were subsequently infected with H1N1 PR8 virus i.n. (3x103
EIU). Splenocytes of infected IL-21 KO recipients that had received WT CD8 cells (WT
CD8) or IL-21 KO CD8 cells (IL-21 KO CD8) or control mouse that was not infected
(n=1) were stained for B220, PNA, Fas, IgD and CD24. Activated germinal center B cells
were determined by B220+PNAhiFashi or B220+PNAhiFashiIgD-CD24hi using flow
cytometry analysis. Percentage of PNAhi Fashi cells (of B cells) and percentage of PNAhi
FashiIgD-CD24hi cells (of B cells) as shown in gate is shown. (B) Lungs slides from
infected mice as in (A) were stained for B220 and GL-7. B220+ cells and GL-7+ cells
were counted in infected IL-21 KO recipients that had received WT CD8 cells (WT CD8)
or IL-21 KO CD8 cells (IL-21 KO CD8). Bars equal 50 µm. (C) IL-21 KO mice that had
received WT CD8, WT CD4, IL-21 KO CD8 and IL-21 KO CD4 cells were infected with
sublethal dose of influenza virus and 14 days later, lung homogenates were stained for
B220, PNA, Fas and IgD. GC B cells were identified by gating in the B220 positive cells
that are PNAhi Fashi.. Within this population, IgD- cells are the true GC B cells. SSC, side
scatter. Error bars represent the mean±SD. p=0.88 for (A), as determined by Student t
test.
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Supplemental Figure S2. Confocal microscopy images of a lymphoid structure in the
lungs of influenza virus infected WT mice showing immunostaining for B220 (red), GL7 (blue), CD4 (yellow) and CD8 (green) as single staining or merged. Scale bars (50 µm)
are shown.
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CHAPTER 5
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CONCLUDING REMARKS
Although IL-6 has long been considered as just a non-specific marker of
inflammation, the success of treating rheumatoid arthritis (RA) and Castleman’s disease
using the humanized anti-IL-6R antibody tocilizumab has emphasized the importance of
this cytokine in the pathophysiology of highly relevant diseases. Over the past decade,
IL-6 has been extensively studied regarding its role in inflammation, autoimmunity and
cancer (Kishimoto, 2005, 2010). Almost all of these studies assign the mechanism
underlying IL-6 signal transduction to the regulation of transcription factor Stat3
(Heinrich et al., 2003). Therefore, uncovering new pathways underlying the function
elicited by IL-6 may unveil novel therapeutic design for the treatment of autoimmune
disorders.
Our studies described in Chapter 2 unmask such a novel pathway. Through the
regulation of mitochondrial Stat3 and subsequently mitochondrial membrane potential
and Ca2+, IL-6 contributes to the effector cytokine production in CD4 effector T cells
(Yang et al., 2015b). This is the first study to show a direct association between IL-6 and
mitochondrial respiration in T cells. Intriguingly, IL-6 was found to participate in
mitochondrial regulation in other cells including cardiomyocytes, cancer cells and muscle
cells (Kang et al., 2012a; Smart et al., 2006; White et al., 2012). Especially, IL-6 was
found maintaining mitochondrial membrane potential and Ca2+ in cardiomyocytes (Smart
et al., 2006). Therefore, it will be worthwhile to investigate whether IL-6 may contribute
to physiological heart function or prognosis in cardiac diseases through the regulation of
mitochondrial Stat3 or mitochondrial function. These suggest that the signaling of IL-6
through mitochondria may be a common mechanism in regulating not only CD4 T cells
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but also a variety of other cells. Thus, IL-6 may elicit broader biological functions
through modulation of mitochondrial metabolism.
Indeed, IL-6 has for long been linked to global metabolic changes in the body,
and high levels of IL-6 in serum are correlated with high BMI (Fried et al., 1998;
Mohamed-Ali et al., 1997). The elevated IL-6 in obese people is suggested to contribute
to the chronic inflammation occurring commonly in obesity – a metabolic disorder that is
highly related to mitochondrial dysregulation (Bournat and Brown, 2010). Rather than
being a byproduct of obesity, whether IL-6 may contribute to the development of obesity
through the mitochondrial regulation is worthy of further investigation.
In addition, our studies in Chapter 2 also provide evidence that some functions
of IL-6 previously assigned to canonical Stat3 signaling are actually mediated by the
regulation of mitochondrial Stat3. For instance, mitochondrial Stat3 contributes to the
induction of IL-21 and IL-4 by IL-6 in CD4 effector T cells (Yang et al., 2015b). As IL21 and IL-4 contribute to the development and progression of autoimmune disorders and
asthma (Kau and Korenblat, 2014; Spolski and Leonard, 2014), targeting mitochondrial
Stat3 may have important therapeutic values. As reviewed in Chapter 3, several
pharmacological inhibitors are implied to suppress mitochondrial Stat3 activities (Yang
and Rincon, 2016). Therefore, testing these existing inhibitors as wells as developing
novel specific inhibitors for mitochondrial Stat3 may shed light into new therapeutic
approaches in treating autoimmune disorders and allergic asthma.
The biology of IL-21 induction by IL-6 in CD4 T cells has been well elucidated
by previous studies as well as our studies described in Chapter 2 (Dienz et al., 2009;
Nurieva et al., 2007; Suto et al., 2008; Yang et al., 2015b). In addition, NKT cells are
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found to secrete IL-21 (Coquet et al., 2007). Besides NKT cells and Tfh, our studies in
Chapter 4 for the first time demonstrate that CD8 effector T cells also produce IL-21
when IL-6 is present. This uncovers a new source of IL-21 during immune response.
IL-21, the most important effector cytokine produced by Tfh, masters the
plasma cell differentiation and antibody production during immune response (Ozaki et al.,
2004; Ozaki et al., 2002). Although several studies implied that CD8 T cells may provide
help to antibody production (Christianson et al., 1997; Cronin et al., 1995; Franco and
Greenberg, 1995; Spriggs et al., 1992), B cell helper function was assigned to CD4 T
cells exclusively. Surprisingly, as described in Chapter 5, our studies challenge the
current dogma and our results lead to a paradigm-shifting proposal that IL-6 can convert
CD8 T cells into B cell helpers for antibody production in local tissues by inducing IL-21
production . Since IL-6 is commonly produced in response to a variety of pathogens, it is
plausible to speculate that CD8 T cells may also make IL-21 during a variety of other
infections restricted to non-lymphoid tissues due to their IL-6-rich environment.
Interestingly, in human, although at low levels, IL-21 was produced by CD8 T cells in
HIV patients (Williams et al., 2011), suggesting that CD8 T cells may compensate parts
of Tfh function in human in vivo. However, whether IL-21 is produced by CD8 T cell
during other infections is still unknown and worthy of further attention.
Furthermore, our studies discover that CD8 T cell-derived IL-21 promotes GC
B cell differentiation. Interestingly, patients with SLE have infiltrated CD8 T cells in
affected kidney (Bagavant and Fu, 2009). Likewise, CD8 T cells also infiltrate in CNS of
patients with multiple sclerosis (Salou et al., 2015). Common to many other autoimmune
diseases, in addition to the higher IL-6 in serum, these disease lesions also produce
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abundant IL-6. Understanding whether CD8 T cells involved in these autoimmune lesions
make IL-21 may shed light into a previously unexplored field of autoimmunity.
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